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Title: Circulating Leptin levels in Patients with Myalgic Encephalomyelitis Chronic 
Fatigue Syndrome and/or Fibromyalgia: a Systematic Review 
 
Objective: The objective of this thesis was to evaluate circulating levels of leptin in 
cases diagnosed with Myalgic Encephalomyelitis Chronic Fatigue Syndrome and/or 
Fibromyalgia Syndrome and to investigate the differences compared with healthy 
controls.  
Background: Myalgic Encephalomyelitis Chronic Fatigue Syndrome is a condition 
that has major symptoms including self-reported fatigue, post exertional malaise and 
unexplained pain across the body. The widespread pain is measured in a systematic 
way and is often referred to as fibromyalgia. The two disorders have many 
similarities but their association with leptin has indicated that leptin may affect the 
role of proinflammatory cytokines and symptom severity. 
Inclusion criteria: This thesis considered observational studies of varying study 
designs including prospective and retrospective cohort studies, case-control 
studies, time-series and analytical cross-sectional studies that included both cases 
and healthy comparators. Cases included a diagnosis of Myalgic Encephalomyelitis, 
Chronic Fatigue Syndrome and/or Fibromyalgia.  Some consider Myalgic 
Encephalomyelitis to be a different condition from Chronic Fatigue Syndrome, but 
for the purpose of this thesis we will use a consistent format ‘Myalgic 
Encephalomyelitis Chronic Fatigue Syndrome’ without prejudice to the community 
perspective.   Controls are those without this diagnosis, usually healthy participants.  
Only studies published in English were included due to limited resources for 
translation.  
Methods: This systematic review is reported based on the Preferred Reporting 
Items for Systematic Reviews and Meta-analysis (PRISMA) checklist and follows 
JBI’s methodology for systematic reviews of etiology and risk.  A comprehensive 
search strategy included PubMed, Embase, Scopus, Science Direct, and 





PsychINFO.  Two reviewers screened, critically appraised eligible articles and 
extracted data using a standardised data extraction tool informed by the JBI System 
for the Unified Management, Assessment and Review of Information (SUMARI) 
software. Data Synthesis: The authors completed a quantitative analysis that 
produced synthesised findings across studies using pooled effect sizes and 
confidence intervals of the measures provided. 
Results: There were 12 case (n=649) vs control (n=658) studies combined 
(n=1307) in meta-analysis which demonstrated a small difference favouring a higher 
level of circulating leptin in cases compared to controls when using a standardised 
mean difference.   There was an overall pooled difference of 0.39, with a 95% 
Confidence Interval 0.04 to 0.74, which was significant (p=0.029).  The meta-
analysis showed a high level of heterogeneity I2=86%.  Re-expressing SMDs 
(Standardised Mean Difference) using the original units of leptin showed a pooled 
effect of 3.26 ng/mL (CI 0.33 ng/mL to 6.19 ng/mL). 
Conclusions: Much of the literature describes the role of leptin as being part of an 
inflammatory response, but this systematic review did not find that studies could 
provide convincing evidence that leptin was higher in cases than controls.  Although 
many studies indicated increased leptin in cases, there were two studies that 
reported lower leptin in cases compared to controls, four studies that showed no 
discernible difference, and six studies that indicated higher levels of leptin in cases.  
Individual study methodology varied between studies causing some difficulties in 
comparison.  A series of investigative benchmarks and protocols need to be 
developed in relation to researching adipokines if exploration of biomarkers in these 
syndromes is to yield useful results.  To provide clarity, clinical investigators need 
to use similar standardised practices and research methods to aid better 
comparison of experimental results between studies. A series of international 
standards and protocols needs to be developed, accepted, and cited across the 
literature as part of clinical operational procedures if we are to advance this area of 
research.  A series of recommendations for future research has been made in 
chapter 5.  





Keywords: Adipokines; cytokines; myalgic encephalomyelitis chronic fatigue 
syndrome; fibromyalgia; leptin. 
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Table 1 Summary of Findings Table 
Leptin Cases compared to Controls SMD for Myalgic Encephalomyelitis Chronic Fatigue Syndrome and/or Fibromyalgia 
Patient or population: [health problem] Chronic Fatigue Syndrome and/or Fibromyalgia vs Controls (Healthy participants) 
Setting: Usually a clinic setting or university / community research recruitment 
Intervention: Circulating Leptin levels Cases 
Comparison: Controls - SMD also re-expressed as original units 
Outcomes 
Illustrative comparative risks* (95% CI) 
Relative effect 
(95% CI) 
№ of participants  
(studies) 
Certainty of the evidence 
(GRADE) 
Comments  
Leptin in those without MECFS or FM 
Leptin Levels ng/mL 
(circulating leptin 




The mean difference in leptin levels in cases was  
SMD 0.39 (0.04 to 0.74) higher in cases than 
controls. This is equivalent to a re-expressed 
result of 3.26 ng/mL higher (0.33 to 6.19) in cases 
as compared to controls. *  
 
n=1307  







All studies used 





*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).CI: Confidence interval; MD Mean Difference 
SMD: Standardised Mean difference.  SMD and CI taken from SUMARI analysis. 
GRADE (Grades of Recommendation, Assessment, Development, and Evaluation)  Working Group grades of evidence 
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different 
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect 
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect  
Explanations: 
a. Downgrade 1 for imprecision Two studies provide evidence of hypoleptinaemia (low leptin), four studies report negligible difference, and 6 studies report hyperleptinaemia (high leptin) in cases.  
b. High heterogeneity (I2 = 86%), downgrade 1.  
c. Downgraded 1 for risk of bias. Confounders such as BMI and time of day (circadian rhythmicity) are not considered in all studies, and some have adjusted their results whilst others have not. The 
results vary significantly, indicating the method of laboratory storage, sample handling, assessment and analysis are different between studies.  
d. Downgraded 1 level for inconsistency with wide confidence intervals, and outcome results presented in opposite directions.   
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1.1 Context and Purpose of the Review 
 
The author is a senior research fellow at the South Australian Health and Medical 
Research Institute and is investigating the role of adipokines (biological messengers 
produced by fat cells) and cytokines (biological messengers produced by immune 
cells) in relation to Myalgic Encephalomyelitis Chronic Fatigue Syndrome (MECFS).  
There have been several reviews and publications that have systematically 
reviewed the role of cytokines in MECFS, but none have specifically focused on the 
role of adipokines, and more specifically circulating leptin levels.  A number of 
published papers have inferred that leptin plays a role in the symptom severity of 
both MECFS and fibromyalgia  (Ataoglu et al. 2018; Cleare, O'Keane & Miell 2001; 
Hornig et al. 2015; Stringer et al. 2013).  One author implied that the diagnosis of 
MECFS and fibromyalgia are often confused by clinicians as they have many 
similarities in syndrome symptoms (Natelson 2019).  There are no current biological 
biomarkers that have been identified in MECFS nor fibromyalgia, hence why both 
conditions are considered syndromes.  A syndrome is a list of symptoms that are 
typically found in a specific condition or illness but have not yet been fully understood 
to the point whereby it can be identified as a recognised ‘disease’ which often has 
clear biological causative symptoms and treatment pathways (Calvo et al. 2003).  
Current investigative research therefore is attempting to find specific biomarkers 
such as cytokines, adipokines, and inflammatory mechanisms that better explain 
these two disorders MECFS and fibromyalgia.  Exploring the biological role of 
inflammatory cytokines, adipokines, and their interaction, may lead to new 
therapeutic interventions for people with neuroimmune type disorders (Straub et al. 
2013; VanElzakker, Brumfield & Lara-Mejia 2018). 
  





1.2 Statement of Review Question 
 
 
Leptin, an adipokine, is a measurable element in our blood or spinal fluid and plays 
a role in the production and circadian pathways of many cytokines and bodily 
functions such as eating, sleeping, resting and mood (Licinio, Negrao & Wong 
2014). The primary objective of this systematic review is to investigate the following 
question: 
Is there a difference in circulating leptin levels in MECFS and/or fibromyalgia 
that can be used as an outcome measure in cases and controls?  Leptin is 
measured in ng/mL and is assessed through the analysis of blood plasma, blood 
serum, or cerebrospinal fluid (CSF) levels (ng/mL). 
Several authors have identified a correlation of symptom severity and the levels of 
circulating leptin in the blood (Montoya et al. 2017; Olama, Elsaid & El-Arman 2013; 
Stringer et al. 2013).  For example, symptom severity and circulating leptin levels of 
participants were tracked over 25 days.  Using an algorithm, the authors were able 
to predict high symptom severity days (Stringer et al. 2013; Younger et al. 2016).  
Whilst some studies indicate high leptin levels predict higher symptom severity, 
there are others which indicate the opposite (Olama, Elsaid & El-Arman 2013; Paiva 
et al. 2017).  This systematic review of the evidence attempted to determine whether 
there is a difference in leptin levels between cases and controls and to assess the 
quality of that evidence.   
 
1.3  The Science of Evidence Synthesis and Systematic Reviews 
 
A systematic review can use several strategies to review the current findings on a 
given topic, with the objective of obtaining the best available information to support 
clinical practice and to guide the direction of future research.  One exemplary 
systematic review looked at the outcome of infant cot deaths (Sudden infant death 





syndrome – SIDS) as alarmingly in practice there had been approximately 100,000 
infant related cot deaths recorded between 1950 and 1990 (Bornstein et al. 2009). 
This much needed review indicated that the practice of laying babies on their front 
side instead of their backs, a popular practice during this period of review may have 
led to an increase in deaths.  The authors of the systematic review concluded that 
the evidence of using the preferred practice of laying babies on their backs reduced 
the risk of cot death by up to 50% and may have saved around 10,000 babies had 
this form of best practice been implemented earlier (ibid.). 
Systematic reviews are a relatively new approach to summarise and reflect on the 
available evidence in the literature.  Meta-analysis has been used by psychologists 
as a method of sifting through the evidence since the 1970’s, but “systematic 
reviews” that use the process of pooling evidence data for analysis was not 
practiced until around 1995  (Cleophas & Zwinderman 2017).  The practice saw the 
rise of new evidenced based practice centres such as Cochrane and the Joanna 
Briggs Institute, which now have centres and affiliates across the world.  The 
Cochrane collaboration was named after a British epidemiologist Archie Cochrane 
and was formally established in 1992 by a so called ‘motley crew’ led by Ian 
Chalmers at Oxford University (Ault 2003).  The Joanna Briggs Institute (JBI) was 
established in 1996 by a visionary of evidenced based practice Professor Alan 
Pearson in a collaboration between the University of Adelaide and the Royal 
Adelaide Hospital (Stannard & Cooper 2014).  The JBI is named after the first 
Matron of the Royal Adelaide Hospital (1849-1866) (Jordan, Donnelly & Pittman 
2006).   Both the Cochrane Centre and the JBI officially formed a partnership in 
2016 (Cochrane 2016), focusing on a worldwide approach to evidenced based 
practice, which is shared and disseminated in the journal ‘JBI Evidence Synthesis’.  
The protocol for this systematic review was published in the same journal on 2nd 
November 2020 (Musker et al. 2020). 
  





1.4  Methodological basis of the chosen approach synthesis  
 
Systematic reviews usually follow an a priori protocol that is based on the literature 
for that type of review and these often use the PICO (patient, intervention, 
comparison, outcome) format which was proposed by Richardson et al. (1995) an 
editorial of American College of Physicians Journal (Eriksen & Frandsen 2018; 
Richardson et al. 1995): 
1) the patient or problem being addressed;  
2) the intervention or exposure being considered;  
3) the comparison intervention or exposure, when relevant;  
4) the clinical outcomes of interest. 
 
When using the above format in the case of MECFS and/or fibromyalgia and the 
role of leptin, it unfolds like this: 
1. Patient: A person with a formalised diagnosis of MECFS or fibromyalgia 
2. Exposure: The exposure is the diagnosis of MECFS or fibromyalgia, and 
the exposure being syndromic symptoms, and this may include how long 
the person has been diagnosed. 
3. Comparator: The comparison is looking at measures of leptin in people 
who are diagnosed with or without the syndrome (healthy people) 
4. Outcome: The outcome is the level of leptin in the persons circulatory 
system (blood or CSF) and this is often linked to symptom severity. 
 
A review into the role of circulating cytokines in relation to a syndrome is somewhat 
problematic in that it does not readily fit into a standardised systematic review 
approach.  It best fits with the area of ‘etiology and risk’ and this is still an emerging 
framework in the context of the systematic review process (Moola, S. et al. 2015).  
There are no current diagnostic tests or effective treatments to compare MECFS 





and or fibromyalgia studies and so this protocol followed an association review 
methodology.  An association review looks at studies that make links between 
different types of evidence and may be used to develop an understanding of a 
disease process, diagnostic method, or in forming a prognosis.  This was further 
elaborated by Riley et al. (2019) p. 2, who stated prognostic variables are 
“associated with the risk of a subsequent health outcome” for people with a specific 
condition.  A proposed methodology for association studies was described by the 
JBI in 2015 (Moola, S. et al. 2015).  A typical systematic review contains the 
following typical elements, and where possible these steps were undertaken in this 
thesis (Munn, Zachary et al. 2019): 
 
(1) Formulating a review question 
(2) Defining inclusion and exclusion criteria 
(3) Locating studies through searching 
(4) Selecting relevant studies for inclusion 
(5) Assessing the quality of studies 
(6) Extracting data 
(7) Analysing and synthesising the results 
(8) Presenting and interpreting the results and establishing confidence in the 
body of evidence (through systems such as GRADE, Grades of 
Recommendation, Assessment, Development, and Evaluation) 
 
However, this review is somewhat atypical and was tailored to meet the diversity of 
the literature presented on the role of adipokines in relation to MECFS and/or 
fibromyalgia.  There are three modes by which the research is compared.  Firstly, a 
meta-analysis of specific measures of leptin in bodily fluids (plasma, serum, or CSF) 
usually recorded in the form nanograms per millilitre (ng/mL); secondly studies may 
vary dramatically in the way they present their findings, so a tabular synthesis of the 
results was necessary, and thirdly a narrative synthesis describing the relationship 





between the studies and systematic review results were formulated.  The above 




One of the challenges in undertaking this systematic review was that there are no 
current objective biological clinical indicators that have been identified to support the 
diagnosis of MECFS or fibromyalgia.  The diagnosis for MECFS is completed by the 
patient self-reporting a series of symptoms against a list of criteria known as the 
‘Canadian Consensus Criteria’ published in 2003 or the ‘International Consensus 
Criterion’ established in 2011 (Carruthers 2007; Carruthers et al. 2003; Carruthers 
et al. 2011).  As there are no diagnostic markers, it was not possible to complete a 
‘diagnostic test accuracy’ systematic review, nor are there enough randomised 
controlled trials that involved the use of leptin changes as a treatment.  There is 
conflicting evidence around the role of leptin in these syndromes in that some 
researchers reported that circulating leptin is higher in cases than controls, whereas 
other researchers have claimed the opposite, and these are discussed in more detail 
later in the thesis.  Further investigation is required to help clarify the current 
evidence in the literature and to support continuing research in this area.  
Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a syndrome that 
has some key major symptoms such as new unexplained headaches, self-reported 
fatigue, myalgias (muscle pain), post exertional malaise and unexplained pain 
across the body to name but a few (Carruthers et al. 2011).  The widespread body 
pain is measured in a systematic way and is often referred to as fibromyalgia 
(Natelson 2019).   
There is an accepted definition for ME/CFS developed by the US Center for Disease 
Control, which is often referred to as the ‘Fukuda definition’ and is frequently 
referenced in the literature as the mode of classification / diagnosis (Fukuda et al. 
1994).  However, this definition is now quite outdated and only covers the most basic 





symptoms.  More recent research will cite the International Consensus Criterion as 
a minimal standard of diagnosis.  There is a comprehensive questionnaire that is 
lengthy (129 questions) and captures most symptoms and lifestyle issues called the 
DePaul Symptom Questionnaire – version 2 (Jason & Sunnquist 2018).  Fukuda 
has quite a simple definition which describes fatigue that endures for at least six 
months, and for some it may last for decades. The Fukuda criterion also state that 
to meet diagnostic criterion, the person will also report symptoms of a minimum of 
an additional four of eight potential symptoms: Impaired memory or 
concentration; sore throat; tender cervical or axillary lymph nodes; muscle pain; 
multi-joint pain; new headaches; unrefreshing sleep; and post exertional malaise 
(ibid.).  The Canadian Consensus Criteria is a series of assessment tools and 
support for diagnostic guidelines produced as a set of guidance tools for 
practitioners known to provide assessment advice (Carruthers et al. 2011).  
The shortened term ‘Chronic Fatigue Syndrome’ continues to be controversial, and 
the use of this term alone is often questioned as to whether it best describes the 
disease phenomena, due to potential for misinterpretation and the resultant 
heterogeneity (Cathébras 2016).  The heterogenous nature of ME/CFS leads to 
speculation that there may be several subgroups within the syndrome, which may 
explain why some people make an apparent recovery and others do not (Williams 




A major symptom of ME/CFS is fibromyalgia and there is considerable overlap with 
these conditions, with patients often given both diagnoses. It is suggested that many 
may be misdiagnosed into either of these classifications (Natelson 2019).  The 
classification criterion determined in 1990 for fibromyalgia is a combination of 
widespread pain across four quadrants of the body with tenderness in a minimum 
of 11 of the 18 identified tender points, and this should have been experienced for 





at least three months (Clauw 2009; Wolfe, F. et al. 2019). The research in 
fibromyalgia and leptin may be more advanced,  than in MECFS and leptin, because 
the diagnosis has a clear focus on the experience of physical pain. Fibromyalgia is 
considered to be a disease of a rheumatic and inflammatory nature and some 
research has reported higher levels of leptin in sufferers vs controls (Ataoglu et al. 
2018).  The author has published an online article during the course of this thesis 
explaining the symptoms of this syndrome in The Conversation “Explainer: what is 




Leptin is an adipokine, which is a hormone produced by fat cells, that influences the 
body's appetite by stimulating leptin receptors in the hypothalamus and other areas 
of the brain (Radic et al. 2003).  Leptin produced by fat cells enters the circulatory 
system and becomes a feedback mechanism to areas of the brain, providing 
information on current fat storage and availability, allowing the brain to control and 
manage energy expenditure (Meinders et al. 1998).  The effects of leptin are 
autocrine (effects the cell producing it), paracrine (effects neighbouring cells) as well 
as endocrine (effects distant cells), but also promotes the production of 
proinflammatory cytokines for example interleukin 6 (Sun et al. 2018).  Leptin's 
association has been investigated in relation to ME/CFS from as early as 2001, 
linking the potential aetiology to hypocortisolism and other disorders (Cleare, 
O'Keane & Miell 2001).  
Faulty leptin signalling can cause problems by promoting autoimmunity (whereby 
the body attacks itself), a relationship with cardiovascular issues like blood pressure 
changes, and more serious diseases like cancer have been reported (Zabeau, 
Peelman & Tavernier 2015).  It is theorised that these changes in inflammatory 
mechanisms (the inflammasome) affect the nervous and immune systems and are 
evidenced by sickness behaviour in the form of fatigue and other pathogenic 





symptoms (Arnett & Clark 2012).  This type of  fatigue like behaviour is also seen in 
animal research as is interpreted as a behaviour that supports rest, recovery, and 
recuperation, but in MECFS and/or fibromyalgia this response can unfortunately 
become prolonged, and often becomes permanent, to the point that it irrevocably 
changes people’s lives for the worse (Fernández et al. 2009; Harden et al. 2015).  
In 2013 Stringer et al. (2013) completed a study on 10 ME/CFS participants and 10 
healthy controls, tracking their blood samples over a 25-day period.  They reported 
that there was a significant correlation of leptin with those participants with ME/CFS 
and their self-report of fatigue.  Using a computer algorithm to correlate leptin 
profiles, the team were able to predict which days the person would feel more 
fatigued.  There have been several publications profiling the levels of leptin in 
humans, but there is no clarity of a ‘normal’ level or range of leptin.  Circulating leptin 
levels change according to a few factors such as BMI level, the menstrual cycle and 
other potential confounders.  This is problematic if we use a one-off sampling 
technique, or a frequency of one sample per day to measure leptin levels because 
they are known to change as part a 24 h circadian cycle (Meinders et al. 1998).  
Samples are often taken in the morning following a period of fasting usually between 
8 and 10 am; however, this is usually the nadir (lowest level) of the leptin cycle and 
may not be representative of a person’s daily circulating leptin levels.   
Additionally, a study that examined 56 female normal subjects, aged between 18 
and 25 years (26 normal and 30 overweight or obese) reported that there are three 
phases of mean leptin in these groups that change across the menstrual cycle: the 
follicular phase (mean and SD serum leptin 9.97 ± 5.48 ng/mL), the ovulatory phase 
(11.58 ± 6.49 ng/mL), with a peak of leptin in the luteal phase (12.52 ± 6.39 ng/mL) 
but a further confounder was that leptin levels were up to 50% higher in those who 
were overweight or obese (Rafique et al. 2018). (see Figure 1)  
  





Figure 1 Leptin Levels in Women (aged 18-25 yrs.) 
 
Menstrual Phase Normal weight 
mean ± SD 
Overweight 
or obese 






8.38 ± 4.58  11.35 ± 5.89 0.02 
Preovulatory 
phase (PO) 
9.67 ± 5.28  13.24 ± 7.04  0.018 
Luteal phase (L)  10.39 ± 4.40  14.37 ± 7.29 0.027 
Adapted from Rafique et al. (2018) 
This is further evidence that taking a sample at one single time point rather than 
multiple samples across the day, may not be the best method of calculating an 
individual’s circulating mean leptin.  It also indicates the importance of BMI on the 
experimental outcomes. An important landmark study by Licinio et al. (1997) (n=6 
healthy men, aged 23-43) took blood every 7 min, providing objective evidence that 
normal leptin changes occur across a 24-h period and that leptin levels have a 
pulsatile nature.  Astonishingly they found that leptin could show a seven-fold 
difference (higher) in obese participants.  The frequency of pulses is consistent 
across weight ranges at 32 ± 1.5 pulses every 24 h which equates to each pulse 
lasting 32.8 ± 1.6 min.  That is, leptin has small peaks and troughs or ‘pulsatility’ and 
the overall level of circulating leptin gradually goes up to a zenith (peak) during the 
evening and overnight (between 8 pm and 4 am) with a nadir (trough) in the early 
morning (8 am to midday), gradually changing over the 24-h period in an upward 
trajectory, demonstrating a pattern of diurnal variation (Licinio et al. 1997).  The 
mean plasma leptin across the 6 male participants across the 24-h period was 4.44 
± 1.81 SEM ng/mL with a mean range of 0.62 ng/mL to 13.11 ng/mL.  There was 
also a pulse height provided which had 5.94 ± 2.90 (Mean ± SEM) within the same 
mean range.  





It has been suggested that the pulses seen in leptin levels are effected by extrinsic 
factors, that is they are not controlled by the adipose tissue but instead they have a 
complex relationship with, and are influenced by, other circulatory biofeedback 
mechanisms such as the levels of growth hormone, cortisol and insulin (Koutkia et 
al. 2003).   
In another sex inclusive study that measured both normal men and women and an 
obese group of men and women, it was noted that serum leptin is higher in obesity, 
and significantly higher across genders in both normal and obese women (Al-Sultan 
& Al-Elq 2006).  This unique paper provides a good benchmark as it includes age, 
BMI, gender, and waist-hip ratios as well as blood pressure levels.  Here is the data 
in a table for comparative reference with other studies (See Table 3): 
Table 3 Serum leptin in healthy men & women 
 
  Normal Weight Obese Weight 
  men women men women 
n= 20 23 25 21 
serum leptin 
mean ± SD 
ng/mL 
2.2 ± 0.3 8.8 ± 2.1 12.5 ± 2.2 23.0 ± 4.0 
Age 25.8 ± 5.3  23.9 ± 1.9  29.4 ± 7.6 28.8 ± 6.2 
BMI 23.1 ± 1.4 23.0 ± 1.8 35.5 ± 5.7 35.6 ± 4.4 
Waist 81.2 ± 7.3 72.8 ± 8.9 109.8 ± 13.1 100.0 ± 13.4 
Hip 100.9 ± 15.6 95.9 ± 7.2 118.7 ± 13.1 119.6 ± 11.7 
Waist Hip 
Ratio 
0.818 ± 0.116 0.758 ± 0.066   0.929 ± 0.063 0.836 ± 0.080 
 
The circadian changes in leptin are just one element our body uses to keep time to 
assist with controlling energy expenditure, sleep, and weight.  Perturbances in this 
system such as disruptions in sleep, work patterns and stress can cause a jet lag 
like effect throwing these mechanisms into desynchrony and may be the causal link 
to a variety of health problems (Dibner & Gachon 2015).  





1.8 Prevalence and Current Findings 
 
The prevalence of ME/CFS is around 14.8 (95% CI 14.5, 15.1) per 100,000 
according to an estimation from an analysis of general practitioner visits in the UK 
(Collin et al. 2017). A meta-analysis found a pooled prevalence estimate of 0.76% 
(95% CI: 0.23–1.29) for the general population who were identified through clinical 
diagnosis for the condition (Johnston et al. 2013). The Center for Disease Control 
in America indicate there are around 836,000 to 2.5 million people with ME/CFS 
costing the economy about $24 billion annually (CDC 2019).  ME/CFS is a 
syndrome without any definitive diagnostic test to confirm its presence or to what 
degree the person is affected by the illness.  There is an apparent stigma associated 
with the illness because there are no obvious biological markers that indicate a 
prognosis or cause (McManimen et al. 2018; Wessely 2002).  Society is more 
tolerant of other forms of sickness that can be medically identified and have known 
causes, for example, if we look more closely at other forms of sickness that cause 
ongoing fatigue like the Epstein Barr virus or glandular fever, these can be easily 
identified by testing for the specific viral reaction through a diagnostic test that 
identifies the virus (antibody test – viral load or titres)(Kristiansen et al. 2019).  The 
prevalence of fibromyalgia is estimated to be between 0.2 and 6.6% in the general 
population  (Marques et al. 2017).  Both MECFS and fibromyalgia syndromes are 
considered to be at a higher frequency in women than in men, around 90% being 
women with fibromyalgia and similar findings have been seen in some MECFS 
studies (Wolfe, F. et al. 2018).  For example one MECFS study has 1309 
participants of which only 9.1% (n=119) were men and of these 1309 participants, 
29% of the men had fibromyalgia compared to 58% of the women (Faro et al. 2016). 
A systematic review was completed by Blundell et al. (2015) to examine if there 
were any studies of cytokines that showed an association with ME/CFS entitled 
‘Chronic fatigue syndrome and circulating cytokines: A systematic review’ (Blundell 
et al. 2015).  The review authors identified 38 papers that reviewed 77 circulatory 
cytokines reporting the results as a combined effect of whether an investigated 





cytokine showed any difference in participants or controls. This review reported the 
outcomes of cases vs controls based upon one of three possible states; higher 
cytokine levels in cases; lower in cases; or no significant difference between cases 
and controls.  The pleiotropic cytokine TGF-β was the only major cytokine identified 
as being higher and this was seen in 63% of cases across the included studies.  
This is a multipotent cytokine that has both pro- and anti-inflammatory effects on the 
immune system (Sanjabi et al. 2009).   Since the Blundell et al. (2015) systematic 
review was published four years ago, there have been further reports investigating 
other potential associations between leptin and MECFS and/or fibromyalgia with an 
inference that leptin may play a role in influencing proinflammatory cytokines 
(Montoya et al. 2017). The role of these cytokines has previously been linked with 
pain, inflammation, depression and autoimmune responses (Miranda et al. 
2018).  Many studies have examined both leptin and proinflammatory cytokines, so 
a more in-depth, systematic meta-analysis that focuses on the difference that the 
measurement of leptin would make is of value, as it is often lost amongst a group of 
analytes with few details being reported, yet it may be the circadian controller of 
these analytes. 
A preliminary search of PROSPERO, MEDLINE, the Cochrane Database of 
Systematic Reviews and JBI Evidence Synthesis (formerly the JBI Database of 
Systematic Reviews and Implementation Reports) was conducted for any similar 
systematic reviews.  A total of 124 systematic reviews were listed in the PROSPERO 
database (searched 15-10-2019) but the majority were unrelated.  One systematic 
review and meta-analysis comparing patients with controls was commenced in 2015 
and had an end date of July 2018 is listed as ‘review ongoing’ (PROSPERO ref: 
ID=CRD42018065182).  This review has now been published (Strawbridge et al. 
2019).    Our proposed protocol differs in that it only reviewed those studies that 
focus on the analysis of leptin, and which provide the raw leptin levels in their original 
units of ng/mL.  There were only 3 articles listed in Cochrane for “Chronic Fatigue” 
and 40 for fibromyalgia; all of these were unrelated to our proposed protocol.  Most 
of the fibromyalgia proposals focused on medication such as pain relief (searched 
15-10-2019).    





A systematic review was completed in March 2015 (Blundell et al. 2015), but within 
this review only one cited study mentioned the role of leptin in ME/CFS.  The cited  
study showed that leptin was higher in ME/CFS participants compared to controls, 
indicating that there was a potential inter-cytokine correlation with other regulatory 
networks (Hornig et al. 2015). Conversely, a meta-analysis that reviewed 64 
cytokines including leptin relied on p-values to compare studies and found the use 
of cytokines as a biomarker was inconclusive; however, the review did not include 
studies on fibromyalgia (Corbitt et al. 2019). Another systematic review that 
reviewed inflammatory proteins in ME/CFS did not include leptin but did find some 
support to indicate an inflammatory component in CFS (Strawbridge et al. 2019).  
We did not find a systematic review that compared leptin in both ME/CFS and 
fibromyalgia as a combined group, but previous researchers have combined the two 
syndromes to investigate cytokines such as C-Reactive Protein, and others have 
hypothesised that it is a unified syndrome as there are few differences between them 
(Abbi & Natelson 2013; Groven, Fors & Reitan 2019). 
 
1.9  The Scope of the Current Literature on MECFS and Fibromyalgia 
 
Clinical researchers have taken a varied approach in tackling the etiology and risk 
factors of MECFS and fibromyalgia.  MECFS is classed as a neurological disease 
by the World Health Organisation and has been since 1969 (Maes et al. 2013).  The 
name itself holds controversy and has many synonyms, but the most consistent 
name appears to be a blend of Myalgic Encephalomyelitis and Chronic Fatigue 
Syndrome. The names used are diverse for example ‘Systemic Exercise Intolerance 
Disease’ (SEID) which was suggested by the Institute of Medicine in 2015 (Clayton 
2015; IOM 2015; Twisk 2016a).  Neurasthenia (or nerve weakness) is thought to be 
an early conceptualisation of MECFS, a condition described by an American 
physician George Beard as early as 1869 (Bynum 2003).  
The name SEID remains controversial with much of the scientific community and 
consumers seemingly not accepting the label, and it appears to be used more as 





another synonym for MECFS, but we have not seen its wholehearted adoption in 
the literature or the community (Jason & Johnson 2020).  A similar reaction occurred 
around the time of moving from the term ‘Myalgic Encephalomyelitis’ to using the 
term ‘Chronic Fatigue Syndrome’ (Prins, van der Meer & Bleijenberg 2006).  To add 
further confusion, there is also the London Criterion for ME which has been shown 
to be more stringent than the International Consensus Criterion as ME requires a 
higher frequency of some symptoms (Sunnquist et al. 2017).  Many practitioners 
even question whether ME or CFS exists and ME seems to have been born as a 
UK-centric concept but is now widely accepted (Mouterde 2001; van Houdenhove 
2001).   Debate following the introduction of the term CFS caused great ire, so now 
both terms are used and are often referred to in the literature as “CFS/ME”, 
“ME/CFS” or MECFS (Clark et al. 2002).  At a similar time, controversy around 
treatment approaches also occurred involving treatments like Graded Exercise 
Therapy, Cognitive Behaviour Therapy and pacing, widely known as ‘The Pace 
Trial’ (White, Goldsmith, Johnson, Potts, et al. 2011; White, Goldsmith, Johnson, 
Walwyn, et al. 2011).  This was a randomised controlled trial that indicated a 
combination of graded exercise and Cognitive Behaviour Therapy provide beneficial 
outcomes, but consumers were left feeling that they were being told that they should 
just ‘do more exercise’, and everything will be fine.  This made them feel even further 
disenfranchised and distressed. 
Fibromyalgia only has one name, but historically has had other potential candidates 
like ‘fibrosis of the musculature’, ‘muscular rheumatism’ and ‘Syndrome of Myalgic 
Encephalomyelopathy’ (Hartrick 2008; Leonhardt 2000; Mehendale & Goldman 
2002).  One author has described and tabled some of the similarities of fibromyalgia 
and ME symptoms due to the similarity in nature of the syndromes sharing 
myelopathic, myopathic, encephalopathic, and neuropathic symptoms (Mehendale 
& Goldman 2002).   The term ‘fibromyalgia’ is well recognised in the community and 
is considered to be a rheumatic condition and treatment is centred in the field of 
rheumatology, but even this diagnosis comes with its own controversies such as 
suggestions of misdiagnosis and the way people are treated is thought to be affected 
by cultural and social forces (Natelson 2019; Wolfe, F. et al. 2019).   





There are many similarities and shared symptoms between MECFS and 
fibromyalgia particularly with the neurological issues of fatigue, the ‘Fibro fog’ or 
‘brain fog’, and pain sensitivities to name but a few (Farhad & Oaklander 2018).  
MECFS is often comorbid with Fibromyalgia, one study indicating around 60% 
(n=30) of 48 MECFS patients, and this combination of symptoms usually leads to a 
picture of more severe outcomes of pain and increased fatigue in this group which 
can result in a condition known as kinesiophobia (fear of movement to avoid pain) 
(Meeus et al. 2016).     
Both MECFS and fibromyalgia have been the focus of previous systematic reviews 
that have examined the role of cytokines, but none of these have reviewed the role 
of adipokines (Strawbridge et al. 2019; Uçeyler, Häuser & Sommer 2011).  The 
author is unaware of any systematic review that has examined the role of leptin and 
its association with both MECFS and fibromyalgia combined.  There is a study on 
leptin and ankylosing spondylitis (fusing of small bones in the spine) which provides 
a similar approach for this type of systematic review, that is it compares the evidence 
using the difference of leptin levels between patients with ankylosing spondylitis and 
healthy controls. (Mei et al. 2016).  It is worthy of note that none of the articles 
identified in the full text review of the Mei (2016) analysis have been found in the 
systematic search in this study, that emphasises that they are unrelated areas of 
disease.  The result of that review found 8 studies which were used in a meta-
analysis that showed no significant difference between cases and controls. 
Circulating leptin plays a major role in the homeostasis of adipose tissues within the 
human body, but it also influences several other systems including the brain, 
immune system, and insulin balance (Friedman & Halaas 1998).  It has been 
investigated for its role in many diseases and the evidence about its effects on the 
body continue to emerge, such as leptin’s role in energy expenditure or osteo-
arthritis (Bi, Loo & Henry 2019; Kelesidis et al. 2010; Yan et al. 2018).  Several 
research studies have reported the association of leptin and MECFS, but they vary 
in their outcomes, creating confusion for the medical community (Cleare, O'Keane 
& Miell 2001; Stringer et al. 2013).  Similarly, several research studies with 
fibromyalgia report both hyperleptinaemia (high leptin) and yet other studies the 





opposing results were found suggesting hypoleptinaemia (low leptin) in participants 
with Fibromyalgia (Homann et al. 2014; Olama, Elsaid & El-Arman 2013).    
These studies use similar methods in defining protocols and scientific analysis, for 
example they use blood samples to detect the circulating leptin levels using enzyme 
linked immunosorbent assays, providing a quantitative measure through 
spectrophotometry (Aydin 2015), yet there are many nuances between these 
studies. A simple example is the time of day that the samples were taken, and 
another is that they use different sample ‘fluid types’ including serum, plasma, and 
CSF.  One of the leading authors in this field, Keiji Fukuda, expressed the need to 
investigate these syndromes systematically to avoid the problems of heterogeneity 
due to its overlapping symptoms with other disorders such as depression and 
fibromyalgia (Fukuda et al. 1994).   The difference in practice and methodologies 
are explored further and discussed in more detail later in section 1.11.   
1.10 Relationship Between Existing Literature and the Proposed Review 
 
There are a number of papers inferring a strong link of symptom severity and leptin, 
starting with Cleare, O'Keane and Miell (2001), who reported an association with 
hypocortisolism and circulating leptin, which they investigated using a placebo-
controlled crossover study between cases and matched controls.  They found no 
basic differences between cases and controls but did notice that there were changes 
in leptin levels in response to injections of hydrocortisone, suggesting that this 
response may provide an avenue for further investigation.  This was followed by 
another significant study from Stringer et al. (2013) who took the novel approach of 
taking a sample from individuals every day for 25 days, rather than a one off sample.  
The outcome of their study was that they reported leptin as a potential driver of 
cytokine changes associated with outcome severity.  They use the data to show that 
self-reported fatigue severity was significantly correlated with leptin levels.  They 
associated the results using a machine learning algorithm to determine the outcome 
that symptom severity could be predicted by circulating leptin levels.  One of the 
problems with this study is that at no time in the paper do they provide actual raw 
circulating leptin results, only correlations and diagrams of their association. There 





is limited information about the algorithm used to calculate these outcomes.  This 
paper is cited in almost every subsequent MECFS study and according to SCOPUS 
(searched on 16/11/2020) it has been cited 54 times (37 of those in the last 5 years) 
and has a journal citation impact factor of 2.18.  The corresponding author was 
contacted by email to see if they could provide any raw leptin results to support their 
study outcome (Younger, J.W.; Department of Anaesthesiology, Stanford 
University, School of Medicine, United States; email: jyounger@stanford.edu), 
however no response has yet been received.  A follow up email was attempted to a 
more contemporary email address but without response (younger@uab.edu).  The 
landmark study was performed 8 years ago.   
A later study by Montoya et al. (2017) indicated that MECFS symptom severity had 
an upward linear trend in association to 17 cytokines, one of which was leptin.  This 
was another example of a project from the team at Stanford University School of 
Medicine, and again in this study, the authors only provide correlations to these 
cytokines with no actual raw circulating leptin levels; i.e., plasma levels in 
nanograms per millilitres (ng/mL) are not stated.  An online link to a supplementary 
index is provided within the article, but this only has a list of spearman correlations 
and significance values (p).  The Montoya paper, according to SCOPUS, is also 
highly cited with 102 citations (all within the last 5 years - searched on 16/11/2020).  
The corresponding author was contacted with no reply (Email: 
mmdavis@stanford.edu.).   
Several other more transparent studies do provide the baseline levels of circulating 
leptin and standard deviations between cases and controls which enabled this meta-
analysis to be completed.  There are only minimal MECFS papers available to 
review and compare these types of results (4 studies in MECFS), but auspiciously 
similar studies have been completed in the area of fibromyalgia (8 studies).  The 
combination of results (12 studies) of these two syndromes provides a more 
comprehensive picture and more thorough meta-analysis. The symptoms of these 
two syndromes, MECFS and fibromyalgia have been considered by some authors 
to be aligned, but no meta-analysis results have been published combining them in 
this way. There are some published articles identifying that symptoms across the 





two syndromes are so similar to the point whereby a diagnosis of either syndrome 
may be made by a practitioner, inferring that doctors may be misdiagnosing patients 
(Abbi & Natelson 2013; Natelson 2019).  It is not surprising as it has been reported 
that up to 75% of patients with MECFS also have comorbid fibromyalgia 
(McManimen & Jason 2017).   
There are many examples of studies that combine the two disorders to assess other 
biological outcomes, but not using leptin as their focus (Alameda Cuesta et al. 2019; 
Almenar-Perez et al. 2019; Amel Kashipaz et al. 2003).  Therefore, it is appropriate 
to examine the role of inflammatory biomarkers such as leptin across these two 
syndromes. 
 
1.11  Measuring Human Leptin and Issues of Heterogeneity 
 
The overarching aim of this study was to examine whether there is a difference in 
leptin levels in people experiencing MECFS and/or fibromyalgia compared to a 
control group of healthy individuals.  Before we can answer this question, we need 
to look at how the units of circulating leptin are measured and what is the current 
evidence.  This question presents issues with multiple confounding factors because 
people’s leptin levels may differ for many reasons and they interact with other bodily 
systems (see Figure 2).  There are limited studies across ethnicity and culture that 
have measured leptin but one study of 1,176 subjects demonstrated there was a 
difference between baseline fasting levels of circulating leptin measured in ng/mL 
between European n=312 (9.21 + 0.85, mean + Standard Error of the Mean [SEM]), 
Chinese n=303 (8.25 SEM 0.77), South Asian n=317 (11.82 SEM 0.94), and 
Canadian Aboriginals n=244 (11.13 SEM 1.21) and in each ethnicity women had 3 
times higher mean leptin than men e.g., European women 13.6 - SEM 1.36 
compared to men 5.93 - SEM 0.86 (Mente et al. 2010).  Therefore, gender is another 
major confounder, but this has been handled by most of the included studies by 
excluding men (7 out of 12) or by including fewer men than women, but this is 





inconsistent across articles and across cases (20/32 females) vs controls (18/32) 
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Figure 2 Conceptual Model of Leptin and MECFS and/or Fibromyalgia    





The ethnicity study used a specific laboratory technique to measure the levels of 
leptin in serum called an ‘Enzyme Linked Immunosorbent Assay’ (or the commonly 
abbreviated acronym ELISA) which comprises a process of using antibodies and 
antigens to support the detection of leptin levels.  Caution is required, however, as 
some studies have used an older system called radioimmunoassay which may have 
a more sensitive detection level and therefore provide a different magnitude of 
results (Kimura, E et al. 2000).  Lastly there are the multiplex type assays which 
combine the analysis of many cytokines on one laboratory plate, making the process 
very efficient, but not as accurate.  These multiplex systems examine between 51 
and 72 analytes all at once, but these are thought to provide different results than 
an individual cytokine/adipokine analysis, potentially being less sensitive, when 
compared to the other methods (de Koning et al. 2012).  It begs the question of 
whether we can make comparison across such studies. 
People who are diagnosed with MECFS and/or Fibromyalgia  experience many 
investigative tests, looking for answers and often receive hundreds of tests to 
investigate their symptoms (Park, JP 2012).  This leads to thoughts of not knowing 
what is wrong with their body. Their experience makes them wonder if they will ever 
get to the bottom of what is causing their sickness, fatigue, pain and a myriad of 
other symptoms such as post exertional malaise (ibid.). 
With so many potential differences in results between studies because of the 
specific methods and laboratory techniques that have been used, results may also 
be affected by the skills of the laboratory personnel.  Laboratory skills include the 
ability to measure samples accurately using pipettes, micropipettes or by machines 
using an automated process to provide precise, replicable volumes. An example is 
the JANUS Automated Workstation (produced by Perkin Elmer) which provides 
precise dilutions and reduces the potential for human error (Enten et al. 2016).   
Many hours are required (up to one whole working day (8 hrs) to work through the 
ELISA process, and includes around 25 process steps or actions (a clear detailed 
description of these processes is provided below – See Figure 3), but one of the 
most frequent and important steps is washing the plates between solutions and this 
can be done in a uniform way by machines or more haphazardly by hand (Chiswick 





et al. 2012).  These minutiae but important details are not provided in any of the 
papers investigated in this systematic review, and the practicality of research 
laboratories using the same techniques, the same antibody solutions, and the same 
methods of measurement are unlikely to eventuate unless an international standard 
is outlined.  However, if the heterogeneity of results is to be reduced, we must work 
toward this type of consistency wherever possible.  
 
A Typical Laboratory Practice Protocol – Adapted from (Chiswick et al. 2012) 
 
1. The ELISA plates must first be printed with the capture antibody specific for the 
cytokines of interest. The printing process is specific to the printer used, and the 
manufacturer’s recommendations should be followed – example follows. 
2. Incubate the printed plates overnight at 4°C. 
3. Block the plate with 150 µL/well of blocking buffer for 1 h. 
4. Standard cocktail preparation: Using dilution buffer, mix each recombinant 
cytokine / adipokine of interest into a heterogeneous cocktail. A 16-point standard 
curve (including the blank) that begins at 50,000 pg/mL/cytokine followed by twofold 
serial dilutions are enough (i.e.: dilutions of 1×, 2×, 4×, n×., 16,384×, or, 50,000–
3.05 pg/mL).  This may differ according the analyte being measured. 
5. Incubate standards, samples, and the detection AB cocktail as with the standard 
ELISA procedure. For the sake of simplicity, dilute all detection ABs into the cocktail 
at the same concentration. 
6. After the detection cocktail incubation is complete, wash the plate and add the 
streptavidin dye conjugate diluted in dilution buffer, 50 µL/well, and incubate for 30 
min in the dark. 
7. Wash the plate and dry thoroughly by spinning upside down in a centrifuge.  
Alternatively use a paper towel and tap gently on against a hard surface. 





8. Inspect surface of plate for fingerprints or other optical obstructions. If necessary, 
clean the bottom of the plate and then place into the scanner. 
9. Scan and analyse as suggested by the specific system used. 
10. See Figure 3 for technical sequence – note this is just an example: 
 
 
Figure 3 ELISA Protocol Adapted from (Chiswick et al. 2012) 
 
The laboratory methodology above is just one example of the potential differences 
in technique that can affect the way results are reported and it could be argued that 
individual results can only be compared within a study or laboratory and not between 
studies. If everyone were to follow the same exact protocol or at least provide 
information of what steps were taken in the analysis and use the same equipment, 
this may enable cross laboratory comparison and reduce heterogeneity in results. 





Other potential anomalies which focus on the individuality of the person being 
investigated, highlight many differences that can explain the increased 
heterogeneity.  One of the most basic differences in people is body mass index 
(BMI) which is used to calculate the level of fat mass when comparing people as 
part of a general population.  We now use well known internationally recognised BMI 
subgroups to explain this aspect of heterogeneity.  Under 18.5 BMI (kg/m2) is 
considered to be underweight, between BMI 18.5 and 24.99 is considered to be the 
normal weight range, BMI 25 to 29.99 being overweight and BMI 30 to 34.99 being 
obese class 1 and between BMI 35 to 39.99 is class 2 (severe obesity) and over 
BMI 40 is class 3 (morbid obesity), and the most extreme is referred to as ‘severe 
morbid obesity’ at over BMI 50 (Abdelaal, le Roux & Docherty 2017; AIHW 2017). 
(See Figure 4) 
  
 
Figure 4 Obesity Scale adapted from the Australian Institute of Health and 
Welfare (AIHW 2017) 
 
The research on leptin has consistently reported that BMI is positively correlated 
with leptin levels, because the more body fat you have the greater the potential 
quantity of leptin those cells are able to produce. The lower the fat mass the lower 
level of leptin produced (Friedman 2011).  Measuring the fat content in your body 
using BMI, which only requires simple tools like a stadiometer and clinical weighing 
scales, serves only as an approximation of adiposity.  There is a procedure known 
as Dual Energy X-RAY Absorptiometry (DEXA or DXA), which uses two beams of 
x-rays at different frequencies (high and low) to highlight the difference between 
tissues such as bone, muscle and fat (El Maghraoui & Roux 2008; Kuriyan 2018). 
More accurate studies use this technique rather than just relying on the 





approximation using BMI.  BMI is weight divided by the square of height 
(BMI=weight/height2). 
People also differ in their lifestyles including diet, sleep patterns, and activity, all of 
which affect circulating leptin levels, hormones, and immune responses (Nieman & 
Pence 2020).  Many of the articles identified in the twelve case control studies refer 
to a ‘fasting period’ prior to the sample being taken, but also provide a ‘time window’ 
of when the sample was taken e.g., between 9 am and 10 am, but not all studies 
provided these details.  These factors are important because leptin is known to have 
a circadian pulsatile like pattern across a 24-h period, being lowest in the morning, 
which is the bodies way to signal the need for activity and food seeking, and leptin 
levels are highest at night which encourages reduced activity, reduced food intake 
and the need for sleep (Licinio et al. 1997; Licinio, Negrao & Wong 2014).  In other 
words, it provides biological cues of when to get up and be active and when to sleep.   
Some studies take samples across different days, but this can be problematic as it 
has been shown that with healthy subjects the inter-day difference can vary from 
10.9% and up to 22.5% (Ma et al. 1996).  To counter these pulsatile changes and 
potential inaccuracy Licinio et al. (1997) estimated that samples are required to be 
taken every 7 min across a 24-h period.  
Other examples that can cause confounding between studies include additional 
sample processing issues such as how long samples have been stored in 
refrigerators before analysis, at what temperature they were stored (-20 or -80 °C), 
and how quickly they were frozen or even defrosted (Mitchell et al. 2005).  These 
issues have been highlighted in the media with concerns over the integrity of Covid 
19 Virus Vaccines that have to be stored at -80 °C degrees.  There is also the 
problem of the type of body fluid used.  If serum is used, then a period of 30 min at 
room temperature is required prior to the sample being centrifuged, but the exact 
time is rarely reported (Rai et al. 2005).   
It is important to provide standardised details of all these timings of sample 
processing such as the time of day that the sample was taken, the amount of time it 
took to store and freeze samples and other processing factors that may create 
anomalies (Mischak et al. 2007). It has been shown that even minutiae detail like 





the centrifugal force and length of spin can affect the outcome of results and so it is 
recommended that the standard of <=1300 g for 10 min should be used for both 
plasma and serum to ensure consistent results between studies (Rai et al. 2005).  
In the articles examined in this review some samples have been frozen at -20 °C 
and some at -80 °C, but most papers have not indicated how long the samples were 
stored prior to thawing for analysis and this may affect results and another concern 
about the ability to compare across studies (Grizzle et al. 2005).  Frozen samples 
may be stored for many years and just like a good wine they can go off (become 
less representative) during storage. A length of storage prior to analysis should be 
declared.   
It can also make a difference in how much the samples are diluted with buffers prior 
to using either an ELISA kit or radioimmunoassay kit which can create inaccuracy 
such as background noise, false positive reactions, and negative results (Waritani 
et al. 2017).  Then there is the type of ELISA kit, microplates, and processing fluids 
used as there are a number of commercial varieties available (Trask 2018).   Very 
few studies provide the detail about the microplate reader or software that was used, 
and few have described the logarithmic calculations used to convert the raw reading 
result to the final actual ng/mL outcome.  These conversions are usually completed 
by software built into the microplate reader or by using an online conversion 
program.   
Many of these laboratory components are described in the NIH (National Institute of 
Health)’s ‘The Assay Guidance Manual’ which explains the differences in some of 
these equipment and methods (Jones, Michael & Sittampalam 2004).  This 
systematic review has only examined the difference in baseline leptin, but clearly 
the handling of samples and type of samples can cause changes in the results and 
outcomes of research studies that attempt to explore changes in leptin over time 
and against environmental variables like smoking, exercise and diet.  A systematic 
review will rarely inter-study to these anomalies.    
We have not yet considered the heterogeneity within the cohort with reference to 
the diagnosis of each syndrome MECFS and/or fibromyalgia.  We earlier discussed 
the differences in these syndromes, but the diagnosis of either of them relies on self-





reported symptoms and not on biological biomarkers or objective physical 
measures.  This alone creates problems with diagnosis and results in a commonly 
reported level of heterogeneity (Lane et al. 1998; Sullivan et al. 2005; Williams et al. 
2017; Wright 1992). 
 
1.12  Heterogeneity 
 
Heterogeneity can be defined as: 
“The extent to which observed effect sizes differ from one another. In meta-
analysis, statistical tests allow for the assessment of whether the variability 
in observed effect size is greater than would be expected given chance (that 
is, sampling error alone).” (Cooper, Hedges & Valentine 2009) p.576 
It should be noted that there are many explanations for the cause of heterogeneity, 
this includes clinical, methodological and statistical heterogeneity.  The 
heterogeneity of a meta-analysis is often expressed using I2 and this is the 
“proportion of total variation in study estimates that is due to heterogeneity” 
calculated by a transformation of H (square root of 2 divided by the degrees of 
freedom) (Higgins & Thompson 2002).  This is obtained through a series of 
statistical calculations that require Cochran’s homogeneity ‘Q statistic’ which is a 
calculation of weight squared deviations, T2 a measure of the between studies 
variance squared, T is the between study standard variation, and I2 which is “the 
ratio of true heterogeneity to total observed variation” (Bornstein et al. 2009) p105. 
Heterogeneity within prognostic studies should be expected because they are 
generally exploratory in nature so there is no set format unlike other typical 
systematic reviews that examine the differences in a common treatment effect, 
frequently using randomised controlled trials (Riley et al. 2019).  It is suggested by 
these authors that a random effects model is invariably used with prognostic types 
of meta-analysis as the research methods used often differ significantly.  When 
using a random effects model it is common to provide an across study variation 





statistic Tau2 which is an estimate of the standard deviation between studies of the 
underlying effect across those studies, squared (Biggerstaff & Tweedie 1997; 
Higgins JPT et al. 2020). 
One of the difficulties in studying syndromes like MECFS and/or fibromyalgia is that 
a diagnosis is made on self-reported symptoms and an assumption that these 
symptoms equate to an identifiable illness but there are opposing reports of 
overdiagnosis and underdiagnosis of both syndromes (Fitzcharles & Esdaile 1997; 
Hauser, Sarzi-Puttini & Fitzcharles 2019; Son 2019; Wolfe, F. et al. 2019).  Even 
more disconcerting is that some general practitioners find the illness contentious 
and for some patients an inappropriate diagnosis is made.  It is not uncommon that 
patients are mistakenly given a diagnosis of MECFS when the person actually has 
fibromyalgia, or vice versa (Bayliss et al. 2016; Natelson 2019).  Fatigue as a 
singular symptom is very common, with over 24% of the general population 
reporting at least 2 weeks of fatigue and with two thirds of those having no 
identifiable medical cause (Fukuda et al. 1994).   
In this systematic review we have combined both disorders MECFS and 
fibromyalgia, investigating them as similar inflammatory based entities that have 
similar pathological effects on the neuroimmune system, and it is worthy of 
acknowledgement that fibromyalgia is a common and comorbid symptom of MECFS 
(Bjorklund et al. 2020; Kristiansen et al. 2019). These syndromes are both chronic 
autoimmune diseases that cause unexplained pain, fatigue, psychological changes 
and significant changes in biology creating potential opportunities to identify 
diagnostic biomarkers (Giacomelli et al. 2019; Hornig et al. 2017).  As described in 
the previous section, not only is there heterogeneity in the diagnostic population, but 
also in sub populations, and in the methodologies used to investigate group 
differences  (Williams et al. 2017). 
  





1.13  Biomarkers 
 
Biomarkers, short for biological markers, are the medical signatures produced by 
the body that enable us to detect disease and also assist in reporting the 
effectiveness of treatments (Strimbu & Tavel 2010).  The NIH is one lead American 
agency that provides guidance and standards in the form of a handbook for the 
exploration of biomarkers and their assessment (Auld et al. 2004; Jones, Michael & 
Sittampalam 2004).  The NIH provides advice and information describing the latest 
research about biomarkers, exposure science, and exposomics which are available 
online from a sub-branch of the NIH called the National Institute of Environmental 
Health Sciences (NIEHS 2020). 
The area of MECFS and fibromyalgia as previously explained is already plagued 
with the problem of heterogeneity within the sample population, making it imperative 
that the science provides solid foundations for researching this field by making 
inroads to reduce the differences in study design and methodology.  MECFS and 
fibromyalgia are not the only topic areas that suffer from these disparities and there 
are international efforts to coordinate systematic investigation into biomarkers and 
blood based analytes (Chiswick et al. 2012; Mitchell et al. 2005).   
 
1.14 Assumptions and Limitations 
 
Assumptions 
The author of this review assumed that we can combine the results of studies that 
examined circulating leptin levels in both MECFS and fibromyalgia as if it were one 
syndrome.  It is also assumed that healthy humans (controls) would have similar 
mean levels of circulating leptin to enable comparison.  There are limited studies 
that have provided such baseline leptin levels for MECFS participants, with only 8 
of the 24 studies selected reporting baseline leptin levels, and just 4 of these were 
case-control studies.  There were 15 of the 24 studies on fibromyalgia with baseline 





leptin results, but only 8 of these could be used as case-control studies because the 
others did not provide a control arm.  The remaining studies provided a cumulative 
group of 12 case-control studies for the meta-analysis.  One of the full text studies 
Kurajoh et al. (2016) only referred to fatigue and didn’t refer to MECFS or 
fibromyalgia other than in a reference.  In summary, after separating out the case 
control studies from the cohort type studies, this resulted in only 12 studies being 
used in the meta-analysis (4 MECFS, and 8 fibromyalgia combined) (See Chapter 
3 for the full meta-analysis).  There were 9 remaining studies in those with a cohort 
design (1 MECFS, and 8 fibromyalgia) which could not be combined, so their 
results are tabled individually with a brief narrative reflection on each study.  (See 




There are no currently accepted objective diagnostic biomarkers for MECFS nor 
fibromyalgia and so if there were a significant difference between cases and controls 
then this would only create a starting point for future investigative research.  That is, 
it would support the assumption that inflammatory mechanisms are at play, and that 
leptin is a worthy biomarker for further investigation.  Leptin has varying known 
effects on other cytokines networks, adipokines, and immune cells, which are 
reported elsewhere in this thesis. Leptin’s influence may therefore have far reaching 
consequences as a biological mediator in both MECFS and fibromyalgia syndromes 
that are of interest and are a logical place to start biomarker investigation (Ataoglu 
et al. 2018; Montoya et al. 2017).  The heterogeneity issues have been described in 
detail in the previous section and will be further highlighted in the final discussion.  
Many confounders have not been managed with the same detail or consistency 
across the studies examined and these factors may have consequences for the 
accuracy and outcome of this meta-analysis.  
1.15  Definitions of Terms and the Controversy of Syndrome Names 
 





The condition of Fibromyalgia does not have any other confusing terms and it is a 
syndrome that was described in the International Classification of Diseases (ICD) 
10 in 1994, but remains controversial to the point that strong debate about the 
diagnostic legitimacy have been called the ‘Fibro wars’ (Hauser & Fitzcharles 
2018). Not so straight forward, MECFS has had many names across the years and 
the table below (Table 4) is a list of some of them were presented in the literature. 
These labels were used as part of the search criterion and are comprehensively and 
astutely described with a pictorial timeline of their historical relevance by Sharif et 
al. (2018) (see Figure 5 displaying historical timeline).   
The term MECFS is often used in the form “ME/CFS” or even vice versa “CFS/ME”.  
There have been some derogatory, pejorative and stigmatising labels used to 
describe MECFS such as ‘Yuppie Flu’, or ‘Bored Housewife Syndrome’, 
exemplifying some of the difficulties associated with this diagnosis (Loblay 1995).  
People diagnosed with either MECFS and/or fibromyalgia have been the targets of 
stigma from a clinical, social, and even familial perspective (McManimen et al. 2018; 
Stahl 2001).  
Although we know little about the cause of MECFS or fibromyalgia syndromes, they 
are potentially an infectious viral disease.  There have been many large outbreaks 
in a number of countries across the world which have been well documented over 
the last century (Underhill 2015), and are not unlike the random outbreaks of SARS 
or COVID 19 (Islam, Cotler & Jason 2020).  The ICD version 11 uses the term Post 
Viral Fatigue in section 8E49 to describe MECFS, and lists ‘benign 
Encephalomyelitis and Chronic Fatigue Syndrome’ as two subheadings. The ICD is 
regularly updated and the previous version ICD version 10  used the reference 
G93.3 (WHO 2018).  The author has published an article during the course of this 
thesis published by the ABC News Australia explaining the history of Post Viral 
Fatigue “What is post-viral fatigue syndrome, the condition affecting some COVID-
19 survivors?” (Musker 2020). 
  





Table 4 Terms used for MECFS across time 
Names Explanation of the Term 
Myalgic 
Encephalomyelitis 
A term suggested in a letter to the editor  of the Lancet in 
1956 by Dene E Hicks of Brighton South Australia as 
benign myalgic encephalomyelitis (Hicks 1956) It is unclear 
if the author of the letter created the name or that it had 
already been identified as part of the 1955 outbreak in the 
Royal Free Hospital in London (Blattner 1956).   
Febricula Cases described as early as 1734 (Sharif et al. 2018). 
Usually, a transient fever but has been found to occur with 
CFS (Numata et al. 2020). 
Atypical 
Poliomyelitis 
An outbreak in 1934 in Los Angeles Country General 
Hospital (Sharif et al. 2018). Cases described in the Lancet 
in 1952 by Gordon Ward (Ward 1953). 
Akureyri or Icelandic 
Disease 
1948-1949 an epidemic involving 465 eases 
occurred in Akureyri, in northern Iceland (Blattner 1956). 
Neurocirculatory 
Asthenia 
A chronic condition of fatigue notices in soldiers following 
wartime campaigns (Paul 1987). 
Royal Free An outbreak that affected 292 medical and admin staff. The 





POTS – as this is a key symptom of MECFS it was used to 
expand the search. (Dahan, Tomljenovic & Shoenfeld 
2016). 







Epstein Barr is a common virus that can go on to have 




A decision by the institute of medicine committee to replace 
MECFS with SEID (Twisk 2015). 
Post Viral Fatigue The name used by the International Classification of 
Diseases G93.3 ICD 10. 
Tapanui Flu An epidemic of 28 cases in West Otago New Zealand that 





• 1750 Febricula 
• 1879 Neurocirculatory asthenia 
• 1937 Atypical poliomyelitis 
• 1948 Akureyri disease 
• 1955 Royal Free disease 
• 1956 Myalgic encephalomyelitis 
• 1984 Tapanui outbreak 
• 1987 Chronic Fatigue Syndrome 
• 2015 Systemic Exertion Intolerance Disease 
 
Figure 5 Illustrative Timeline adapted from Sharif et al. (2018)  
  





The first stage of the literature search had to deal with the juxtaposition of numerous 
names / terms that have been used to describe MECFS.  Using the MECFS term 
alone is controversial as there are some groups that believe that Myalgic 
Encephalomyelitis and Chronic Fatigue Syndrome are different illnesses that have 
now been grouped together, so in its written form it is often separated by a forward 
oblique ‘Myalgic Encephalomyelitis / Chronic Fatigue Syndrome’ or even written in 
the reverse order.  Fortunately, some of these name issues have been dealt with by 
previous authors and the ‘Medical Subject Heading (MeSH) term ‘Fatigue 
Syndrome, Chronic’ which was introduced in 1990, provides some clarity (NCBI 
2020; Twisk 2016a).  The NCBI has updated the term to include the majority of 
regularly used synonyms.  These accumulating synonyms that are provided by the 
MeSH database are listed below, showing the complexity of the search and it is 
comprehensive: 
 
List of current MeSH Entry Terms: 
 
• Myalgic Encephalomyelitis 
• Encephalomyelitis, Myalgic 
• Chronic Fatigue Syndrome 
• Chronic Fatigue Syndromes 
• Fatigue Syndromes, Chronic 
• Chronic Fatigue-Fibromyalgia Syndrome 
• Chronic Fatigue Fibromyalgia Syndrome 
• Chronic Fatigue-Fibromyalgia Syndromes 
• Fatigue-Fibromyalgia Syndrome, Chronic 
• Fatigue-Fibromyalgia Syndromes, Chronic 
• Postviral Fatigue Syndrome 





• Postviral Fatigue Syndromes 
• Infectious Mononucleosis-Like Syndrome, Chronic 
• Infectious Mononucleosis Like Syndrome, Chronic 
• Royal Free Disease 
• Chronic Fatigue and Immune Dysfunction Syndrome 
• Chronic Fatigue Disorder 
• Chronic Fatigue Disorders 
• Fatigue Disorder, Chronic 
• Fatigue Disorders, Chronic 
• Systemic Exertion Intolerance Disease 
• Fatigue Syndrome, Postviral 
• Fatigue Syndromes, Postviral 
Adapted from NCBI 2020 MeSH Library (NCBI 2020) 
 
The MeSH term covers most of the commonly used names in the literature, but 
working with the librarian, a more extensive search was completed using many 
additional terms, such as obscure terms like ‘Akureyri disease’ named after a 
mystery disease outbreak in New Zealand.  Similar outbreaks occurred in a number 
of other places across the world over the last century, each of them adding  to the 
name list, one of the largest outbreaks being at the Royal Free Hospital in London 
on 13th July 1955 (Geffen 1957) with over 200 hospital personnel and patients 
presenting with strange symptoms. Hence the term ‘Royal Free Disease’, another 
synonym for MECFS.  Adding such diverse ‘fatigue’ focused outbreaks and labels 
for MECFS is a good example of how heterogeneity, inconsistency and imprecision 
is supported by this ongoing labelling issue. 
To avoid such indiscriminate application of these labels, researchers should 
consistently be using the International Consensus Criterion, which provides clear 





symptom descriptors of symptoms that are experienced by consumers, and should 
help to avoid further ambiguity (Carruthers et al. 2011).  This trend has been adopted 
by the most recent research as the baseline criteria for assessing patients as cases.  
It is unfortunate that the latest recommended label ‘Systemic Exertion Intolerance 
Disease / Chronic Fatigue Syndrome’, has not been fully accepted or used as a term 
in the literature. Most recent articles use MECFS in some form or other and the new 
term has many challengers (Twisk 2016b). So, the naming convention controversy 
continues and is unlikely to be settled any time soon.  We explore this further in 
chapter 3 where we provide more detail about how the search was completed. 
  


















2.1 Review Question 
 
Question: Is there a difference in circulating leptin levels in MECFS and/or 
fibromyalgia that can be used as an outcome measure in cases and controls? 
(Leptin is measured in ng/mL and is assessed through the analysis of blood plasma, 




To gather the evidence of scientific studies that have examined the levels of the 
adipokine leptin in the circulatory system of the body in two syndromes MECFS and 
fibromyalgia.  Then to compare the results between studies, and to complete a meta-
analysis of the results to see if there are any differences of the baseline level of 
circulating leptin in a comparison of cases and controls. 
 
2.3 Criteria for Considering Studies 
 
The aim of this review was to cast a wide net and capture the current available 
evidence about leptin in MECFS and/or fibromyalgia.  The following section will 
provide in detail the decisions of inclusion and exclusion. 
  





2.4 Types of Studies 
 
This review considered observational studies of varying study designs including 
prospective and retrospective cohort studies, case-control studies, time-series and 
analytical cross-sectional studies that include both cases and healthy comparators. 
Following the search, all identified citations were collated and uploaded into 
EndNote v.X9 (Clarivate Analytics, PA, USA) and duplicates were removed. Titles 
and abstracts were independently screened by two reviewers for assessment 
against the inclusion criteria (MM & ML). This process was completed using 
COVIDENCE (Veritas Health Innovation, Melbourne, Australia) and a third reviewer 
was used to arbitrate discrepancies (AM). Potential, relevant studies were retrieved 
in full and their citation details imported into the JBI System for the Unified 
Management, Assessment and Review of Information (JBI SUMARI; JBI, Adelaide, 
Australia). The full text articles of selected citations were assessed in detail against 
the inclusion criteria by two independent reviewers (MM and ML). Reasons for 
exclusion of full text studies that do not meet the inclusion criteria were recorded 
and reported in this systematic review in the form of a summary table. (See Table 
5).  The exclusion reasons for the 85 excluded full text articles are recorded in 
COVIDENCE, and a complete list of reasons is provided in the appendix with a brief 
abstract about each study (See Appendix 1): 
 
Table 5 Summary of reasons for exclusion – 85 full text articles 
26 No results provided
20 No leptin results in paper
15 Wrong patient population
13 Leptin is not discussed in article
5 Another major disease
3 Foreign language
2 Wrong comparator or outcome
1 Sytematic review - exclude  





2.5 Types of Participants 
 
The review considers studies that include people of any age diagnosed with 
MECFS, and/or fibromyalgia. Reference to diagnostic criteria must be detailed; for 
example, diagnosis by a general practitioner, Fukuda definition, International 
Consensus Criterion, or other descriptions indicating the method of diagnosis 
(Carruthers et al. 2011; Fukuda et al. 1994). Attention to the diagnostic method for 
both MECFS and fibromyalgia is an important factor for heterogeneity. Where no 
reference or details are provided about diagnostic method, attempts were made to 
contact the authors where appropriate.  Other language terms for MECFS or 
fibromyalgia were included; for example, if it states that there is ‘‘chronic fatigue’’ 
that lasts for at least six months, then this warranted further investigation at the full 
text level.  There continues to be debate about which names to use for MECFS and 
getting a consensus remains controversial. 
 
2.6 Types of Interventions / Exposure of Interest 
 
The exposure is a diagnosis of MECFS and/or fibromyalgia. The diagnosis were 
described by operational criteria such as a diagnosis from a general practitioner or 
those described by the Fukuda definition, Canadian Consensus Criterion, or 
American College of Rheumatology (Carruthers et al. 2011; Wolfe, F. et al. 1990).  
The level of exposure was not addressed in this review, except to provide 
information about one cohort study which made references to ‘short’- and ‘long-term’ 
exposure.  The study used a 3-year anniversary cut off period for short-term and 
beyond this time period, exposure was considered long-term (Hornig et al. 2017).  
This same study also distinguished between typical and atypical exposure, dividing 
cases by the pattern of onset and the link to comorbid issues.  As part of the critical 
appraisal process, exposure was considered an all or nothing principle rather than 
a level of exposure.  That is, the person had MECFS or fibromyalgia, or they did not. 





2.7 Comparators / Context 
 
The comparator was healthy participants without other physical disorders, such as 
cancer or medical illness like hepatitis or rheumatoid arthritis, that would likely cause 
symptoms of pain and fatigue. Different methods of recruitment have been 
described, where some researchers recruited specifically for a specific study, but 
others made comparisons to another historical healthy cohort that had previously 
been studied, for example using results from a clinical biobank. 
 
2.8 Types of Outcome Measures 
 
The outcome is circulating leptin levels, and whether there is a difference between 
comparators and those with the condition / exposure. Included studies measured 
levels of plasma leptin or other methods of measuring leptin such as serum levels, 
or CSF levels. When comparing study outcomes, issues such as the way leptin was 
measured, the frequency of when samples were taken (hourly, daily or once only), 
and confounders such as BMI were considered. Where BMI is included in the article, 
these were recorded and compared across studies in both cases and controls. 
Leptin levels were used as a comparative outcome; however, the differences in 
study design proved difficult to compare across studies and resulted in a 
standardised mean difference being used. This was managed by focusing on the 
leptin levels being translated into ng/mL and discrepancies between study methods 
identified. An example included whether they measured serum, plasma, or CSF and 
whether there was an indication of when (specific time of day) the samples were 
taken.  The circulating leptin levels reported across studies appeared to be on 
different scales / magnitude, a further reason for the need to use a standardised 
mean difference.  The cohort studies all investigated unique conditions, groups and 
parameters, making them difficult to compare and resulted in them being reviewed 
individually or in pairs.  A narrative synthesis is provided for each study in chapter 
4.  





2.9 Review Methods 
 
The systematic review was reported based on the Preferred Reporting Items for 
Systematic Reviews and Meta-analysis (PRISMA) checklist and followed the JBI 
methodology for systematic reviews of etiology and risk (Moola, S et al. 2019). By 
including a broad, inclusive review approach assessing any difference of leptin 
between MECFS and/or fibromyalgia and controls, the results of this review may 
provide a springboard into the development of future research, treatments, 
diagnostic tests, or prognostic models for people with MECFS and/ or fibromyalgia.  
It will also provide a source for new and experienced researchers looking for 
information on the raw leptin results for participants with MECFS and/or 
fibromyalgia, assisting with analysis and preparing future research projects.  A 
series of recommendations is provided for future research in Chapter 5. 
 
2.10 Search Strategy 
 
The search strategy aims were to locate both published and unpublished studies. 
An initial limited search of Scopus (Elsevier), PubMed (NIH National Library of 
Medicine), and Embase (Elsevier) was undertaken to identify articles on the topic. 
The text words contained in the titles and abstracts of relevant articles, and the index 
terms used to describe the articles were used to develop a full search strategy for 
PubMed, Embase, Scopus, Science Direct (Elsevier), and PsycINFO (Ovid). The 
search strategy included all identified keywords and index terms, and the format was 
adapted for each included information source, including unpublished studies such 
as theses, conference abstracts, and government reports found using Google 
Scholar. The reference list of all articles selected for critical appraisal was screened 
for additional studies. Studies were not date limited but the human equivalent of 
leptin was not discovered until 1994, so naturally there are no studies available prior 
to this date (Zhang et al. 1994). Only studies published in English were included due 
to limited resources for translation. 





2.11 Assessment of Methodological Quality / Critical Appraisal 
 
Eligible studies were critically appraised by two independent reviewers at the study 
level for methodological quality in the review. The quality assessment used the 
relevant study type assessment tool identified by JBI, including the JBI Critical 
Appraisal Checklist for cohort studies, case-control studies, case series, case 
reports, and cross-sectional studies, where these studies were identified for 
inclusion (Moola, S et al. 2019). Any disagreements that arose were resolved 
through discussion, or with a third reviewer. All studies, irrespective of 
methodological quality, were included in the review, except those that do not provide 
leptin as an outcome measure.  A table is provided for the two critical appraisal 
checklists, one for case control studies (See Table 11 in Chapter 3, page 85) and 
one for cohort studies (See Table 27 in Chapter 4, page 135). 
 
2.12 Date Extraction 
 
The data extracted included specific details about the outcome of interest 
(circulating leptin levels), plus other information like populations, study methods and 
outcomes or dependent variables of significance to the review question and specific 
objectives (Munn, Z., Tufanaru & Aromataris 2014). The extraction tool 'The Joanna 
Briggs Institute Critical Appraisal tools for use in JBI Systematic Reviews Checklist 
for Case Control Studies' was used (Moola, S et al. 2019).  Demographics and 
participant type were extracted such as sex, age group, BMI and any context 
provided in the study for example how the participants were selected, and whether 
participants were fasted, or if measures were continuous or completed over a 
number of days, or months in a time series.  Corresponding authors of papers were 
contacted to request missing or additional data where this was required, but only a 
few of them returned emails.  Those that kindly responded with comments or original 
data were (see next page):  





• Dr Samy Metyas; (<drmetyas@gmail.com>) 
• Barb Cameron; (<barbcameron55@gmail.com>)  
• Vanessa Ribeiro; (<vafisio.ribeiro@gmail.com>) 
• Ana Cristina Lacerda; (<lacerdaacr@gmail.com>) 
 
2.13 Data Synthesis 
 
The authors completed a quantitative analysis that synthesised findings across 
studies using pooled effect sizes and confidence intervals of the measures provided. 
However, this method could only be used for the case control studies that provided 
the baseline results for both cases and controls in their original units ng/mL.  The 
cohort studies were quite different in their design and some were completed across 
a timeline and explored different phenomena such as smoking, exercise, typical and 
atypical MECFS.  Dekkers et al. (2019) recommended that where the experimental 
design is not exact and it is unclear whether the same phenomenon is being 
measured, a random effects model should be considered and this advice was 
adhered to. Standard meta-analysis for continuous outcomes were pooled using the 
JBI SUMARI platform, and a ‘standardised mean difference’ rather than ‘mean 
difference’ was used which is explained in detail elsewhere. Heterogeneity was 
assessed using an appropriate method (I2). An overall effects score that provided a 
standard mean difference was calculated as per the JBI Manual for Evidence 
Synthesis (Moola, S et al. 2019).  A potential limitation of the study is that details at 
the level of measurement (e.g., nanograms per mL [or equivalent e.g., picogram mL 
or mg per 100mL]) was not provided in several studies. Where results were provided 
for the cohort study, a tabular and narrative synthesis was completed that provides 
a useful summary of information for each study, but mainly for the cohort design 
studies (Munn, Z., Tufanaru & Aromataris 2014).  See Chapter 4 for more 
information about the cohort studies included in this review. 
 





2.14 Assessing Certainty of Findings 
 
The Grading of Recommendations, Assessment, Development and Evaluation 
(GRADE) approach for grading the certainty of evidence was followed, and a 
Summary of Findings (SoF) was created using GRADEPro GDT (McMaster 
University, ON, Canada) (Alonso-Coello et al. 2016; Neumann et al. 2016). The SoF 
is presented with some of the following information: Standardised mean difference 
for the cases and control and a ranking of the quality of the evidence based on the 
risk of bias, directness, heterogeneity, precision, and risk of publication bias of the 
review results. The outcomes reported in the SoF includes the level of 
























3 Literature Search & Meta-analysis 
 
3.1 Literature Search and Results 
 
This chapter will explain the process of the literature search using the platform NCBI 
PubMed (NIH National Library of Medicine) as the example.  It will also describe 
how the documents found were organised using the Endnote v.X9 (Clarivate 
Analytics, PA, USA)  and COVIDENCE (Veritas Health Innovation, Melbourne, 
Australia)  platforms.   
 
3.2 The Literature Search Explained 
 
A systematic search of the literature was completed using five search platforms 
Embase, PsycINFO, PubMed, Science Direct, and Scopus on 3rd April 2020 
(updated on 27/7/20).  All preliminary (3/4/20)  and follow up searches (27/7/20) 
were performed on the same date for all databases.  The results for the searches 
are as follows: 
Table 6 Systematic Search Results 
Database Found Endnote Screening 
Embase 220     
PsycINFO 273     
PubMed 54     
Science Direct 411     
Scopus 51 duplicates New Total 
Total Records Found 1009 196 813 
 
All 1009 selected searches were imported into EndNote v.X9 (Clarivate Analytics, 
PA, USA) and duplicates removed.  This resulted in 813 records being reviewed at 
the title and abstract level, resulting in 107 articles selected for full text review.  As 





part of this full text review 2 additional articles were found in the references, resulting 
in a total of 109 articles being selected for review by two reviewers (MM & ML).  The 
full text review was completed by two independent reviewers using COVIDENCE 
(Veritas Health Innovation, Melbourne, Australia) and a third reviewer was identified 
to arbitrate discrepancies (AM).  However, the third reviewer was not required, but 
did provide objective supervision of the process. 
An example of how the search was completed is shown in the logic table used in 
the PubMed search (See Table 7 and 8):  
Table 7 Logic Grid Search Terms 
MECFS Fibromyalgia Leptin 
fatigue syndrome, Chronic"[Mesh] OR “Chronic Fatigue 
Syndrome” OR Myalgic Encephalomyelitis OR ME/CFS OR 
MECFS OR ME-CFS OR Febricula OR “Neurocirculatory 
Asthenia” OR “Atypical Poliomyelitis” OR Akureyri OR 
“Royal Free” OR Tapanui OR “Chronic Epstein Barr” OR 
“Systemic Exertion Intolerance Disease” OR "postural 







A MeSH term is assigned by the National Library of Medicine (NLM) and each new 
term entered in the database is assigned around 10-12 labels associated with that 
phenomenon (Baumann 2016). Following advice from the librarian, as part of this 
search MeSH terms were used as well as the individual terms within MeSH, as this 
ensured the most recent publications were located.  A full list of the MeSH terms for 
MECFS are provided in Chapter 2.  The systematic search was updated on 
27/7/2020 to ensure the most up to date articles were included in this review.  There 
are many publications about leptin receiving 37,623 hits, with more articles 
published on the subject of fibromyalgia (n=11766) than Chronic Fatigue Syndrome 
(8719).  The terms were then combined using Boolean operators and with all the 
terms and synonyms when combined yielded just 54 articles from the PubMed 
database (Ecker & Skelly 2010).  
The same strategy was then completed for the other databases which were not as 
accurate at pinpointing articles and therefore the net was cast with less precision 





than PubMed creating more work for the reviewers. The greatest yield was from 
Science Direct identifying 411 articles but many of these were unrelated, then 
PsycINFO with 273, then Embase with 220, and finally Scopus with 51 articles.  
These searches were all imported into EndNote and the simple process of ‘Find 
Duplicates’ was used, which identifies articles that have the same titles enabling the 
reviewer to check each duplicate (Kwon et al. 2015).  This process can miss some 
duplicates because their indexing may be slightly different in EndNote, but they are 
then discovered as part of the next phase of the review using the online reviewing 
software COVIDENCE (Covidence.org 2020).  
Table 8 Example Search Strategy 









  Leptin   37,623 
  Fibromyalgia   11,766 
  Chronic Fatigue Syndrome   8,719 
Combined 
Search 
((“fatigue syndrome, Chronic"[Mesh] OR “Chronic Fatigue 
Syndrome” OR Fibromyalgia OR Myalgic 
Encephalomyelitis OR ME/CFS OR MECFS OR ME-CFS 
OR Febricula OR “Neurocirculatory Asthenia” OR 
“Atypical Poliomyelitis” OR Akureyri OR “Royal Free” 
OR Tapanui OR “Chronic Epstein Barr” OR “Systemic 
Exertion Intolerance Disease” OR "postural orthostatic 





All searches were then uploaded to COVIDENCE from EndNote, all 1009 which 
were assessed at title and abstract level by the first author.  Articles were excluded 
at this level if they were clearly investigating another disease or met the exclusion 
criterion set out in the a priori protocol.   Wherever possible, the ‘Best Practice 
Guidelines for Abstract Screening’ described by the Cochrane Handbook (version 
6.1 online, chapter 4) and others were followed (Higgins JPT et al. 2020; Polanin et 
al. 2019). COVIDENCE enables the user to define exclusion criterion in the form of 
a ‘TAG’ and these tags are then assigned by the reviewers as they include or 





exclude articles, providing summary information on the reasons for exclusion at the 
end of this sorting process.  During the full text search, two additional articles were 
found in the references of other included papers.  See PRISMA Diagram (Figure 6) 
on the next page: 
  






























Figure 6 PRISMA (Preferred Reporting Items for Systematic Reviews and 




































(n = 2) 
Records after duplicates removed using Endnote (n = 813) 
Records screened Title and Abstract 
(n = 813) 
Records excluded 
(n = 704) 




reasons (n = 85) 
Of the 24, half used for narrative & 
tabular synthesis (n = 12), n=12 for meta-
analysis 
Studies included in quantitative synthesis 
(meta-analysis) (n = 24) 
Records identified through database 
searching (total n = 1009) 
Embase (n = 220) 
PsycINFO (n = 273) 
PubMed (n = 54) 
Science Direct (n = 411) 
& Scopus (n = 51) 
Reasons for Exclusion (85) 
26 No results provided 
20 No leptin results in paper 
15 Wrong patient population 
13 Leptin not discussed  
5 Another major disease 
3 Foreign language 
2 Wrong comparators  
1  Wrong outcome 
1 Systematic review  





Following an initial scan of the literature a series of reasons for common exclusion 
were entered in the platform COVIDENCE to support the reviewers during the setup 
process and prior to screening.  The first two reasons show that there were ‘no 
results’ published in the article; this often meant that the paper was an explanatory 
paper about the illness and did discuss leptin but at no point reported any actual 
results i.e., the first item in the reasons for exclusion table above (See right side of 
Prisma Diagram Figure 6) ‘no results provided’ but the absence of these results 
could not be determined at the title and abstract phase of the search.  Some studies 
did include clinical results of other cytokines or adipokines but at no time provided 
leptin results, so these had to be excluded, hence the heading – ‘no leptin results’ 
rather than just ‘no results provided’.  An example of an alternative result that could 
not be used in this meta-analysis was the circulating levels of adiponectin, another 
adipokine, which has a similar relationship with adipocytes to leptin but they appear 
to counter each other in their biological actions (Park, KG et al. 2004).   
Whilst some papers mentioned fatigue, for example, they were describing it in the 
context of a different illness or population such as the elderly therefore, ‘wrong 
population’ was selected as the exclusion criterion.  Another example would be an 
article that described the role of fatigue in cardiac or hepatitis patients.  The most 
apt exclusion criterion for these articles was ‘another major disease’ in that the 
article was clearly talking about a disease like cancer, or heart disease which meant 
it was part of the exclusion criterion described in the a priori protocol.  Again, these 
exclusions could not be determined at the title and abstract phase. Thirteen articles 
did not mention leptin in their results and therefore they were not relevant to this 
review and hence excluded.  The reason they got past the title and abstract phase 
was because some had mentioned leptin as a reference or made a passing remark 
about leptin in the paper but did not discuss leptin in any detail.  Some articles, whilst 
not useful for this review, did mention other pro-inflammatory cytokines which are 
important factors such as interleukin 6 or interleukin 1 beta, and these cytokines  are 
thought to have a strong relationship with the levels of circulating leptin (Azim et al. 
2018; Phitak et al. 2018).  Finally, three articles were downloaded but were in a 
foreign language and did not provide any translation into English and, as no 





resources were available for translation, they were all excluded.  For each article 
excluded, a record is elicited in COVIDENCE and was downloaded into a CSV excel 
file, which provides all the references reviewed and why they were excluded.  At the 
full text phase two reviewers provided reasons for exclusion and then a consensus 
was sought where disagreement occurred (MM & ML).  There was no requirement 
for a third reviewer, although a third author was assigned to provide arbitration (AM).  
See the appendix for full text exclusion details, where a brief extract for each article 
is provided with the reason for exclusion in the right-hand column of the table.  The 
abstract has been included to support future researchers on this topic area. 
 
3.3 Full Text Articles 
 
Twenty-four articles appeared to provide some detailed data that could be extracted 
for a systematic review, but only half of these were suitable for comparison in the 
form of a meta-analysis.  Initially 15 papers appeared suitable for data extraction, 
but on closer inspection, three did not provide enough detail i.e., a baseline level of 
circulating leptin for cases and controls.  Additionally, some papers only provided p 
values and correlations to symptoms of fatigue, but not with enough detail to 
calculate the raw units of circulating levels of leptin in ng/mL. Twelve publications 
were suitable for data extraction, and 3 of the 15 were excluded from this part of the 
analysis.  Specific reasons for their exclusion are provided in Table 12 (section 3.7) 
with a rationale explained in section 3.7.  A list of the 24 included studies are 
provided in a table below (See Table 9).   
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 Israel No Yes To analyse potential changes 
in leptin levels among female 
fibromyalgia patients 
compared with healthy 
controls, and to evaluate the 
















 Turkey No Yes The aim of this study was to 
investigate the correlation 
between serum leptin level, 
disease activity, and markers 
of inflammation, and to 
compare the leptin level in 
patients diagnosed with FMS 







































Yes No Divided Post Infective patients 
and controls and measured 3 
times across 12 months.  
 Baseline, 3 months and 12 
months. We will use 12-month 
results as baseline for 
comparison of cases vs 
controls.  Longitudinally 
collected clinical data and 
blood samples from 
participants. Examined the 






4 650 Cleare 
2001 
Plasma leptin in 
chronic fatigue 
syndrome and a 
placebo-
controlled study 




UK Yes No The effects of hydrocortisone 
on leptin in CFS patient’s vs 
controls using a placebo-
controlled trial. Also included 































5 634 Covelli 
2005 
Drug targets in 
stress-related 
disorders 
Italy Yes No IFN-Gamma leptin, a hormone 
which regulates food intake, 
fluctuates within normal ranges 
in CFS individuals. Quite 
interestingly, in depressed 
patients, used as controls, 
leptinaemia was more elevated 
















Yes No Analysed cerebrospinal fluid 
from 32 cases, 40 subjects 
with multiple sclerosis and 19 
normal subjects’ frequency-
matched for age and sex using 
a 51-plex cytokine assay.  This 
study uses samples from a 
biobank and compares 3 












present early in 
United 
States 
Yes No Cases being short term 
<=3years and long term 
MECFS >3 years.  "report here 
distinct alterations in plasma 































the course of 
illness 
= 52) relative to healthy 
controls (n = 348) that are not 
present in subjects with longer 












Yes No To determine whether a 
signature of serum cytokines 
could be associated with 
ME/CFS and correlated with 
disease severity and fatigue 









body adiposity in 
women with 
fibromyalgia 
 Brazil No Yes The effect of fibromyalgia 
(patients vs. controls) on the 
relationship of leptin and 
acylated ghrelin with 
anthropometric indicators 
[body mass index, waist 












Brazil No Yes  investigated the relationships 
between these two 































various pain characteristics in 
patients with fibromyalgia 






factor levels with 






Turkey No Yes This study aimed to investigate 
leptin, growth hormone (GH), 
and insulin-like growth factor 
(IGF-1) levels in FMS, and 
their relationship with body 






12 195 Olama 
2013 






Egypt No Yes Aim: Recently, a large body of 
studies has focused on the 
leptin levels in psychiatric 
disorders. This study aimed to 
measure serum leptin levels in 
fibromyalgia syndrome (FMS) 
due to a significantly higher 
prevalence of psychiatric 































relationship between leptin and 
FMS. 
13 189 Paiva 
2017 









Brazil No Yes to evaluate the serum levels of 
adipokines in women with 
fibromyalgia with and without 
overweight/obesity, and to 
correlate the adipokines levels 
with clinical parameters 
associated with fibromyalgia 














Brazil No Yes The aims of this study were 1) 
to characterize the intensity of 
the vibration stimulation in 
women diagnosed with 
fibromyalgia (FM) compared to 
a control group of healthy 
women (HW) matched by age 
and anthropometric 
parameters, and 2) to 
investigate the effect of a 































vibration (WBV) on 
inflammatory responses. 















Yes Yes To evaluate the role of 











Beneficial roles of 
IGF-1 and 
resistin? 
Sweden No Yes The aim was to examine 
effects of exercise on fatigue, 




































levels and higher 
pain experience 
in patients with 
fibromyalgia 
Sweden No Yes Evaluates the possible relation 
between pain, cigarette 
smoking, and levels of IGF-1 in 















Sweden No Yes The effect of cigarette smoking 
on adipokines and pain 
parameters, in 62 women with 
fibromyalgia (FM) pain 
















Yes No analysis of cerebrospinal fluid 
in myalgic encephalomyelitis / 
chronic fatigue syndrome with 










































No Yes Leptin levels were assessed in 
27 fibromyalgia syndrome 









21 245 Younger 
2016 
Association of 
Leptin with Body 
Pain in Women 
United 
States 
No Yes To explore the association of 
Leptin with self-reported body 
pain in 3 women.  Study 2 was 
a retrospective study of leptin 
results in postmenopausal 
women who experience 














No Yes To measure inflammatory 
markers using a method called 
Vectra DA.  This provided a 
mean baseline Leptin result, 









































Japan No No to examine the impact of sleep 
condition, cardiac autonomic 
dysfunction, and subclinical 
atherosclerosis on 
cardiovascular events. The 
present study is a sub-analysis 














IGF-1 and leptin 
Sweden No Yes To evaluate the role of 
metabolic factors in lean, 
overweight 
and obese women during 
resistance exercise, in relation 
to symptom severity and 
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To enable this review to compare results across studies the authors had to 
demonstrate that it was appropriate to include them in the comparison.  It was 
necessary for included studies to report a similar methodology and provide data on 
circulating leptin that could be compared in nanograms per millilitre using both cases 
and controls.  This was not always self-evident, and some studies had to be 
translated from picograms to nanograms or the authors had to be contacted for 
clarification about their results. 
Another problem encountered was that some papers only provided pictorial graphs 
of the results, which could not readily be interpreted into the basic mean values.  
More importantly, they did not provide the standard deviation (SD) of the results, 
which was necessary to make an effective comparison, and even more difficult to 
discern from a graph than say the mean average.  One study by Hornig et al. (2016) 
for example provided the standard error of the mean (SEM) and this figure had to 
be converted back to SD to enable it to be used in the meta-analysis.  The 
calculation for this result is explained below and the converted result SEM to SD, 
was used in the final analysis.  It is suggested that some articles use the SEM format 
instead of SD because it is always a smaller figure than the SD and may make the 
evidence look more precise than it actually is (Brown 1982). 
The SD tells us the measure of dispersion and can be calculated by first finding the 
mean of the group, that is by adding the results of each participant, then dividing the 
total by the number of participants = .  The SEM is how far the sample mean is 
from the true population mean; that is how much discrepancy from the mean.   We 
often make assumptions and interpretations of data based on the normal Gaussian 
distribution or bell curve (Livingston 2004).  We know that 95% of the population will 
fall within 2 SD of the mean (Altman & Bland 2005).  You then take each result and 
work out the difference from the mean (-x).  Then square the difference for each 
participant (-x)2 and add them all together (i-x)2.  Note all numbers become 
positive, as when you square a minus figure, this means a minus multiplied by a 
minus becomes a positive number.  Then to obtain the variance 2 we find the mean 
of the sum of the squared differences / divided by the mean ((i-x)2/n) which gives 
the average distance between the results of participants.  The SD is then the square 
root of the variance.   





Because we are working on a sample and not the whole population, we must make 
a correction known as Bessel’s correction, which is not just dividing these 
differences by n, but n-1 which is called ‘the sample variance’.  This is a complicated 
correction to remove the risk of sampling error and provides a better estimate of the 
true standard deviation within a sample population (Biau 2011).  Then take the 
square root of the sample variance to get the sample standard deviation or (m-
i)2/(n-1).  Some studies provide the SEM and this can be calculated by dividing the 
standard deviation by the square root of the sample (n) or SEM=SD/n (Curran-
Everett 2008).  You can also then calculate the SD from the SEM, because you 
simply reverse the calculation, that is the square root of sample (n) multiplied by the 
SEM or SD=n x SEM instead of dividing it.  See the example used to convert the 
Hornig study in this meta-analysis and as you can see the cases SD (55.47) is much 
larger than the SEM (9.8).    
Method for Converting the Hornig (2016) results: SEM to SD 
• CASES: CFS 68.2 (SEM 9.8); NB.  These are CSF samples - n is 32 (Square 
root of 32 is 5.66) 9.8 ng/mL x 5.66 = SD 55.47 ng/mL 
• Controls 41.6 (SEM 10.2) n = 19 i.e., healthy participants only (Square root of 
19 = 4.36) 10.2 ng/mL x 4.36 = SD 44.47 ng/mL 
Making comparisons across studies which measure the same continuous outcome, 
for example levels of circulating leptin in the body, where the experiments have 
slightly different methodologies would require the use of a Standardised Mean 
Difference (SMD) rather than just a mean difference.  A SMD uses a common metric 
or Z score across studies to compare differences (Walwyn & Roberts 2017).  A Z 
score represents how many SD from the population mean a raw score is. 
  





3.4 Description of Studies 
 
In this section we explore some of the methodological and quality aspects of the 
research using the JBI critical appraisal checklist and explain why some studies 
could not be included in the analysis.  
 
3.5 Methodological Quality of Included studies 
 
Two reviewers used the critical appraisal tool for case controls studies provided in 
the JBI Manual for Evidence Synthesis [Chapter 7 section 2] (Moola, S et al. 2019).  
If the study met the criterion then a ‘Yes’ was given, and these were added together 
as a cumulative score of +1 (for each yes) up to a total possible score of 9 out of 9.  
The higher the score reflects the quality of the article in that it contained consistent 
information that would be expected from this type of case control study.  One of the 
10 questions was not applicable for this type of case control study, which is ‘Was 
the exposure period of interest long enough to be meaningful’.  In this study the 
exposure was MECFS and/or fibromyalgia, and as we were only interested in the 
outcome of the baseline measurement of leptin, the period of exposure was not 
measured and not relevant.  It would be unusual for a study to declare how long the 
person has had the diagnosis for, unless it was part of the study design.  Hence only 
9 questions were utilised.  The purpose of this exercise is to consider the quality of 
the study and whether studies should be included in the meta-analysis.  We did not 
exclude any studies based on the critical appraisal outcome; however, some 
analysis was completed to see if low quality studies had an impact on the outcome.   
As is made clear in the next section, a series of sub-group meta-analysis were 
completed based on the critical appraisal score and the outcomes were unaffected 
by the removal of low scoring studies.  As part of this investigation, an iterative 
process was used to remove two ‘low quality’ studies from the analysis (Hornig 2016 
MECFS scored a critical appraisal score of 2, and Cameron 2010 MECFS scored 2) 
facilitated by REVMAN (Cochrane’s Review Manager software), but it made little 





difference to the overall result i.e., SMD REVMAN 0.41 (CI -0.07, 0.89) p=0.10.  
Further to this process, removing any study with a critical appraisal score lower than 
7 was then completed and resulted in the further removal of two more studies Hornig 
(2016 MECFS, score 6) and Ataoglu (2018 FM, score 6), but still this made little 
difference to the overall pooled outcome i.e., SMD REVMAN 0.28 (CI -0.17, 0.74) 
p=0.22.  Finally, we then tried using just the four highest quality studies in the 
analysis which achieved a 'Yes' for all 9-quality criterion i.e., scored 9 out of 9, but 
even then, the results showed minimal difference to when all 12 studies were 
included.  It reduced the overall difference and significance SMD REVMAN 0.47 (CI 
-0.19, 1.13) p=0.16.  To summarise, when the analysis is reduced to the highest 
quality studies, the difference between cases and controls is slightly higher but the 
results also become less significant.  All these iterations are provided in the table 
below (See Table 10): 
 












Lower CI Upper CI Significance 
SMD/RA All 12  studies 0.39 -0.04 0.82 0.08 
SMD/RA >2 10  studies 0.41 -0.07 0.89 0.1 
SMD/RA >6 8    studies 0.28 -0.17 0.74 0.22 
SMD/RA =9 5    studies 0.47 -0.19 1.13 0.16 
 
3.6 Critical appraisal process - checklist for case-control studies 
 
A critical appraisal checklist was uploaded to COVIDENCE as a series of questions 
and this was adapted from the JBI Manual for Evidence Synthesis chapter 7: 
Systematic Reviews of etiology and risk, appendix 7.2 ‘Critical appraisal checklist 
for case-control studies (Moola, S et al. 2019).  The checklist was completed by two 
reviewers within COVIDENCE and the results transferred to excel.  Where there 
was disagreement about an item, both reviewers discussed the difference and 
decided upon a consensus.  There was no need for a third reviewer as agreement 





was obtained following discussion for each item post review.  Table 11 is provided 
on the next page below showing the consensus outcome.  Where there is a ‘yes’ 
item this meant that the condition was met.  At the end of the table all the questions 
that received a yes were given a score of plus one as described earlier, and this has 
been summarised as a total score.  The higher the score was indicative of the quality 
of the paper.  Only two of the papers scored lower than 6, and 5 papers received 
the full score of 9 out of a possible 9.  These scores were used to try out different 
analysis in REVMAN, as illustrated in the previous section removing low quality 
scoring papers made only a small difference to the overall outcome.  A table of the 
results from the critical appraisal checklist is provided in alphabetical order and with 
total scores displayed in the right-hand column (Table 11). 
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Table 11 Critical appraisal checklist for case-control studies 
Study Author & 
Year
















n of cases 
and 
controls






















Q7 of 10: 
Were 
strategies 

















enough to be 
meaningful?













Ablin 2012 No Yes Unclear Yes Yes Yes Yes Yes N/A Yes 7
Ataoglu 2018 Yes No Yes Yes Yes No No Yes N/A Yes 6
Cameron 2010 Unclear Unclear Yes Unclear Unclear No No Unclear N/A Yes 2
Cleare 2001 Yes Yes Yes Yes Yes Yes Yes Yes N/A Yes 9
Homann 2013 Yes Yes Yes Yes Yes Yes Yes Yes N/A Yes 9
Homann 2014 Yes Yes Yes Yes Yes Yes Yes Yes N/A Yes 9
Hornig 2015 Yes Yes Unclear Yes Yes No No Yes N/A Yes 6
Hornig 2016 Unclear Unclear Unclear Unclear Unclear No No Yes N/A Yes 2
Koca 2018 Yes Yes Yes Yes Yes Yes Yes Yes N/A Yes 9
Olama 2013 Yes Yes Yes Yes Unclear Yes No Yes N/A Yes 7
Paiva 2017 Yes Yes Yes Yes Yes Yes Yes Yes N/A Yes 9
Ribeiro 2018 Yes Yes Yes Yes Yes Yes Unclear Yes N/A Yes 8  
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3.7 Review Findings/Results and Description of Full Text Studies  
 
There was a total of 24 articles that were initially thought suitable for meta-analysis 
on the first screening by two reviewers.  Fifteen papers were identified as case-
control studies and nine as cohort type studies that provided circulating leptin 
results, but on closer examination 3 of the case-control studies had to be excluded 
from the meta-analysis (See Table 12 below).  These excluded studies with reasons 
for exclusion are provided below: 
 
Table 12 Full text exclusions case controls 
(Covelli et al. 2005) This paper has a diagram of the results but labelled the 
results in pg/mL, which would make the results of a 
different order of magnitude i.e., outside usual measures 
by approximately 100-fold.  If you were to switch the label 
to ng/mL the results would not fit the analysis.  The 
seeming incorrectly labelled diagram is available in the full 
text.  Another reason for exclusion is that it did not write the 
results anywhere in the article.  Results in the diagram are 
most likely reporting leptin ng/mL, but this cannot be 
verified, and the authors did not respond to email queries.   
(Montoya et al. 
2017) 
This article also has a diagram where leptin is shown to be 
lower in the mild group, whereas moderate and severe 
cases are closer to controls, indicating that leptin relates to 
severity of symptoms in an upward trajectory, but no raw 
results to elucidate this are provided.  There are no raw 
leptin results in the article nor in the supplementary.  There 
are only p values in relation to other factors such as linear 
trend of disease severity.  The linear relationship with 
severity was statistically significant even after correction for 
multiple comparisons, even though these 17 cytokines did 
not distinguish cases from controls overall.   





(Stringer et al. 
2013) 
Another example using correlations of symptom fatigue are 
provided, but no raw results in ng/mL are provided and 
resulted in exclusion of this important and highly cited 
article. The research offers a diagrammatic view of the 
results for each individual in the study, but only shows 
correlations comparing standardised leptin levels with 
fatigue. 
 
Whilst it was tempting to use the leptin results from the Covelli et al. (2005) study by 
extrapolating the data from the graph (approximately 9 pg/mL SD 13 cases vs 15 
pg/mL SD 10 controls), but because of what appears to be incorrect labelling, pg/mL 
instead of ng/mL, it was decided by both reviewers to exclude this from the analysis 
but include in the discussion.  Mainly because it is of the wrong order of magnitude, 
and the results are not confirmed in the text.  To interpret these results from 
picograms to nanograms, it is necessary to divide by 1000 i.e., (approximately 0.009 
ng/mL SD 0.013 cases vs 0.015 ng/mL SD 0.01 controls).  These results would not 
be valid using these figures, as a mean leptin result is rarely below zero and not to 
this degree. 
The Montoya (2017) study is the most highly cited article (102 citations) but also 
fails to provide actual circulating leptin results in ng/mL, making it unsuitable for 
meta-analysis. Stringer et al. (2013) provided impressive graphics showing 
correlations of symptom severity using a complex algorithm but this was unhelpful 
in our meta-analysis.  These levels closely track symptoms, but we don’t know what 
the circulating leptin levels are.  All three studies described above were excluded at 
this stage. 
Twelve studies were used in the final meta-analysis which had a pooled outcome 
that leptin is slightly higher in cases than controls by approximately 0.39, 95% CI 
0.04, 0.74.  The 95% confidence interval did not cross the line of significance, 
making this outcome significant using SUMARI (See Figure 9).   The level of 
significance was lost when using another platform REVMAN (See Figure 8), possibly 





due to the differences in weighting used to calculate the pooled outcome, and this 
is explored later.  A series of forest plots clearly highlight that two studies (Olama, 
Elsaid & El-Arman 2013; Paiva et al. 2017) reported hypoleptinaemia (lower leptin) 
in cases vs controls as opposed to the other 10 studies which erred toward it being 
of no difference or higher in cases.  Further explanation is provided in the next 
section.   
 
3.8 Significance of Results & Forest Plots 
 
The following forest plots provide a list of studies that are ordered alphabetically, 
and they used a standardised mean difference, and random effects model to 
calculate whether the cumulative outcome shows a pooled difference.  Whilst using 
SUMARI the results showed an overall effect of 0.39 with a 95% confidence interval 
(CI) of 0.04,0.74 indicating that the difference is significant (p=0.029) (See Figure 
9).  However, when the same results were placed in REVMAN 5 (See Figure 8) this 
provided the same pooled difference of 0.39, but then reported a negative 95% CI -
0.04,0.82 removing the significance of the result from p=0.029 reported in SUMARI 
(Figure 9) changing to p=0.08 reported in REVMAN (Figure 8).   
It also had a slightly higher I2 result moving from 86% in SUMARI to 91% in 
REVMAN (See Figure 9).  Either way the heterogeneity is very high, which reduces 
the precision of the results and is not supportive of the precision of these studies.  It 
is explained elsewhere in this thesis that a standardised mean difference was used 
due to differences in methodology; however, an alternative ‘mean difference’, 
random effects model meta-analysis was also completed in SUMARI (See Figure 
10) and REVMAN  (See Figure 11), showing slightly different results.  It is notable 
that the largest study of 646 participants (Hornig 2015 study) is charted very 
differently when using a ‘mean difference’ model, when compared to a ‘standardised 
mean difference model’.  In the mean difference modelling, this appears in the forest 
plot to show little difference (actual mean difference of cases vs controls is only 0.51 
ng/mL) being plotted on the line of no difference, yet in the standardised mean 





difference chart this appears to have a much bigger influence on the charted result 
(compare Figures 9 SMD and Figure 10 MD for example).  
A series of analysis was completed using both REVMAN and SUMARI and a 
summary table is provided following the forest plot diagrams to provide an easy 
comparison between all analysis type and platform (See Table 14, page 99).  A 
potential explanation for the differences between REVMAN and SUMARI is the way 
the software programs ‘weight’ studies, there is a noticeable difference in the largest 
study (Hornig 2015) (See Table 13) showing the slight differences in weights 
between platforms (9.6% compared to 10.28%).  The standard mean difference and 
confidence intervals are identical for each study across both platforms. 
 







Ablin (FM) 2012 7.9% 7.71% 0.19% 
Ataoglu (FM) 2018 8.8% 9.04% -0.24% 
Cameron (MECFS) 2010 6.9% 6.32% 0.58% 
Cleare (MECFS) 2001 8.6% 8.70% -0.10% 
Homann (FM) 2013 7.7% 7.40% 0.30% 
Homann (FM) 2014 7.3% 6.90% 0.40% 
Hornig (MECFS) 2015 9.6% 10.28% -0.68% 
Hornig (MECFS) 2016 8.3% 8.18% 0.12% 
Koca (FM) 2018 8.9% 9.21% -0.31% 
Olama (FM) 2013 9.0% 9.27% -0.27% 
Paiva (FM) 2017 9.0% 9.25% -0.25% 
Ribiero (FM) 2018 8.0% 7.75% 0.25% 
 
  





3.9 Explanation of the Following Forest Plots  
 
This series of forest plots provides a graphical view of the comparison of baseline 
leptin in cases vs control.  Cases are those participants who have been diagnosed 
with either of MECFS or fibromyalgia (FM) syndromes, and controls are healthy 
participants.  They are listed in alphabetical order of author followed by what type of 
syndrome the paper was reporting i.e., Ablin et al. (2012) is the first author.  This 
information is then followed by the date i.e., Ablin (FM) 2012 (See Figure 7).  All full 
references can be found in the reference section at the end of the thesis. 
 







The forest plot provides the raw mean results of cases and then controls, which is 
juxtaposed to the SD, followed by the number of participants in the group.  Each 
study is then weighted which is calculated by the software used, either REVMAN (in 
the first forest plot) and SUMARI (in the second forest plot).  At the right side of the 
forest plot, the SMD is listed, then the confidence intervals are in brackets e.g., for 
Ablin -0.03 is the SMD, and the confidence interval for this study is -0.68 to 0.62 
meaning that the actual result may fall anywhere between these intervals.   
Author, Syndrome year SMD, Confidence Interval 
Mean, SD, n-participants 





These results are then plotted on the chart to show both the standardised mean 
difference in the centre of the confidence intervals which are represented by a line 
on the graph.  This is then repeated for each paper.  A summary of the results is 
provided at the base of each forest plot showing the total population of all studies 
included for all combined cases (649) and cases (658), followed by the overall SMD 
(0.39) and finally the overall confidence intervals (0.04 to 0.82). 
A list of statistical references reflecting the heterogeneity are also provided: Tau2 = 
0.3, Chi2 = 118.65, df = 11 (p<0.00001); I2= 86%.  Test for overall effect: Z=2.18. 
There are six forest plots that follow (13-18).  Both the REVMAN and SUMARI 
version of the forest plot are provided for some comparisons to enable the reader to 
see the differences in weighting between these 2 software programmes.  You will 
note that the raw means and standard deviations are unchanged across all forest 
plots.  There was a decision to use the SMD due to the difference in methodologies 
across studies.  This further supported the decision to use a random effects model 
rather than a fixed effects model.  In an ideal world all studies would have used the 
same methodology and the observer could be confident that the same analyte was 
being measured in a systematic way, then the ‘mean difference’ and a fixed effect 
model would have been used.  The ‘mean difference’ forest plot is provided for the 
curious reader to review the results in the original unit format rather the SMD format.  
We have also separated studies into just the MECFS studies – See Figure 12 (4 
papers, 781 of the total 1307 participants of all 12 studies) in just one forest plot, 
then another forest plot for ‘fibromyalgia only’ studies – See Figure 13 (8 papers, 
526 participants of the total 1307 participants in all 12 studies).  This allows us to 
review the differences in the two separate syndromes, which, as can be seen from 
the forest plot results, does not vary much from the whole 12 study outcome.  A 
table is provided at the end of the forest plots allowing the reader to make a quick 
comparison of all the different comparison results. 
 
  





Several forest plots are provided in the following order: 
1. REVMAN - All 12 studies using Standardised Mean Difference (Figure 8) 
2. SUMARI – All 12 studies using Standardised Mean Difference (Figure 9) 
3. SUMARI – All 12 studies using Mean Difference (Figure 10) 
4. REVMAN - All 12 studies using Mean Difference (Figure 11) 
5. REVMAN - MECFS studies only using Standardised Mean Difference  
(Figure 12) 
6. REVMAN - Fibromyalgia studies only using Standardised Mean Difference 
(Figure 13) 
7. Summary table indicating differences in results (Table 14) 
 
Series of Six Forest Plots follow on next few pages: 
  Page 
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Forest Plot generated in REVMAN 5 of all twelve case control studies – Standardised Mean Difference 
  
Figure 8 Forest Plot using all 12 Studies Standardised Mean Difference (REVMAN) 
Meta-analysis: Forest Plot using Standardised Mean Difference. Heterogeneity Tau2 = 0.49, Chi2 = 118.42, df = 11 (p<0.00001); I2= 91%.  











Forest Plot generated in SUMARI of all twelve case control studies – Standardised Mean Difference 
 
Figure 9 SUMARI Forest plot all 12 Studies Standardised Mean Difference 





Forest Plot generated in SUMARI of all twelve case control studies – Mean Difference (natural units) 
 
Figure 10 SUMARI Forest plot all 12 Studies Mean Difference   





Forest Plot generated in REVMAN 5 of all twelve case control studies – Mean Difference (natural units) 
 
Figure 11 REVMAN Forest plot all 12 Studies Mean Difference 
 





Forest Plot generated in REVMAN 5 - Four MECFS studies only – Standardised Mean Difference 
 
Figure 12 REVMAN Forest plot MECFS Studies only Standardised Mean Difference 
 





Forest Plot generated in REVMAN 5 - Eight Fibromyalgia case-control studies – Standardised Mean Difference 
 
Figure 13 Forest plot REVMAN Fibromyalgia Studies only Standardised Mean Difference   























Tau2 Chi2 df Cases Controls All 
 
1 Fig 8 SMD All 12 REVMAN 0.39 -0.04 0.82 0.08 91% 1.77 0.49 118.42 11 649 658 1307 
2 Fig 9 SMD All 12 SUMARI 0.39 0.04 0.74 0.029 86% 2.18 0.3 118.65 11 649 658 1307 
3 Fig 10 MD All 12 SUMARI 2.35 -0.82 5.53 0.146 100% 1.45 22.9 64.27 11 649 658 1307 
4 Fig 11 MD All 12 REVMAN 0.13 -0.12 0.38 0.3 83% 1.04 0.03 64.27 11 649 658 1307 
5 Fig 12 SMD MECFS 
only 
REVMAN 0.57 -0.05 1.18 0.07 86% 1.81 0.32 20.79 3 372 409 781 
6 Fig 13 SMD Fibro 
only 












REVMAN 1.76 -0.5 4.01 0.13 84% 1.53 8.18 61.81 10 351 310 661 
 
Table 14 provides a summary of all forest plot results for quick reference.  The first 6 results are provided in the forest plots above (See 
figure 8-13) and the last two results (table item 7 & 8 – See Table 14) where an additional analysis was completed without the largest study 
by Hornig et al. 2015 which accounts for almost half of all people in the studies combined, containing 646 participants of the total 1307 
participants.  The SMD and mean difference (MD) summary results for the remaining 11 studies are provided.  Removing this study reduced 
the pooled difference by just 0.1 (0.39 to 0.29). 
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3.10 Meta-analysis  
 
The meta-analysis was used to compare baseline leptin results in cases (those 
studies that described a diagnosis of chronic fatigue and/or fibromyalgia) and 
controls (healthy participants).  It was decided to use a standardised mean 
difference because the methodology of each study was very different, although they 
were measuring the same continuous variable circulating leptin in ng/mL.  An 
example of the differences in studies were, the type of circulating fluid used including 
serum (5 studies), plasma (6 studies) and just one study used CSF (Hornig et al. 
2016) (see Table 9 and 16 for more details).  This latter study showed that leptin is 
more concentrated in CSF compared to serum or plasma by approximately 5-fold, 
which is visually displayed in the histogram (Figure 15 page 102) (Hornig et al. 
2016).  The other major difference was that this review has combined two 
syndromes MECFS (4 studies) and fibromyalgia (8 studies); both use similar 
methodologies and measure the same continuous measure of circulating leptin, but 
not with enough coherence to use a ‘mean difference’ or fixed effect.   
Of the twelve studies only 5 included male and female participants (Cameron et al. 
2010; Cleare, O'Keane & Miell 2001; Hornig et al. 2016; Hornig et al. 2015; Koca et 
al. 2018) and men were invariably at a lower ratio than women, reflecting the higher 
frequency of women with MECFS and/or fibromyalgia by gender in the general 
population.  For example, Hornig (2015), the study with the highest population 
(n=646) in this meta-analysis had a total number of MECFS cases = 298 (female 
220) and controls = 348 (females 260). This represented a ratio of around 74% 
females (n=480) i.e., 3:1.  MECFS has a prevalence of around 0.3% in the general 
population whereas fibromyalgia has a 10 fold higher general population prevalence 
at around 4% (Natelson 2019).   
Prins, van der Meer and Bleijenberg (2006) completed a literature review of the 
research and also found 75% of participants in their review were female, the mean 
age was 25-35, and the duration of illness was between 3 to 9 years.   There are 
varying reports on the sex ratio of male to females with fibromyalgia, but a study 
across 5 different European countries reported a ratio of around 1:3 (Castro-
Sanchez et al. 2012).  Both illnesses may have a psychobiological basis in the form 





of a stress based experience or life event causing neural sensitisation (Prins, van 
der Meer & Bleijenberg 2006).  With reference to diagnostic precision, the 
heterogenous nature of these syndromes is well reported, and is further highlighted 
with the results of this meta-analysis.   
The forest plots (Figures 8 – 13, page 92) reflect the results of the 12 studies which 
are also provided in the form of a basic means table shown below (See Table 15).  
This table provides the raw results for the whole study population 649 cases and 
658 controls (total n = 1307) and a simple raw mean difference (without weighting) 
of cases compared to controls (mean of cases 17.42 ng/mL – mean of controls 11.79 
ng/mL) = mean difference of 5.63 ng/mL (raw difference i.e., original units).  The 
total mean of all cases n= 649 cases (17.42 ng/mL) + mean of all controls 658 
controls (11.79 ng/mL) = 29.21 ng/mL (cases + controls) and divided by 2 = 14.6 
ng/mL (mean of 1307 participants). The overall simple mean is 14.6 ng/mL of 
circulating leptin.  However, because the Hornig et al. (2016) study is using CSF 
which is 5 times higher, this makes the mean of all 12 studies of 14.6 ng/mL higher 
than if only blood samples were used.  Removing this study from the raw mean 
provided a mean result of 10.03 ng/mL.  This is another example of why the use of 
SMD was essential. 
  






Table 15 Simple Raw Mean Differences Cases vs Controls (low to high) 
  Cases SD Controls SD Difference favours 
Hornig MECFS 2015 1.51 0.08 1.4 0.1 0.11 cases 
Ribeiro FM 2018 1.8 0.06 1.75 0.14 0.05 cases 
Cameron MECFS 2010 2.67 2.65 2.75 2.9 -0.08 controls 
Ablin FM 2012 15.74 7.3 15.96 8.9 -0.22 controls 
Olama FM 2013 7.1 6.8 9.4 4.5 -2.30 controls 
Paiva FM 2017 12.81 8.62 18.32 10.19 -5.51 controls 
Koca FM 2018 10.3 6.4 6.2 3.3 4.10 cases 
Cleare MECFS 2001 13.8 13.33 10.2 8.37 3.60 cases 
Homann FM 2013 22.4 10.6 13.3 17.9 9.10 cases 
Homann FM 2014 22.4 10.6 9.1 6.7 13.30 cases 
Ataoglu FM 2018 30.32 57.25 11.5 7.06 18.82 cases 
Hornig MECFS 2016 68.2 55.47 41.6 44.47 26.60 cases 
Mean i.e., Total / 12 17.42 14.93 11.79 9.54 5.63 cases 
N (population) 649   658    Total  1307 
 
Difference from the mean in cases (n=649) is (cases 17.42 – sample mean 14.6 = 
2.82 ng/mL) 19.32% difference greater than the total sample mean (n=1307).  
Difference from mean in controls is (11.79 – 14.93 = -3.14) or 21.51 % lower than 
the total sample mean.  Using the SUMARI meta-analysis calculator, selecting the 
option of standardised mean difference, including both means and standard 
deviations provided by each study, this equated to a difference between cases and 
controls of 0.39 and the 95% confidence intervals are 0.04 to 0.74, of which the 
lines do not cross the point of significance, so the difference is just significant 
p=0.029.   
The re-expression calculation can be summarised as Standard Deviation (SD) of 
the control group mean 8.37 ng/mL (represented by the Cleare, O'Keane and Miell 
(2001) study) multiplied by the Pooled Standardised Mean Difference of 0.39 = 3.26 
ng/mL.  The re-expressed result in the original units is a close match with the basic 
raw calculation above i.e., re-expressed result of 3.26 ng/mL higher (0.33 to 6.19) 
in cases compared to controls.  This is very close to the simple calculation (in Table 





15) shown earlier demonstrating a difference from the total mean for cases = 2.82 
ng/mL, (3.26-2.82 =0.44 ng/mL) suggesting the use of SMD was an effective and 
representative method for this meta-analysis.   
However, when we used REVMAN, this appears to use slightly different weightings 
in the calculations and the confidence intervals change very slightly to -0.04 to 0.82 
resulting in the result now not being significant p=0.08.  When the calculations are 
completed using a mean difference model using SUMARI rather than a SMD model, 
then the difference becomes slightly smaller at 2.35 ng/mL (CI -0.82 to 5.53) 
p=0.146 but also scored a heterogeneity score of 100% I2 (See  
Figure 14 below). 
 
Figure 14 Pooled Difference 
 
All formats favour that leptin is higher in cases than controls in both the Mean 
Difference (2.35 ng/mL CI -082,5.53) and Standardised Mean Difference (re-
expressed 3.26 ng/mL) or even the simple unweighted mean difference as provided 
in Table 15 (2.82 ng/mL).  We can assume the difference to be between 2.35 ng/mL 
to 3.26 ng/mL with an average of these three results being 2.81 ng/mL.   The small 
difference however of around 2.81 ng/mL could readily be explained by changes in 
BMI, menstrual phase, or even the changes in leptin across the time of day and 
therefore this difference is not large enough to be of clinical significance without 
controlling and accounting for these confounders in all studies (Rafique et al. 2018).  
So, the results are not convincing and require further research. 
  





Here is a list of 3 different means MD, SMD, and Raw results: 
MD result:    2.35 ng/mL 
SMD result:   3.26 ng/mL – re-expressed (used Controls) 
Raw mean difference: 2.82 ng/mL – (see Table 15) 
Average of above:  2.81ng/mL – (average of all 3 above) 
 
We can assume the difference falls between 2.35 and 3.26 ng/mL.  Cases have a 
mean leptin at 2.81 ng/mL higher than controls.  As more studies are completed in 
the future, this trend may be clarified. 
 
3.11 Study Design  
 
There were 4 studies completed in Brazil, two in the United States and the remainder 
from other countries and are displayed in the following table (Table 16).  There are 
only 4 studies that are MECFS related and 8 fibromyalgia related.  Most studies had 
an average of around 109 participants, but some were much lower than the average 
(the smallest being 20 participants), and the study that stands apart is the Hornig et 
al. 2015 study with 646 participants (49% of total sample 1307).  If we remove the 
Hornig study the average would be only 60 participants per study.   
Every study included females but only 5 studies had male participants, and these 
were of a much lower proportion of the study population at around 25% males 
compared to female participants.  The 1:3 ratio is representative of the general 
population prevalence of MECFS as discussed earlier, but most articles had a 
higher female representation in fibromyalgia studies, but it can be seen that some 
did not include males at all providing little rationale for this strategy (Natelson 2019).  
Around half of the studies used plasma (6) and the other half used serum (5), with 
only one study using CSF.  Standard Operating Procedures suggest that plasma 





has to be kept on ice as soon as the sample is taken, and it must be centrifuged 
within approximately half an hour of the sample being obtained (Tuck et al. 2009).   
Serum can be left at room temperature as it requires at least 30 min to allow it to 
clot.  The fact that it does not have to be placed on ice or in a freezer immediately 
makes it easier to manage in a study, but there is evidence that the sooner it is 
placed on ice following coagulation and stored, the higher the integrity of the sample 
and the ensuing results (Timms et al. 2007).  It was noted that in one study when 
comparing both serum and CSF, the results for people who had fibromyalgia and 
were non-smokers had a serum level of  28.8 ng/mL [SD 16.4–48.0] and a CSF level 
of 165 ng/mL [SD 114–225]: therefore 165 divided by 28.8 = 5.85 times higher in 
CSF (Bokarewa et al. 2014). The fact that CSF levels of leptin may be over five-fold 
higher than the serum level of leptin provides another reason for using a 
standardised mean difference in the analysis because one of the studies only 
provided the results from circulating CSF (Hornig et al. 2016).  Removing this study 
from the analysis (n=51 of total 1307) made very little difference using the SMD.  A 
table demonstrating study design differences is provided in Table 16.  




Table 16 Study design differences of 12 studies 




























1 Ablin 2012 Israel No Yes 37 16 21 No Yes Yes No No Yes 
2 Ataoglu 2018 Turkey No Yes 84 48 36 No Yes No Yes No Yes 
3 Cameron 2010 Australia Yes No 20 10 10 Yes Yes No Yes No No 
4 Cleare 2001 UK Yes No 64 32 32 Yes Yes Yes No No Yes 
5 Homann 2013 Brazil No Yes 33 17 16 No Yes Yes No No Yes 
6 Homann 2014 Brazil No Yes 32 17 15 No Yes Yes No No Yes 
7 Hornig 2015 United 
States 
Yes No 646 298 348 Yes Yes Yes No No Yes 
8 Hornig 2016 United 
States 
Yes No 51 32 19 Yes Yes No No Yes No 
9 Koca 2018 Turkey No Yes 102 60 42 Yes Yes No Yes No No 
10 Olama 2013 Egypt No Yes 100 50 50 No Yes No Yes No No 
11 Paiva 2017 Brazil No Yes 100 50 50 No Yes No Yes No No 
12 Ribeiro 2018 Brazil No Yes 38 19 19 No Yes Yes No No No 
 Totals  4 8 1307 649 658 5 12 6 5 1 6 
  





It helps to provide an initial visual analysis, and when the raw baseline means are 
plotted in a graph, it shows that 4 studies have negligible difference, and 2 studies 
favour controls, whereas 6 studies are clearly in favour of cases having a higher 
level of circulating leptin than controls.  The results of the Hornig 2016 study 
displaying CSF results demonstrate the five-fold increase in leptin levels.  This can 
be seen on the far right of the next graph.  See the following page (Figure 15) to 
explore the visual differences.  
  





Figure 15 Histogram of Mean Differences of leptin ng/mL (Cases in blue) 
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3.12 Grade and Summary of Findings Table 
 
GRADE is an acronym for Grades of Recommendation, Assessment, Development, 
and Evaluation.  The idea behind GRADE is to provide an assessment of the best 
available evidence and then to provide a statement of the certainty of that evidence.  
The principle is usually to review the findings offered in guidelines and to provide a 
grading of the certainty of the evidence supporting clinicians to assist with decision 
making (Brozek et al. 2009).  A summary of findings table provides a quick reference 
to assess the overall certainty of the evidence and is now used by professional 
organisations across the world, as well as high quality journals (See Table 17). 
 
3.13 Assessing Confidence Using Grade  
 
The outcome for the certainty of findings for this systematic review were ‘very low’ 
(See Table 17, page 112).  According to Brozek et al. (2009) p. 672 those studies 
that are categorised as very low would include:  
“Randomised trials with very serious limitations and inconsistent results; 
Observational studies with serious limitations, unsystematic clinical observations 
(e.g., case series or case reports).” 
The highest quality of research is considered to be pooled findings from randomised 
controlled trials that have few limitations, are properly blinded and have little 
imprecision and heterogeneity.  Observational studies, such as the ones found in 
this systematic review, which includes case control studies and cohort studies, 
would prove difficult to obtain a high certainty rating, before we even start the 
downgrading process.  The inconsistency in the design and methodology resulted 
in starting at a ‘low level’ but the following issues gradually downgraded the score 
to ‘very low’ certainty, and any evidence or recommendations from this research 
would be considered as weak. 





There are five dimensions to consider when making an overall certainty rating 
decision and these include, inconsistency, indirectness, imprecision, risk of bias, 
and publication bias (Guyatt, G et al. 2013). 
A series of publications are available that discusses the issues of quality that may 
affect certainty, and one of these include issues of imprecision. This can usually be 
seen in the size of the confidence intervals (Guyatt, GH, Oxman, Kunz, Brozek, et 
al. 2011).   A wide confidence interval suggest the results could fall anywhere within 
a large range, indicating the real mean result is questionable.  In this review the 
confidence intervals were wide for most of the included studies considering the size 
of the population investigated (usually <=100 and as small as 20).   So, this results 
in a downgrade of one level to low certainty. 
Another issue for consideration is inconsistency which can be seen through the 
heterogeneity (showing widely differing magnitudes of effect and differences in 
direction of results), high variation of point estimates and overlapping confidence 
intervals (Guyatt, GH, Oxman, Kunz, Woodcock, Brozek, Helfand, Alonso-Coello, 
Glasziou, et al. 2011).  A high I2 represents high heterogeneity which was observed 
in this systematic review (86% heterogeneity) resulting in a further downgrade of 
one to very low certainty.  When the comparison was completed using just a ‘mean 
difference’ the heterogeneity was at the maximum of 100%. 
A key issue with comparing the quality of studies in this review was indirectness, 
which refers to the difficulty in comparison across research studies (Guyatt, GH, 
Oxman, Kunz, Woodcock, Brozek, Helfand, Alonso-Coello, Falck-Ytter, et al. 2011).  
The results had to be analysed using a standardised mean difference and random 
effects model because of apparent differences in methodology, body fluid types 
used, and the variation in magnitude of results.  We cannot downgrade the findings 
any further, so the GRADE recommendation remains very low for certainty of 
evidence.  
With reference to publication bias, the results included studies with 3 differing 
outcomes, some indicating low leptin or hypoleptinaemia (2), some showing hardly 
any difference between cases and controls (4), but the majority indicated higher 





levels of leptin or hyperleptinaemia in cases (6).  On balance when the point 
estimates are published in the form of a funnel plot, you can usually identify patterns 
of publication bias (Guyatt, GH, Oxman, Montori, et al. 2011).  This did not seem to 
be a problem in this review.  See the funnel plot provided in Figure 16 (on page 
114), which demonstrates a reasonably symmetrical figure.  However, this is limited 
image as there are only 12 publications to plot. 
Lastly, the selected studies for the meta-analysis had some quality issues of 
concern such as managing confounders consistently, limited details about the 
method, and protocols, not providing transparent results, and the difficulties in 
comparing these studies in the natural measurements.  A summary of findings table 
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Table 17 Summary of Findings Table 
Leptin Cases compared to Controls SMD for Myalgic Encephalomyelitis Chronic Fatigue Syndrome and/or Fibromyalgia 
Patient or population: [health problem] Chronic Fatigue Syndrome and/or Fibromyalgia vs Controls (Healthy participants) 
Setting: Usually a clinic setting or university / community research recruitment 
Intervention: Circulating Leptin levels Cases 
Comparison: Controls - SMD also re-expressed as original units 
Outcomes 
Illustrative comparative risks* (95% CI) 
Relative effect 
(95% CI) 
№ of participants  
(studies) 
Certainty of the evidence 
(GRADE) 
Comments  
Leptin in those without ME, CFS or FM 
Leptin Levels ng/mL 
(circulating leptin 




The mean difference in leptin levels in cases was  
SMD 0.39 (0.04 to 0.74) higher in cases than 
controls. This is equivalent to a re-expressed 
result of 3.26 ng/mL higher (0.33 to 6.19) in cases 
as compared to controls.*   
 
n=1307  







All studies used 





*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).CI: Confidence interval; MD Mean Difference 
SMD: Standardised Mean difference.  SMD and CI taken from SUMARI analysis. 
GRADE Working Group grades of evidence 
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different 
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect 
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect  
Explanations: 
a. Downgrade 1 for imprecision Two studies provide evidence of hypoleptinaemia (low leptin), four studies report negligible difference, and 6 studies report hyperleptinaemia (high leptin) in cases.  
b. High heterogeneity (I2 = 86%), downgrade 1.  
c. Downgraded 1 for risk of bias. Confounders such as BMI and time of day (circadian rhythmicity) are not considered in all studies, and some have adjusted their results whilst others have not. The 
results vary significantly, indicating the method of laboratory storage, sample handling, assessment and analysis are different between studies.  
d. Downgraded 1 level for inconsistency with wide confidence intervals, and outcome results presented in opposite directions.  









*Re-expression of SMD to original units 
To translate the Standardised Mean Difference (SMD) (0.39) back to the original measure of ng/mL, it is necessary to take a representative study and take the SD of the 
control group, which is then multiplied by the SMD.  The study Cleare, O'Keane and Miell (2001) as assessed by two reviewers of being of high quality and has a low risk 
of bias was used.  The re-expression calculation can be summarised as Standard Deviation (SD) of the Control group mean 8.37 ng/mL multiplied by the Pooled 
Standardised Mean Difference of 0.39 = 3.26 ng/mL.  Re-expressing SMDs using a familiar instrument in a method recommended by Cochrane is 0.39 x 8.37 ng/mL = 
























Figure 16 Funnel Plot with Study Details
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3.14 Funnel Plot and Publication Bias  
 
The funnel plot above on the previous page indicates that there is a low risk of 
publication bias.  There are the same number of studies on the left of the mean 
difference, as fall on the right, and an equal number of studies fall in the centre.  
They are also spread across all quadrants of the funnel plot, which indicates a low 
risk of publication bias.  There are not enough studies to formulate the usual inverted 
triangle which would normally suggest a low risk of publication bias (Guyatt, GH, 
Oxman, Montori, et al. 2011).  















4 Cohort Studies 
 
4.1 Cohort Studies  
 
There were 9 cohort type studies that provided baseline leptin levels, but these were 
not in the form of a traditional case control study and were not included in the meta-
analysis as they had no controls.  They do however provide information on baseline 
leptin, and leptin levels when conditions are changed within a cohort such as when 
measuring exercise groups across time or when comparing a health condition such 














A summary of leptin results is provided in the Table 18 below:  




Table 18 Summary of Cohort Studies 
Study Author 
& Year 
Title Brief Summary of Article Baseline Leptin Cases 
ng/mL 
Male Female  Total 
N 




roles of IGF-1 
and resistin? 
The aim was to examine effects of exercise 
on fatigue, in lean, overweight and obese 
FM patients -Baseline FIQ fatigue correlated 
negatively with serum leptin (r = -0.345; P = 
0.016).  Leptin levels were lowest in lean 
patients and tended to be higher in 
overweight patients (P = 0.067) and were 
highest in obese patients (P <0.001). 
Baseline Lean 
(Median Range) 
16ng/mL (10.3 to 
25.6 ng/mL); baseline 
overweight (Median 
Range) 27.7 ng/mL 
(19.2 to 45.5 ng/mL); 
baseline Obese 
(Median Range); 45.3 
(34.5 to 86.3 ng/mL) 
No Yes 48 
Bjersing 2017 Benefits of 
resistance 




IGF-1 and leptin 
This is a sub-study of a previous registered 
randomised clinical trial of physical exercise 
vs relaxation exercise. This published article 
looked at lean, overweight and obese 
women with FM and response to exercise. 
IGF-1 (p= 0.047), IGFBP3 (p= 0.025) and 
leptin (p= 0.008) were significantly 
decreased in lean women (n= 18. The 
clearest clinical response to resistance 
exercise was found in lean patients with FM.  
Median levels 
reported. All (27.7 
ng/mL), lean (21 
ng/mL), overweight 
(39 ng/mL), obese (23 
ng/mL). 
No Yes 43 
 
 





Study Author & 
Year 
Title Brief Summary of Article Baseline Leptin Cases 
ng/mL 
Male Female Total 
N 
Bokarewa 2013 Smoking is 
associated with 
reduced IGF-1 
levels and higher 
pain experience 
in patients with 
FM 
This is an abstract only and provides Leptin 
levels for 63 women with FM all aged 52 years.  
Leptin levels were measured and described in 
relation to their smoking behaviour of smokers 
vs non-smokers (those who have given up 
smoking) = (median: 16.9 vs 34.8 ng/mL, 
p=0.013). Evaluates the possible relation 
between pain, smoking and levels of IGF and 
leptin 
Median of 16.9 ng/mL 
in smokers vs 
34.8ng/mL in non-
smokers 
No Yes 63 





levels and higher 
pain experience 
in patients with 
FM 
Present study addressed the effect of cigarette 
smoking on adipokines and pain parameters, in 
62 women with FM pain syndrome with 
unknown etiology.  Current smokers (n= 18) had 
lower levels of leptin compared to ex-smokers 
(n= 25).  Smoking may be responsible for lower 
levels of leptin which usually reduces pain levels, 
but smokers had higher levels of pain as well as 
lower leptin levels.  
Current smokers 
(n=18) leptin median 
(IQR) 19.4 ng/mL (11.7-
28.7 ng/mL); non-
smokers (n=19) leptin 
median (IQR) 28.8 
(16.4-48.0); ex-
smokers (n=25) leptin 
median (IQR) 36.8 (28-
55.7 ng/mL) 
No Yes 62 
 
  





Study Author & 
Year 
Title Brief Summary of Article Baseline Leptin Cases ng/mL Male Female Total 
N 
Hornig 2017 Immune network analysis 
of cerebrospinal fluid 
(CSF) in myalgic 
encephalomyelitis 
(ME)/chronic fatigue 
syndrome (CFS) with 
atypical and classical 
presentations 
Analysed CSF from 32 cases with 
classical ME/CFS and 27 cases 
with atypical ME/CFS using a 51-
plex cytokine assay. Analysis of 
CSF in ME/CFS with atypical and 
classical presentations 
Leptin ng/mL atypical CFS duration 
short <3 yrs. (n=13) 44.07 ng/mL SD 
26.65 ng/mL; atypical CFS duration 
long >=3 yrs. (n=6) 66.35 ng/mL SD 
54.02 ng/mL and classical CFS 
duration short (n=14) 55.44 ng/mL 
SD 45.25; classical CFS duration 
long (n=18) 78.13 ng/mL SD 61.80 
NB: remember these are CSF 
samples and are therefore 5 times 
higher than that of plasma. 
Yes Yes 59 
Katz 2017 Leptin, a hypothalamic 
signalling hormone, is 
elevated in FM patients 
Leptin was found to be higher in 
FM when compared with 
rheumatoid arthritis patients. 
Leptin levels varied between 1.7 
and 70.7 ng/mL (mean 28.0 ng/mL) 









Study Author & 
Year 
Title Brief Summary of Article Baseline Leptin Cases ng/mL Male Female Total 
N 
Kurajoh 2016 Plasma leptin 
concentration is 
associated with fatigue 
severity in patients with 
cardiovascular risk 
factors- HSCAA study 
This cross-sectional study 
included 347 patients with 1 or 
more cardiovascular risk factors, 
who participated in the Hyogo 
Sleep Cardio-Autonomic 
Atherosclerosis (HSCAA) Study. 
Subjects who underwent a 
complete fatigue scale 
examination and plasma leptin 
measurement were included 
2.32 ng/mL ± 0.75 ng/mL 
moderately fatigued 
Yes Yes 347 
Quismorio 
2014 
Elevated serum leptin 
concentrations in a subset 
of FM patients with high 
inflammatory markers 
Abstract Only: The purpose of 
the study is to measure 
biomarkers using the Vectra-DA 
in FM.  In a subset of FM 
patients with elevated 
sedimentation rate (ESR) and / 
or C-reactive protein.  The 
elevated levels of leptin in this 
subset of FM pts, independent 
of BMI, suggest that factors 
other than obesity may account 
for this  elevation 
45% of subjects had leptin 
concentrations exceeding the range 
reported in rheumatoid arthritis (1-
45 ng/mL). The mean leptin in FM 
was 42.3 ng/mL (range 30-81 
ng/mL). 
6% 94% 33 
 
 






Study Author & 
Year 
Title Brief Summary of Article Baseline Leptin Cases ng/mL Male Female Total 
N 
Younger 2016 Association of Leptin 
with Body Pain in 
Women 
There are two studies, both cohort 
studies. Study 1 analyses the daily 
leptin levels of women with FM (n=3) 
over 25 continuous days, like the 
Stringer study of 2013.  Study 2 is a 
retrospective study (n=5676) of 
generally health postmenopausal 
women, comparing a single blood draw 
with symptoms of self-reported body 
pain. Body weight for the three 
participants was as follows: 60.2, 82.1, 
and 101.2 kg.  
0.7 ng/mL (range 0.2‚-
2.0),10.2 ng/mL (range 5.8‚-
17.1), and 20.5 ng/mL (range 
11.21-38.7 ng/mL)  










4.2 Overview of Cohort Studies and Significance of Results 
 
The nine studies are difficult to compare as they have very different study designs 
and a few of the studies are by the same authors e.g., Bokarewa and Bjersing 
produced two papers each.  These nine studies mostly reported results for 
fibromyalgia, and two studies did not fit under either syndrome description but were 
thought to be important studies by both full text reviewers (Kurajoh et al. 2016; 
Younger et al. 2016).  These were included because they provide good benchmark 
information about the relationship of leptin, pain, and fatigue.  The results to each 
study or pairs of studies are presented in separate tables which summarise the 
changes in leptin during conditional changes during each research project.  These 
research studies usually have small groups of participants and have been 
completed over many weeks, or even months.  The Younger et al. (2016) study had 
just 3 participants in the first part of the study, then it divided the article to include a 
second study which contained an unrelated 5676 participants.  This is just one 
example of how divergent the cohort studies can be from the case-control studies 
presented earlier.  We will now discuss each cohort study in more detail. 
 
4.3 Bjersing et al. (2013 and 2017)  
 
In the first of nine research studies are the two by Jan Bjersing et al. (2013) using 
resistance exercise in a cohort of 48 patients with fibromyalgia over 30 weeks.  
There were three different BMI ranges of lean (n=9), overweight (n=26), and obese 
women (n=13).  We are provided with a median and range of leptin levels at 
baseline, 15 weeks and finally at 30 weeks for women who all had fibromyalgia.  
There are no control subjects. The results are divided into subgroups of weight 
range (lean, overweight and obese).  The participants were all exposed to one of 
two types of exercise, randomised across the cohort and these exercises were a 
moderate-to-high-intensity Nordic walking (NW) program or a supervised low-





intensity walking (LIW) program.  The overall results were that leptin significantly 
negatively correlated with fatigue (r = -0.345; P = 0.016) . 
In the Bjersing 2013 study: “Exercise and obesity in fibromyalgia: Beneficial roles of 
IGF-1 and resistin?”, leptin levels are provided as pg/mL in the tables which have 
now been converted to ng/mL (See Table 19) for comparison in this review which is 
calculated by dividing the picogram result by 1000, providing a result in ng/mL.  The 
changes at 15 weeks and 30 weeks are provided; note that this is the change  from 
baseline and not the actual level of leptin.  There were no significant changes in 
leptin, but a reduction was seen by week 30 in lean patients only.  It is noteworthy 
that only 9 of the 13 obese participants were measured at 30 weeks.  The large 
range in the changes in all categories, lean, overweight and obese are so great that 
these results do not provide confidence.  The range of the changes cited compared 
to the median changes at 15 weeks are so great that it does not allow the researcher 
to make any clear prediction or to discern any value from these results, for example 
the range at baseline in the obese cohort of 13 participants was 34.46 to 
86.31ng/mL.  Therefore, a mean change in the obese group at 15 weeks of between 
-5.53 to 9.05 ng/mL suggests either a reduction or an increase in leptin.  Intuitively, 
you would assume leptin to lower following 15 weeks of exercise training, as this 
would coincide with a potential weight loss.  The figures presented do not provide 
clarity about the effectiveness of these interventions in their ability to influence the 









Table 19 Serum levels of leptin Bjersing et al. (2013) 
 
Four years later  Bjersing et al. (2017) published a similar study: ‘Benefits of 
resistance exercise in lean women with fibromyalgia: Involvement of IGF-1 and 
leptin’ including 43 women with fibromyalgia again using three subgroups of BMI 
ranges of lean (n=18), overweight (n=17), and obese women (n=8).  They had to 
complete an exercise regimen twice per week for 15 weeks and were measured at 
baseline and at 15 weeks and the changes in leptin levels can be seen in the table 
below (Table 20).  These results again provided little confidence as the change in 
lean participants is not very different to the changes in obese participants and have 
a similar upper and lower interquartile range.  Whilst there is no change in 
overweight participants, it could be argued that this merely shows the fluctuations 
of leptin across time in 3 groups of people may be high.  Whether the exercise 
routine has made any changes in these levels would be hard to determine without 
a control cohort who did not do the exercises.  In table 2 on page 5 of the article 
some of the numbers use a comma instead of a period, placing doubt in the 
interpretation of these results.  However, the authors state that leptin was 
significantly decreased over the course of the 15 weeks in lean women with 
fibromyalgia (p = 0.008), which coincided with a reduction in pain and fatigue.  It  
was not significant in overweight or obese women with fibromyalgia. See Table 20 



















Baseline 16.01 10.25 to 
25.63 
27.66 19.22 to 
45.50 
45.30 34.46 to 
86.31 
Changes at 
 15 weeks 
2.14 -4.12 to 
5.40 
1.42 -6.06 to 
6.86 
5.27 -5.53 to 
9.05 
changes at 
 30 weeks 
-4.46 -10.47 to 
2.25 
1.76 -9.91 to 
9.78 
1.45 -3.06 to 
8.13 





Table 20 Serum levels of leptin Bjersing et al. (2017) 
 
 
4.4 Bokarewa et al. (2012 and 2014)  
 
The next two studies were by Bokarewa et al. (2012 and 2014).  The first paper 
(2012): ‘Smoking is associated with reduced IGF-1 levels and higher pain 
experience in patients with fibromyalgia’ is only an abstract and appears to be a 
summary of the following paper published in 2014 as the numbers of participants, 
division of smokers and non-smokers are the same i.e., 45 non-smokers and 18 
current smokers and cites that smokers had lower levels of leptin than non-smokers 
(ng/mL, median: 16.9 vs 34.8, p=0.013).  The abstract provides only limited 
information about the cohort, so we relied on the full paper for more detailed results 
and we did not include either studies in the meta-analysis.  Why smokers would 
have lower levels of leptin is unclear, but the difference cited is quite significant, 
almost halving the amount of leptin compared to those that have never smoked.  
The second Bokarewa paper (2014) appears to be a more expansive report on the 
study provided than that offered in the abstract: ‘Smoking is associated with reduced 
leptin and neuropeptide Y levels and higher pain experience in patients with 
fibromyalgia’ is the full paper on the study and provides much more detail.  This 
study provides results for serum leptin as well as CSF leptin results for the same 
group.  The relationship with serum leptin and CSF leptin suggests that it is more 
than five-fold higher in CSF compared to serum.   






























-15.9 -23.6 to -
0.1 
0 -3 to 
19.6 
-12 -23.1  to 
-2.3 





The research includes 62 women with fibromyalgia and reports that current smokers 
(n=18) have lower levels of leptin compared to those that have never smoked (25).  
It is noteworthy that the CSF levels provided are for just half of the participants (n=32 
of the total 62).  The leptin results of smokers, non-smokers and ex-smokers are 
provided in Table 21 below.  The conclusion of the paper is that lower leptin normally 
has an inverse relationship with neuropeptide Y i.e., the lower the leptin the higher 
the neuropeptide Y and the lower the pain.  However, it was noted that smoking 
does not reduce the experience of pain and suggested that it may cause a change 
of the relationship between leptin, neuropeptide Y and pain.  
Table 21 Serum & CSF Leptin in Smokers Non-Smokers and Ex-Smokers 
 
4.5 Hornig et al. (2017)  
 
The next cohort study is a paper by Hornig (2017) which compares classical MECFS 
and atypical MECFS; ‘Immune network analysis of CSF in myalgic 
encephalomyelitis/chronic fatigue syndrome with atypical and classical 
presentations.’  This study included 32 classical cases of MECFS which were 
previously used in an earlier study (Hornig et al. 2016), and 27 atypical cases which 
included a more unusual onset, having higher cognitive dysfunction as well as other 
neurological issues.  The atypical group met the full criterion for MECFS (either the 
Center for Disease Control’s Fukuda definition or the 2003 Canadian Consensus 







































Serum 19.4ng/mL 11.7–28.7 28.8 16.4–48.0 36.8 28.0–55.7 
CSF 104ng/mL 91–151 165 114–225 178 104–244 





seizures or autoinflammatory disorders (Hornig et al. 2017).  The two groups were 
further divided using a 3-year anniversary to determine short-term cases (⩽3 years) 
or long-term cases (>3 years).  Leptin was not found to be significantly different 
when compared to all other groups with the lowest correlation comparison being 
atypical short vs classical long (p=0.143).  The leptin levels are provided in ng/mL 
and have been assessed using CSF, which we have previously advised is likely to 
be five-fold higher than circulating blood levels.  Although the results appear to be 
expressed in ng/mL, the tables provided in the paper have no labels to signify 
whether these results are ng/mL or pg/mL but comparing this to the previous study 
mentioned earlier it is highly likely to be expressed in ng/mL.  This is a good example 
of poor labelling which was found in many papers selected for the full text phase 
which state results without their type of measurement, particularly as they offer the 
results of other cytokines which are clearly measured in pg/mL.  This leaves the 
reader to assume the type of measurement from the text and method, which is also 
opaque. See Table 22. 




Assumed to be ng/mL but not specified in article. 
4.6 Katz (2017)   
 
The study by Katz (2017), ‘Leptin, a Hypothalamic Signalling Hormone, Is Elevated 
in Fibromyalgia Patients’ provides the results in an abstract only, with very limited 
details and was published as part of a poster session.  It compared 27 fibromyalgia 
participants to 6 people with rheumatoid arthritis.  Stating that leptin levels in the 
fibromyalgia participants varied between 1.7 and 70.7 ng/mL (with a mean of 28.0 
ng/mL) compared to 0.6 to 33.0 ng/mL in those diagnosed with rheumatoid arthritis.  
It goes on to state that the leptin levels to BMI ratio for those with fibromyalgia was 
Atypical short 
duration (N = 13) 
Mean SD  
Atypical long 
duration (N = 6) 
Mean SD 
Classical short 
duration (N = 14) 
Mean SD 
Classical long 
duration (N = 18) 
Mean SD 
44.07 (26.65) 66.35 (54.02) 55.44 (45.25) 78.13 (61.80) 





1.0 and the ratio for those with rheumatoid arthritis was 0.5.  They use these results 
to suggest that leptin is elevated in those diagnosed with fibromyalgia, but also show 
that those with rheumatoid arthritis are less obese.  See Table 23. 





4.7 Kurajoh et al. (2016)  
 
The next paper does not discus MECFS nor fibromyalgia but does discuss leptin 
and fatigue.  It was agreed by the full text reviewers (MM&ML) to include this study 
as it provides information about types of fatigue and their relationship with circulating 
leptin.  Kurajoh et al. (2016) in their paper ‘Plasma leptin concentration is associated 
with fatigue severity in patients with cardiovascular risk factors – HSCAA study’ 
which examined the plasma leptin levels of 347 participants with cardiovascular risk.  
They found that leptin was significantly, positively correlated with a fatigue score.  
Leptin was higher in the group with moderate fatigue (n=53: 2.33 SD 0.75 ng/mL) 
than the ‘normally-fatigued’ group (n=295: 1.85 SD 1.02 ng/mL) p<0.001.  In reality, 
this is a tiny difference that could be accounted for by many factors such as sampling 
error, such as the time when samples were taken, BMI, or even the methodological 
quality at the laboratory level.  The leptin levels provided are quite low across both 
groups i.e., less than 2.5 ng/mL, which is dramatically lower in comparison to the 
other cohort studies cited earlier.  The paper also provides two models which 
produce odds ratios (OR) for higher leptin and the risk of those moderately fatigued. 
In one statistical model they combine the leptin concentration age, male sex, BMI, 
presence of diabetes, hypertension, dyslipidaemia, past cardiovascular events, 
current smoking and other covariates such as alcohol to determine an odds ratio of 
1.904 (CI 1.130-3.211).  Model 2 used leptin levels and alcohol use to calculate an 
Katz 2017 FM (27) mean RA (6) mean 
Leptin levels range ng/mL 1.7-70.7 28 0.6-33.0 10.1 
BMI / Leptin Ratio 1.0   0.5   





OR 1.818 (CI 1.069-3.094), then model 3 leptin and an apnoea hypopnea index 
(AHI) which gave an OR of 1.943 (CI 1.148-3.290).  Another five models provided 
further results in the form of odds ratios – see original article for more details. 





4.8 Quismorio et al. (2014)   
 
The next article is an abstract by Anne Quismorio et al. (2014) and her team, 
‘Elevated Serum Leptin Concentrations in a Subset of Fibromyalgia Patients with 
High Inflammatory Markers’ in the Journal of Arthritis and Rheumatology which 
contained thousands of abstracts from the American College of Rheumatology 
annual meeting held in November 2014.  The study reviewed biomarkers of 
participants with fibromyalgia using a commercially available test kit known as 
‘Vectra DA’ which provides an overall score of 1-100 from the analysis of 12 
analytes, and is normally used to assess rheumatoid arthritis (Segurado & Sasso 
2014).  The test also provides leptin levels which according to the authors was 
significantly higher when compared to patients with rheumatoid arthritis (1-45 
ng/mL).  The result for this cohort who have fibromyalgia showed that 45% of the 
participants had leptin levels exceeding 45 ng/mL with a mean of 42.3 ng/mL (range 
30–81 ng/mL).  This is an example of how circulating leptin levels can be presented 
as wildly different from the previous study by Kurajoh et al. (2016) which cites levels 
of less than 2.5 ng/mL for both cohorts, making it extremely difficult to compare 
between studies.  As this is an abstract only the minimum details of this study are 
provided which included that participants were of a mean age of 43.5 and 94% were 
female.  As part of the development of this thesis, the author of this review 
exchanged email correspondence with one of the American team Dr Sam Metyas, 





Leptin levels ng/mL  2.33 ng/mL 0.75 1.85 ng/mL 1.02 
BMI  25.5 5.5 24.3 4.6 





who advised that the Vectra DA is a common test used by rheumatology clinics in 
America.  They were unable to provide the raw results of leptin.  
 
4.9 Younger et al. (2016)  
 
The last cohort study by a team from a group of American universities including 
Stanford University led by Jarred Younger (2016), ‘Association of Leptin with Body 
Pain in Women’ which examined a cohort of just 3 patients, taking blood every day 
for 25 days, whilst asking the participants to complete a visual analogue scale of 
pain levels experienced during the daytime on a score of 0 to 100. This was 
completed using an android phone each evening prior to bed.   
The researchers hypothesised that leptin is positively correlated to pain even after 
controlling for BMI as a confounder.  This paper is unusual as it has two research 
studies in one article, the second examining the results of samples from a biobank 
donated by 5676 post-menopausal women (aged 50-79) who provided a serum 
sample. These samples included any patients who had yielded a leptin result and 
had completed a questionnaire for self-reported pain.  For the first study, mean leptin 
results are provided with BMI and were analysed using a mixed linear model (not 
described in detail).  The authors reported that higher leptin levels were significantly 
associated with daily pain reports (F (1, 63) = 12.804, p = 0.0007).  Leptin levels 
were higher and were associated with greater self-reported pain levels.  It seems 
odd that in the first study they provide the weight in kg of each participant instead of 
their BMI.  Yet one of their hypotheses is that BMI (not weight) could be a 
confounder.  They explain how the timing of the sample was controlled, but it 
remains a little vague in the details.  The authors also provided information regarding 
the needle type and location of the blood draw, but they don’t state whether the 
samples were taken after a period of fasting blood, which is of greater importance.  
The article provides graphed correlations for pain and leptin levels which are highly 
correlated at r=0.77 (p=0.0001) for two of the participants, and r=0.5 (p=0.18) for 
the third participant.   





The results in the table below (Table 25) are similar to the leptin levels provided in 
other studies for these weight ranges; all participants are within a range of 0.7 to 
38.7 ng/mL.   Overall, this paper is well balanced and describes some but not all 
details of the protocol and method of analysis.  It provides the full leptin results as 
well as the correlations, so it is refreshing to see both are reported and sets a good 
standard for future research. 
Table 25 Study part 1 mean leptin and weight 
 
In the second study of the same paper, it appears that both serum and plasma 
samples were used as it reports collecting samples using various methods of tubes; 
EDTA (plasma tubes) and citric acid (serum tubes), so the results may be of a 
combination of either fluid type.  It is clearer in study 2 that BMI has been assessed 
as a confounder and this is described in the statistical analysis and provided in the 
table.  The following table provides the pain level associated with leptin levels, but 
also the BMI range within each level.  It is evident from this table that as BMI 
measures increase, so does the mean leptin level.  The higher the pain level, the 
more people fall into the combined ‘overweight and obese range’ (i.e., percentage 
BMI in the bottom two rows), and these graduate upwards at approximately 10% as 
it moves up one pain level.  See Table 26 on the following page:  











0.7  0.2-2.0 10.21 5.8-17.1 20.5 11.21-38.7 
Weight kg 60.2   82.1   101.2   
Pain Level None Very Mild Mild Moderate Severe 
N 1344 2120 1216 1012 49 
Leptin ng/mL 13.8 15.3 18.3 20.3 23 
IQR 16.7 18.4 22.9 23.3 29.6 
BMI kg/m2 25.28 26 27.29 27.94 28.92 
SD 5.71 6.39 7.36 7.73 10.27 








index; IQR, interquartile range; SD Standard Deviation 
 
It becomes self-evident that these 9 cohort studies are very different, and the 
authors approach the issue of circulating leptin and MECFS and/or fibromyalgia 
from very different perspectives, making it difficult to compare results between 
studies.  The way samples are collected, the study design and the outcome 
measures use different timescales and interventions.  For example, the first two 
studies by Bjersing are about exercise, fibromyalgia and the experiences of fatigue.  
The following two studies by Bokarewa are about smokers, fibromyalgia and pain.  
The remaining studies have other differences which make them unique, but this only 
allows for a tabular and narrative summary of these studies. 
 
4.10 Critical Appraisal Checklist for Cohort Studies  
 
A critical appraisal checklist was adapted from the JBI Manual of Evidence 
Synthesis chapter 7: Systematic Reviews of etiology and risk, appendix 7.1 ‘Critical 
appraisal checklist for cohort studies (Moola, S et al. 2019).  The checklist helped 
to identify low quality studies, and these can be seen with lower scores in Table 25 
below, and are mainly assigned to the three papers that were written in the form of 
abstracts e.g., (Bokarewa et al. 2013; Katz 2017; Quismorio et al. 2014).  The 
abstract from Katz received a score of zero because it essentially just states the 
results in the abstract without any method or information about recruitment and 
related factors.  The abstracts were kept in the review due to the limited number of 
studies which included leptin levels in MECFS and/or fibromyalgia.  Only one of the 
nine cohort studies was related to MECFS (Hornig et al. 2017) with the remainders 
focusing on fibromyalgia. 
Normal BMI % 46.8 40.8 31.8 27.4 20.7 
Overweight  % 33.6 34.9 36.2 33.3 36.8 
Obese  % 17.9 23.1 30.7 38.5 41.4 





Further details and information about each study can be found in the previous 
section, but the critical appraisal checklist provides a quick overview of what areas 
were covered by each study and those that were not covered.  Only one study 
received an upper score of 8 out of a possible 10 (As one question was not 
applicable to all studies, as there are 11 questions in the original JBI cohort critical 
appraisal checklist).  The highest scoring paper was by Younger et al. (2016), and 
the score reflects that it had explained the methods clearly and provided most of the 
information covered by the questions in the critical appraisal questionnaire.  It did 
not receive a positive response for using similar cohorts because it presented two 
different studies in the one paper with extremely different sample populations e.g., 
the first study has 3 participants, and the second cohort had a sample population of 
5676.  The paper did not try to compare the cohorts but used the two studies to 
explore body pain and its relationship to circulating leptin in women.   
The low scores across the 9 cohort studies reflected the difficulties in trying to 
compare results between papers, which can be seen from the results tables from 
each paper displayed in the previous section.  The following table are the results of 
the critical appraisal checklist in full (See Table 27 on next page): 
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4.11 Outcomes of Cohort Studies  
 
Several interesting results have been presented in the cohort studies, with each 
paper offering unique perspectives.  Bjersing et al. (2017) provide evidence that 
regular exercise can influence leptin levels over time and reduce pain.  Bokarewa 
et al. (2014) indicate that smoking interferes with the leptin / neuropeptide Y 
relationship causing a reduced leptin level in smokers.  Where a fall in leptin would 
normally be expected to reduce the experience of pain, this was found not to be the 
case with smokers because of the changes in neuropeptide Y which it is thought to 
have countered this response.  Hornig et al. (2017) compared classical MECFS with 
atypical MECFS and then subdivided these into short-term (less than or equal to 3 
years and long-term greater than 3 years), resulting in four categories.  No other 
papers have divided these syndromes in this way, making the results difficult to 
compare for the purpose of systematic review.  Leptin levels were not found to be 
significantly different across the four groups. 
Katz (2017) in an abstract provides the mean difference for participants with 
fibromyalgia and those with rheumatoid arthritis, indicating that leptin is higher in the 
cohort with fibromyalgia.  Few details are provided about the method and how the 
results were calculated.  Kurajoh et al. (2016) make a comparison between those 
who experience a normal level of fatigue and those who experience a moderate 
level of fatigue in a group with heart risk factors.  The moderately fatigued group 
had significantly higher levels of leptin, however the overall mean leptin level for the 
total population was less than 2 ng/mL with an SD of 0.99.  Other studies present 
leptin levels for participants that are much higher, like a mean of 35 ng/mL, so when 
comparing these results to this study from a macro multi-study perspective it is 
difficult to understand how they get such contrastingly low measures of circulating 
leptin.  For comparison, the mean of all cases and controls (n=1307) in ng/mL ± SD 
combined was 14.61 ± 12.24 (17.42 ± 14.93 cases and 11.79 ± 9.54 controls).       
The Quismorio et al. (2014) study is another abstract with limited information and 
offers similar results to the Katz study discussed earlier, comparing patients with 
fibromyalgia and those with rheumatoid arthritis.  They do provide a little more 
information about the cohort and the tests involved, whilst citing leptin levels from a 





commercially made analysis kit VECTRA DA.  These kits allow for the test to be 
completed at the point of care, but the high levels of leptin presented (30–81 ng/mL) 
are not seen in most of the case control studies reviewed earlier in this thesis.   
Finally, the study by Younger et al. (2016) presents leptin levels in 3 women with 
fibromyalgia across 25 days, and the higher leptin levels show a high correlation 
with pain.  It should be noted however, that this cohort is small, at only 3 participants.  
In contrast to their second cohort – referred to as study 2, which is the largest of any 
cohort or group in all the studies examined in this review with 5676 participants.  The 
team provide a range of pain levels, BMI, and levels of leptin which range from 13.8 
ng/mL (mean) in those with no pain and up to 23 ng/mL for those with severe pain.  
A clear incremental increase of results from those with mild pain to those with severe 
pain are provided.  These differences relate to repeated themes raised throughout 
the cohort and case control studies including, BMI, symptom severity, pain, fatigue 
and other symptoms like difficulty with sleep or levels of exercise.  The 24 studies 
selected in this systematic review all offer some insight into the role of leptin, 
however, many of them use such different methodologies that it makes them difficult 
to compare.  If this area of research is to progress, then the science in the area 
needs to be more coherent in diagnostic criteria, methodology, process, and 
outcomes.  This would reduce the high level of heterogeneity and allow for effective 





















5 Discussion and Conclusion 
 
5.1 General Discussion 
 
Heterogeneity in the research population of MECFS and/or fibromyalgia is partly 
caused by the fact that they are both considered syndromes.  A syndrome is a 
collection of symptoms which are common to a clinical presentation.  These 
diagnoses rely on clinicians to have knowledge and experience of the condition, but 
because these symptoms are not easily objectively measured, it creates uncertainty 
in the diagnosis.  Another factor that doesn’t help the confusion around diagnosis is 
the changing terminology and social attitudes about the actual existence of these 
syndromes (reviewed in depth in Chapter 1, section 1.15).   
There is a lack of consistency and methodological process in studies which make it 
difficult to compare results.  In an ideal world, future research studies that are 
investigating MECFS or fibromyalgia will use methodology that can be reproduced 
by others.   It is critical to report the results and that they are presented in full and in 
a transparent way to enable a simple comparison across research projects.  It was 
challenging in this systematic review to make such comparisons. Not only were the 
methods and protocols different, but it was extremely hard to find similarities 
between studies, particularly those of a cohort design (See Chapter 4).   
There are several highly cited papers which have been conducted at a research 
laboratory at Stanford University such as Stringer et al. (2013), Montoya et al. (2017) 
and Younger et al. (2016) that provide their results using statistical correlations, yet 
they don’t provide the raw circulating leptin levels to allow consumers or other 
researchers to scrutinise their results.  It is not possible to work out the raw leptin 
levels from the data that is provided, so it is left to the reader to have faith in the 
authors’ output and to assume that these calculations and methods are accurate 
and precise.  It would be helpful for the authors of future studies to publish their 
results in a similar format which includes the original units of measurement that 
enable other researchers to perform a meta-analysis.  Another difficulty was finding 





a comparative level of leptin in humans as this is also inconsistent in the literature.  
We reported a well-rounded exemplar study that provided a comparative circulating 
level of leptin alongside other confounding factors (See Table 3, Chapter 1). The 
example range in this study across gender and BMI range was between 2.2 ± SD 
0.03 ng/mL and 23 ± SD 4.0 ng/mL serum leptin (Al-Sultan & Al-Elq 2006).  A wide 
range! 
The original a priori question was “Is there a difference in circulating leptin levels 
in MECFS and/or fibromyalgia that can be used as an outcome measure in 
cases and controls?”  
In short, the meta-analysis showed a small difference with cases having higher leptin 
levels (hyperleptinaemia) than controls, in fact 3.26 ng/mL higher (CI 0.33 ng/mL to 
6.19 ng/mL).  To put these results in context, those individual research studies that 
did provide baseline circulating leptin results in their natural units (ng/mL) appear to 
be using different magnitudes of measurement. These surprisingly large differences 
reduce the investigators’ confidence in the results. For example, one study (n=38) 
provided a mean result of both cases and controls within a range of between 1.0 
ng/mL and 2.0 ng/mL (cases 1.8 ng/mL – controls 1.75 ng/mL) (Ribeiro et al. 2018), 
whilst another (n=84) reported the results using a range between 11.5 ng/mL to 
30.32 ng/mL (Ataoglu et al. 2018).  That’s a difference of between 10 and 28 ng/mL 
or a magnitude of 10!  Other studies, described earlier, have reported leptin levels 
as high as 70 ng/mL or even higher.   
All case control studies included in this review are measuring human circulating 
levels of leptin in the blood (11 of 12 studies) but there are great disparities and 
making sense of these results is difficult from a scientific perspective.  It adds doubt 
to their credulity and usefulness for translation.  Not all of these studies can be 
representative of the average circulating leptin, because they are so different.  Each 
study included in the meta-analysis were using healthy controls, but we must 
question how the author’s measurements of the mean leptin can be so different. 
These differences in leptin levels point to potential but puzzling discrepancies in 
methodology, laboratory protocols and analysis as discussed in earlier chapters.  
When reviewing these published articles, however, these methodological 





differences cannot be readily discerned from the material presented.  Few details 
are provided about recruitment, sampling techniques, and laboratory methods.   
Imprecision was evident when comparing results. The mean level of circulating 
leptin of controls across all studies should in theory be around the same level, 
however, as you can see from the forest plots in chapter 3 (Figure 8 - 13), they are 
very different.  When we compare this to other blood-based analytes such as the 
level of glucose, insulin or cholesterol then we have a reliable reference level or 
range to rely on. The average human will be expected to fall within a known range, 
and the scientific knowledge about these common biomarkers is based around 
these ‘normal’ ranges.   
These known reference ranges enable a doctor or consumer to make evidenced 
based decisions about interventions, or about changes in stages of a disease.  It is 
an ideal to strive for in MECFS and/or fibromyalgia research.  If you go to your 
general practitioner for example and have a test for diabetes, this can be achieved 
through a simple blood test to check your HbA1c (glycated haemoglobin test). When 
your fasting blood sugar is less than 100 mg/dL (5.6 mmol/L), then we know you are 
unlikely to have diabetes based on these results.  These types of biomarkers are 
simple and objective, allowing clinicians to benchmark against whole populations 
with confidence about their clinical implications.  In current practice using leptin as 
a biomarker is far from this ideal due to the inconsistent reports of baseline 
circulating leptin levels.  As an investigator who is researching leptin and trying to 
advance the understanding of results across studies, it was not easy to work out the 
justification for the differences reported. We can only assume that investigators are 
using very different analytical techniques and methodologies.  Having inconsistent 
results which report both hypoleptinaemia and hyperleptinaemia for the same 
syndrome is unhelpful in advancing this area of research.   
To make sense of these outcomes and to make a valid comparison it was necessary 
to use a standardised mean difference, but this makes it difficult to be certain of the 
changes of raw circulating leptin levels from the pooled result because the pooled 
effect has to be re-translated from the SMD outcome back to the original 
measurement units in ng/mL using one of the controls groups means.  This method 





is explained in more detail in Chapter 3.  Before we can justify further research in 
MECFS and/or fibromyalgia and leptin, we need to find a way of developing a 
baseline range which uses the same methodology so that when research is 
compared between subjects, we have a reference range that we can rely upon 
similar to the standards of HBa1c test.  Once we have a reliable reference range, 
we can then start to interpret observed effects in relation to the introduction of other 
independent factors like smoking or exercise, but until we have these benchmarks 
then the benefit of diverse cohort research of this nature will be limited. 
As previously stated, the results of the meta-analysis of the twelve combined case 
control studies indicated that leptin is slightly higher in cases compared to controls 
by 3.26 ng/mL (See Table 17, Chapter 3, page 112). This was calculated in SUMARI 
with an overall pooled difference of 0.39, with a 95% Confidence Interval 0.04 to 
074, which was significant (p=0.029) (Tau2 = 0.3, Chi2 = 118.65, df = 11 (p<0.00001); 
with a very high level of heterogeneity at I2= 86%, Z=2.18.  The re-expressed result 
in the natural units 3.26 ng/mL indicates leptin is higher in cases (CI 0.33 ng/mL to 
6.19 ng/mL) compared to controls reflecting the standardised mean difference 
reference 0.39 (CI 0.04 to 074).  Many combinations of subgroup meta-analysis 
were completed to establish new information. 
When comparing results however, we have to consider the precision of these leptin 
levels because as we have discussed they can change throughout the day, as there 
are intraday and inter-day differences that can also be vastly influenced by many 
confounders (See Figure 2 Chapter 1) (Al Maskari & Alnaqdy 2006; Licinio et al. 
1997). The pooled difference (3.26 ng/mL) is only a starting point to begin new 
investigation.  If we use the raw mean leptin level for all participants (1307) which 
was 14.61 ng/mL with an SD (12.24 ng/mL), it provides a benchmark for currently 
available studies. The SD (12.24) however is high, meaning that an increase of 3.26 
ng/mL from the mean level would likely lose any clinical relevance.   It would not 
necessarily support a diagnosis that the person with a higher reading will have 
MECFS or fibromyalgia, as it may be due to an increased level of BMI or be 
influenced by the peak phase of the person’s menstrual cycle (the luteal phase) (See 





Chapter 1, Figure 1).  Alternatively, it may be due to their, sex, sleep quality, activity 
level, or simply unexplained individual difference.   
Future research in this area, through good design, should consider all these 
confounding factors when making comparisons across populations, and only then 
can we begin to make inferences about the biological effects about the levels of 
circulating leptin.    Any published research needs to be transparent and to provide 
all the results where practicable, not just correlations and complex statistical 
extrapolations.  The clinical science and scientific method rely on the basic premise 
of identifying observable changes and effects, but we cannot observe effects if we 
don’t have the data.  We need to see the results. 
A good example of study design were those studies that had taken multiple samples 
from the same individual over 24 hours (Licinio et al. 1997; Licinio, Negrao & Wong 
2014).   Two other studies that were examined at the full text stage of this review, 
but then excluded due to them not including raw leptin results, demonstrated that 
there is a correlation with leptin and symptom severity, particularly pain and fatigue.  
The authors showed that these symptoms correlated to transient levels of leptin 
across 25 days, as described by Stringer et al. (2013) which is an MECFS study 
(n=10 MECFS & 10 healthy controls) and Younger et al (Younger et al. 2016) which 
examined body pain in women (n=3 cases but no controls). There is also evidence 
to suggest that higher amounts of leptin (hyperleptinaemia) influence other pro-
inflammatory cytokines, promoting their production and dispersion, as well as 
influencing many other immunomodulatory mechanisms (Montoya et al. 2017; 
Procaccini, Jirillo & Matarese 2012). 
So how did the meta-analysis results compare to the separate results of individual 
studies?  Visual inspection of the forest plots (Figures 8 – 9), highlight imprecise, 
variable results that are inconsistent and have wide confidence intervals with 
overlapping boundaries.  There are few logical patterns other than to state that on 
average there are more studies showing higher levels of leptin in cases (6 studies), 
than those showing no difference (4 studies) or an opposing difference (2 studies).  
Several previous systematic reviews on blood based analytes in MECFS have 
simply stated whether cytokines are higher or lower in cases or controls (Blundell et 





al. 2015).  This provides limited information for clinical practice, hence the reason 
for this current systematic review being completed to find some numerical baseline 
reference range for circulating leptin in cases of MECFS and/or fibromyalgia and 
controls.  However, as indicated by the systematic review by Blundell et al. (2015), 
the search for other novel biomarkers is suffering from similar difficulties in 
establishing a ‘normal’ or population-based reference range.  Whilst science is 
making rapid advances, the interaction of human cytokines and adipokines is not 
yet fully understood.    
Another key issue that decreases confidence in the results is the very high degree 
of heterogeneity in the pooled results (I2=86%).  The pooled outcome was 0.39 
SMD, however there are wide confidence intervals, and the fact that two studies 
report the opposite to most of the other studies sows seeds of doubt. The second 
factor is the inconsistency of research design in each study, leading to the lack of 
precision with diagnostic categorisation.  This may be due in part to the ongoing 
controversial nature of both syndromes, a lack of funding for this area of clinical 
practice, or that practitioners question their belief in the existence of these 
syndromes, creating diagnostic confusion (Natelson 2019).   
Thirdly, there is a potential risk of bias caused by confounders not being 
systematically included and accounted for in most of the full text studies including 
BMI, age, sex, menstruation, diet, activity and ethnicity.  Whilst many authors 
included BMI statistics, not all did, and all confounding factors have not been 
systematically considered. 
In summary, leptin is potentially higher in cases of MECFS and/or fibromyalgia but 
we cannot be confident or certain of these results.  The clinical value of this small 
but significant difference is limited. Further research is warranted under more 
stringent conditions that take account of confounding factors, and further attempt to 
reduce heterogeneity.  A single sample at one time point is likely to be insufficient 
to account for a person’s baseline result, in which to compare those that are 
symptomatic and those that are well or to show changes in groups.  Instead, it is 
preferred that multiple samples are taken from the same individual within a 24-h 
period, or even across a series of days.  Once consistency in results is achieved, 





we can then work toward the behavioural challenges targeted in some of the cohort 
research such as mild exercise or smoking.  BMI differences have been shown to 
have the biggest impact on circulating leptin, there are already some good examples 
in the literature of this being completed in healthy cohorts as described earlier (Al 
Maskari & Alnaqdy 2006; Al-Sultan & Al-Elq 2006).  These exemplary studies are 
few and this area warrants further investigation supporting a systematic review 
process. 
The individual differences in leptin levels may be best limited to ‘intra-person’ style 
studies similar to the one described by Stringer et al. (2013).  They used the method 
of including a small sample size but taking several bloods tests across multiple days.  
‘Intra-person’ is a suggested method whereby an individual provides many samples 
across a set period of time, and the ensuing analysis is done by associating that 
person’s symptoms with their own fluctuating levels of leptin.  The two association 
studies described earlier have only limited participants (as few as 3), but the design 
is more reliable as the investigators describe the correlated changes in daily leptin 
levels as opposed to a mean average change for a group (Stringer et al. 2013; 
Younger et al. 2016).  A criticism is that the studies did not provide raw results, but 
instead used graphical representations pairing leptin levels and standardised 
correlation figures for each person.  There were no leptin levels provided in 
supplementals either.  
Some authors may not have published their raw data because of the inherent 
variation of leptin between individuals, which can be problematic, as there is no clear 
understanding for these differences other than key factors like BMI and genetic 
variation, which are yet to be fully established (Erez et al. 2011).  A healthy person 
may naturally have high leptin levels which can be caused by leptin resistance 
(Myers et al. 2012), whilst another person who is unwell may have a low leptin level.  
We need to research the nature of individual and group variability, so we can better 
understand the pathological disease process or at a minimum develop a useful 
diagnostic marker.  A consistent finding is that the higher the adiposity, or BMI, the 
higher the leptin level (Izquierdo et al. 2019).  Higher leptin levels have been linked 
to multiple symptoms like neuropathic sensitivity to pain and in the role of fatigue but 





further research is required to explain these links (Kurajoh et al. 2016; Maeda et al. 
2009).  
Was it appropriate to combine both MECFS and fibromyalgia in this systematic 
review?  In several studies the research across both areas examined similar 
syndrome factors such as pain and fatigue, but not consistently enough to provide 
a subgroup analysis.  It was useful to combine results to be able to report an overall 
comparison, as well as providing the ability to see the differences between the two 
types of syndromes. When the results were separated into each syndrome for this 
subgroups analysis, there was only a small change in the overall outcome, and this 
was supportive of combining these investigations. One author has even suggested 
that MECFS and fibromyalgia may be the same phenomenon (Abbi & Natelson 
2013).  As discussed earlier, authors have previously combined these disorders to 
compare symptoms in other areas. 
 
5.2 Impact of any limitations and operational definitions 
 
Whilst it seemed like a straightforward idea to do a meta-analysis to compare leptin 
levels across various research studies, it created many complexities. The lack of 
certainty in outcomes plagues the research of MECFS and/or fibromyalgia, which is 
not assisted by the controversies associated with the syndromic names discussed 
earlier.  Organisations like the National Health and Medical Research Institute 
(NHMRC) and the American College of Rheumatology are working to consolidate 
the research approach providing an advisory document entitled ‘Myalgic 
Encephalomyelitis / Chronic Fatigue Syndrome Advisory Committee’ in 2019 
(NHMRC 2019; Wolfe, F et al. 2010).  Similarly, the NIH recognised the need to 
progress cohesive research in this area and formed a collaboration known as the 
‘Trans-NIH Myalgic Encephalomyelitis / Chronic Fatigue Syndrome Working Group’ 
examining shared interest across agencies and in 2017 announced the ‘Centre for 
myalgic encephalomyelitis/chronic fatigue syndrome research’ (NIH 2017).   





In 2007 the National Institute of Clinical Excellence produced guidelines in the UK 
to support treatment approaches and research ‘Chronic fatigue syndrome / myalgic 
encephalomyelitis (or encephalopathy): diagnosis and management’ (Hairon & Nice 
2007).  These guidelines were recently updated in 2020 with a contrasting position 
to their original recommendations, stating that there is a ‘lack of evidence’ to support 
cognitive supportive and graded exercise therapies (Turner-Stokes & Wade 2020).  
This shows the changing landscape and the controversy that continue to surround 
these syndromes. The International Consensus Criterion which was developed by 
an international collaboration of clinicians and researchers identifies the preferred 
term for Chronic Fatigue Syndrome as Myalgic Encephalomyelitis and the 
International Consensus Criterion are available from the NHMRC website in the form 
of a primer document (Carruthers et al. 2011).   
Even with issues surrounding the naming consensus the research continues to 
publish with the term ‘Chronic Fatigue Syndrome’, so the contemporary literature 
uses both terms together in the title of publications, which contain either an oblique 
separating the two terms, or the conditions are merged together in the form of 
“MECFS”, as in the format chosen in the title of this thesis.  
This is not necessarily the right format but the preferred term to encompass the 
literature and it is used for convenience rather than correctness.  There are at least 
a dozen recent articles using the term “Chronic Fatigue Syndrome” and can be found 
in PubMed as recent as February 2021.  Many authors have commented on the 
labels used in Chronic Fatigue Syndrome but the term CFS has been used since at 
least 1988 (Twisk 2018).  Other issues about the descriptors have been discussed 
in detail earlier in this thesis. 
All studies were included in the meta-analysis regardless of sample size with a range 
n=20 to 646, with a mean number of participants n=108 across the twelve studies.  
Including studies with n<=50 participants, which equated to half of all studies. 
The consistency of publishing the measurement outcome was problematic.  Leptin 
is an adipokine that can be measured in serum, plasma or CSF but in some papers, 
it is reported in pg/mL, and in others ng/mL.  Where pg was used then a simple 
calculation to convert the results was used i.e., dividing the result in picograms by 





1000 to provide ng.  It appeared that some graphs and tables are mislabelled, and 
one study was excluded because of this obvious error (Covelli et al. 2005). 
An issue of concern is that leptin has a pulsatile circadian rhythm, and leptin levels 
change across the day and therefore the levels reported in many of the articles may 
not be an accurate representation of an individual’s mean circulating leptin. The 
baseline can also be very different across the population and is dependent on 
multiple known factors such as BMI, ethnicity, gender, and others (Challet 2015; 
Licinio et al. 1997).  Not all studies that were selected for the full text phase provided 
enough detail required for analysis, particularly potential factors that may confound 
the outcome.  Leptin affects many different systems in the body but having the ability 
to cross the blood brain barrier it is known to have an influencing effect on one of 
our brain’s master coordinators, the hypothalamus. This in turn affects the 
hypothalamic-pituitary-adrenal axis through circulating hormones and our nerve 
pathways (Challet 2015). Making assumptions about leptin mean values are 
precarious in that people have different baselines (Zhou & Chen 2018).   
 
5.3 Implications for practice 
 
The inspiration behind this thesis was the need to find a ‘normal’ level of leptin to 
compare with MECFS and/or fibromyalgia patients to see if there was an obvious 
difference, with the hope it would be a potential biomarker for research.  The 
implications for practice are that the current evidence on leptin in MECFS and/or 
fibromyalgia is weak.  To support advances in treatment it would be helpful to know 
how leptin behaves and how it contributes to the disease process.  If we were able 
to modify the frequency that we measure leptin across populations then we would 
have a better measure of how and why changes might be occurring.   
Considering its pleiotropic, hormonal, immunological and neurological influences, 
we need to know how this adipokine is affecting the ‘normal’ human body before we 
can make assumptions about its effects within the disease process.  As leptin was 
only discovered in 1994, when it was declared to be a major factor in obesity and 





weight changes, we have come a long way in realising the importance of this 
adipokine and its pleiotropic effects on our system.  A basic search for the word 
leptin in pub med reveals 38,490 hits, indicating that a lot of new research is 
underway.  Much of the work on leptin has been done in animal research, which is 
where the animal and human homologue of the original Ob gene (Lep gene) was 
discovered (Zhang et al. 1994).  A way forward for clinical practice may be to include 
leptin levels in the standard blood test used during an essential annual health check.  
For example, just as cholesterol, iron and glucose levels are tested, leptin levels 
could also be tested.  This would establish a population benchmark to work from.  In 
the meantime, mass data obtained from international biobanks to generate some 
baseline comparators could another approach.  To this end, the author has 
contacted the UK Biobank to register a research request. 
 
5.4 Implications for research 
 
Large cohort and case control studies should be performed to discover the normal 
range of leptin in healthy humans before we can investigate changes in a syndrome 
such as MECFS and/or fibromyalgia. Many current studies rarely amount to more 
than 100 participants.  With large biobanks being developed in different countries, 
this population could be accessed to obtain some comparative data for leptin.  It is 
necessary to be able to distinguish and predict changes between the effects of 
confounders such as BMI, age, sex and adiposity before we can start to investigate 
outside these parameters.   Evidence is growing that links hyperleptinemia with the 
sensitisation of pain and the outcome of symptoms like fatigue, but the research is 
often completed in diseased cohorts such as arthritis patients, cardiovascular 
disease, or inflammatory diseases like hepatitis, diabetes and cancer.  Sifting out 
which symptoms that might be caused by leptin is lost in the noise of these comorbid 
diseases.  Indeed, in this systematic review we came across interesting and novel 
research into exercise, smoking, and obesity which exhibited effects on baseline 
leptin between cohorts across time, but the results are of limited for translation into 
clinical practice.  However, the research completed does provides some guidance 





to future experiments, providing preliminary data and timelines for similar sized 
cohorts.   
 
5.5 Recommendations for future research 
 
Following an exploration of the literature for this systematic review the author has 
created some practice protocol recommendations for future publications and 
research.  These 10 recommendations consider some of the issues and challenges 
experienced during this review: 
 
1. Confounders are identified such as BMI, adiposity, age, ethnicity, sex, 
lifestyle (e.g., level of fitness and activity, comorbid issues, and historical 
factors such as previous major illness).  The phase of the menstrual cycle is 
rarely mentioned but has been reported to significantly alter leptin levels 
across time. Leptin levels in men and women should be investigated 
separately, as there is a threefold difference in women.  Use international 
biobank data such as the UK Biobank to obtain datasets on these factors, 
e.g., BMI, sex, age, and leptin ranges. 
2. Consistent use of circulating fluid type:  Many studies have used serum, but 
a consistency of fluid type would be helpful. When trying to compare serum 
levels in one study against plasma or CSF in another remains problematic.  
Serum is more stable, is less time critical and more practical to collect and 
allows for 30 min at room temperature before the need to aliquot and freeze. 
3. Clarify time parameters: because leptin has circadian changes across 24 h, 
supporting the body’s time clock is one of its functions, so it is important to 
know at what time the person started their fasting and what time the sample 
was taken.  When the sample is taken, it should be within a time window and 
the same for everybody in the study i.e., between 9-10 am, or at another time 
which is made very clear in the protocol.  For some studies samples have 





been taken daily for 25 days.  A consistent time should be used and needs 
to be reported in the results.  The method of taking a series of samples across 
24 h will provide a more accurate reflection of the individual’s leptin levels. 
4. Measure activity and diet: these are basic communication pathways that 
affect hormones within our body, therefore leptin levels need to be linked to 
these factors.  For example, one participant may be active, and another 
bedridden.  These will have major effects on the leptin outcome.  Diet is 
another factor because leptin is a hormone that controls activity such as food 
consumption in animals and humans.  Some people are believed to have 
leptin resistance – not dissimilar to the process of insulin resistance.  It has 
an interplay with other hormones such as ghrelin, insulin and circadian linked 
controlling clock mechanisms.  
5. Specify frequency of sampling: If samples are going to be taken across time, 
then evidence has been provided that the pulsatile nature of leptin means the 
levels change approximately every 32 min but has been taken as frequently 
as every 7 min in some studies for a 24-h period.  The highest level of leptin 
occurs between 10 pm and 4 am in the morning, yet samples are taken at the 
known trough which is around 8 am until noon.  This would be the least 
representative time to take a leptin sample, yet most studies have taken the 
levels at this time.  It would be more representative to take a sample in each 
of the time zones, but this is impractical and difficult to do if the person is 
assessed after fasting.  We know that fasting has little effect on leptin levels, 
so further investigation is required to see if it needs to be part of the research 
design.  To obtain a representative serum level it is recommended to take a 
minimum group of samples across the four quadrants in the 24-h period. 
6. Method of intra-person or inter-person measures: leptin is different between 
individuals and the pattern in humans is inconsistent.  Therefore, comparing 
measures across a group of people may not be the best approach, but 
instead comparing relative changes as part of one individual’s leptin profile 
may be a way of disambiguating the results.  This has been done in several 
studies where they took results once per day for just a few individuals. An 





exemplar is the study by Licinio et al. (1997) which measured individuals 
across 24 h and provided the leptin level changes every 7 min (but not in 
MECFS or fibromyalgia).  They also demonstrated it in another study with a 
group of healthy controls collecting 2070 samples from 10 healthy 
participants over 24 h (approx. 207 each) (Licinio, Negrao & Wong 2014).  
Whilst this may appear excessive, from a research perspective this method 
may be more productive than taking just one sample per day.  A compromise 
would be an increase in frequency of measures within a day e.g., a minimum 
of 4 to 12 timepoints across 24 h.  Some studies have taken one sample at 
15 weeks and 30 weeks, but as leptin fluctuates from day to day, this may be 
a fruitless method, and an intraday sampling at these timepoints needs to be 
considered.  It is important to include the measures of other biological and 
activity changes which are confounding factors such as weight, diet and 
activity which may have all changed across time e.g., in someone dieting. 
7. Accurate sampling, sample handling, storage and analysis: Every study has 
slight differences in how the sample is taken, how long it takes from sampling 
to centrifugation, what speed and length of time centrifugation occurs 
(including simple factors like G-Force), and how quickly the serum, plasma 
or CSF is frozen or unfrozen.  How long samples are stored and how many 
times they have been defrosted is relevant to the level of analytes measured.  
There are also different types of analysis such as radioimmunoassay as well 
as enzyme linked immunosorbent assay.  There are different commercial kits, 
providing potentially different results for the same group of samples.  It is 
recommended that wherever possible similar methods are used across 
studies. 
8. Regulate the use of questionnaires used to assess levels of symptoms and 
comorbid issues: these need to be the same across these types of 
syndromes, but also so that symptoms can be compared across syndromes 
and other diseases.  An example of a consistent measure is the Fibromyalgia 
Impact Questionnaire (Revised) or using a visual analogue scale of pain on 





a scale of 1-100.  Whatever measures are selected they need to be 
consistent across studies to enable systematic symptom data investigation. 
9. Publishing results with transparency: Some research papers have not made 
their raw data available, that is the levels of leptin and other analytes, in their 
natural form of measurement such as nanograms or picograms per mL.  
Whilst associations are useful to link severity within a study, unless the raw 
results are provided it limits the researcher’s ability to compare across 
studies, reduces transparency, increases the risk of bias, and makes the 
evidence difficult to translate. 
10.  Increase objective measures: The controversy of diagnosis remains, and a 
greater reliance on objective evidence rather than self-report measures need 
to be developed.  It’s a cyclical argument but we need to used discovery 
research to identify these biomarkers before we can use them objectively, 
supported by consistent scientific methods which provide objective 
measures. The full armoury of current technology needs to be used including 
CAT scans, regular blood measures, ECG, EEG’s, genetic variants and 
epigenetic mRNA changes (both mitochondrial and cellular), and a greater 
reliance on objective evidence from wearable devices.  Another method is 
performing post-mortem examinations of organ changes such as the brain, 
and heart, which can be performed at both the macro and cellular level.  This 





Based on the combined results of this systematic review, leptin is slightly higher in 
cases in MECFS and/or fibromyalgia syndrome patients than healthy controls.  The 
degree of confidence in these findings is of very low certainty, and other confounding 
factors may be an explanation for such difference.  Following an initial scoping of 
the literature, it was hypothesised that cases would indeed be higher than controls, 





as this was foreshadowed in several articles on the pro-inflammatory effects of 
leptin. However, upon completing this review, two studies reported results in the 
opposite direction, which has left us with a landscape of confusion.  That is, two 
studies reported hypoleptinaemia (lower leptin), in cases compared to healthy 
controls.  The cohort studies were so unique that they offered little use for 
comparison across this type of study design and were not used in the case control 
meta-analysis.  For example, trying to compare the difference in patients with 
fibromyalgia who are smokers, and the difference in people who exercise would not 
make sense.  Others compared arthritic patients, patients with depression or 
multiple sclerosis to fibromyalgia patients, and some of these articles were of low 
quality in the form of abstracts which only offered limited evidence or design detail. 
Much of the literature describes the role of leptin as being part of an auto-immune 
process, but upon reviewing the evidence presented in this systematic review, it can 
only be concluded that leptin there is no clear evidence to support this.  Therefore, 
though regularly reported, the relationship to inflammatory processes could not be 
substantiated by this review.  As discussed earlier, the inconsistency of results was 
disconcerting, as there were two studies that reported lower leptin in cases 
compared to controls, and four studies that showed no discernible difference, and 
six studies that indicated significantly higher levels of leptin in cases.   
There are too few studies of similar design to draw confidence from the current 
available evidence.  The methodology is very different in each study, causing some 
difficulties in comparison.  A series of benchmarks and protocols need to be 
developed if exploration of biomarkers in these syndromes is to yield useful results. 
To provide clarity, clinical investigators need to use similar standard practices and 
methods to aid comparison of circulating leptin levels.  This challenge includes the 
way results are reported and published, but as a minimum the publication of the 
baseline leptin levels need to be provided.  Additionally, a standard list of 
confounders including age, sex, ethnicity, BMI, diet, activity level, menstrual cycle 
phase, and an accurate time of when the sample was taken.   





The preferred design would be to provide a minimum number of measures from one 
individual across a 24-h period to capture the zenith (peak) and nadir (trough) levels 
of circulating leptin.  Further to this, it would be better to examine changes of an 
individual’s fluctuations of leptin in relation to other behavioural parameters or 
introduced changes than across a group.  The mean amplitudes of these individual 
results still lend themselves to for comparison across similar groups (e.g., lean, 
overweight and obese).   
Our current understanding of circulating leptin differences across subpopulations is 
insufficient, as an intra-day, intra-person method is the only objective design that 
makes any scientific sense.  If a person’s baseline leptin is consistently measured 
at 8 am, 4 pm, 10 pm and 4 am, then we could add new parameters such as exercise 
for that individual, once their usual levels are known.  Further work about disease 
longevity, how long the person has  suffered from the syndrome, is required to 
determine if there are differences in short term and long-term cases.  Where studies 
are completed across time, then it is important to note changes in daily activity 
against these differences.  That is, consideration of the environment, life 
experiences and biological interactions over time.  The person environment 
interaction.  Researchers should publish all the details including the cofounders, the 
raw measurements as well as the effect of the parameter being investigated.  The 
method described earlier in this thesis of taking samples every 7 min may be too 
frequent as we know that leptin changes only every 32 min with a similar number of 
pulses across 24 h (Licinio, Negrao & Wong 2014).  There are two consistently 
reported diurnal changes with low leptin in the morning, and high leptin in the middle 
of the night, but a few additional measures would provide helpful interquartile 
changes.  The ideal frequency to obtain a mean average 24-h leptin would require 
further investigation, but once per day is clearly not enough.   
The controversy surrounding the diagnosis of both MECFS and fibromyalgia is 
problematic and further investigation and discovery of biological objective measures 
may help overcome these challenges.  Pain and fatigue have been identified to be 
some of the key symptoms correlated with circulating leptin. A symptom focused 





approach could be a way forward.  However, severity of symptoms are usually 
obtained from self-report, and  more objective measurements for these symptoms 
would be helpful.  There may be better objective and technological ways to measure 
symptoms like pain such as changes in EEG, or muscle changes, and for fatigue 
we could use heart and breathing rate collected by wearable devices to obtain 
changes in VO2 Max (a measure that indicates the amount of oxygen you can 
access during exercise) (Keller, Pryor & Giloteaux 2014; Nelson et al. 2019).   
Whilst the literature review did not provide strong evidence for leptin being the 
biomarker of choice for investigating these syndromes, it did highlight the need for 
objective, empirical scientific evidence and a reduction in heterogeneity for the 
investigation of MECFS and/or fibromyalgia.  This thesis has presented the 
difficulties that will continue to ensue if consistent protocols for future research and 
publication are not developed.  There needs to be a consensus for the investigation 
methods in MECFS and/or Fibromyalgia. The sooner we achieve some shared 
standards then we can form a foundation of evidence for understanding the 
biological mechanisms in these syndromes. 
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Table 28 All Database Searches 
Embase, PsycINFO, PubMed, Science Direct, and Scopus on 3rd April 2020 
(updated on 27/7/20).   All databases were searched on the same date. 
Search 
Database 
Search Terms - Exact Comments Found  
Pub Med ((“fatigue syndrome, Chronic"[Mesh] 
OR “Chronic Fatigue Syndrome” OR 
Fibromyalgia OR Myalgic 
Encephalomyelitis OR ME/CFS OR 
MECFS OR ME-CFS OR Febricula OR 
“Neurocirculatory Asthenia” OR 
“Atypical Poliomyelitis” OR Akureyri 
OR “Royal Free” OR Tapanui OR 
“Chronic Epstein Barr” OR “Systemic 
Exertion Intolerance Disease” OR 
"postural orthostatic tachycardia 
syndrome" OR POTS) AND (Leptin OR 
"Leptin"[Mesh])) 
Search is exact 52  
Embase ('chronic fatigue syndrome'/exp OR 
'chronic fatigue syndrome' OR 
'fibromyalgia'/exp OR fibromyalgia OR 
'myalgic encephalomyelitis' OR 'me cfs' 
OR mecfs OR ME-CFS OR febricula 
OR 'neurocirculatory asthenia' OR 
'atypical poliomyelitis' OR akureyri OR 
'royal free' OR tapanui OR 'epstein barr 
virus infection'/de OR 'chronic epstein 
barr' OR 'systemic exertion intolerance 
disease' OR pots OR 'postural 
orthostatic tachycardia syndrome'/de 
OR 'postural orthostatic tachycardia 
syndrome') AND ('leptin'/exp OR leptin) 
Removed ME 
as this is an 
abbreviation but 
can be mistaken 




((Chronic Fatigue Syndrome or 
Fibromyalgia or Myalgic 
Encephalomyelitis or MECFS or ME-
CFS or Febricula or Neurocirculatory 
Asthenia or Atypical Poliomyelitis or 
Akureyri or Royal Free or Tapanui or 
Chronic Epstein Barr or Systemic 
ME was only 
searched in title 
as it is too short 
and can be 
confused for the 
pronoun 
‘me’.  All other 
273  







Search Terms - Exact Comments Found  
Exertion Intolerance or POTS).af. or 
ME.ti.) and Leptin.af. 




('chronic fatigue syndrome'/exp OR 
'chronic fatigue syndrome' OR 
'fibromyalgia'/exp OR fibromyalgia OR 
'myalgic encephalomyelitis' OR 'me cfs' 
OR mecfs OR ME-CFS OR febricula 
OR 'neurocirculatory asthenia' OR 
'atypical poliomyelitis' OR akureyri OR 
'royal free' OR tapanui OR 'epstein barr 
virus infection'/de OR 'chronic epstein 
barr' OR 'systemic exertion intolerance 
disease' OR pots OR 'postural 
orthostatic tachycardia syndrome'/de 
OR 'postural orthostatic tachycardia 
syndrome') AND ('leptin'/exp OR leptin) 








"Chronic Fatigue Syndrome" AND 
Leptin = 81 
Fibromyalgia AND Leptin =137 
Leptin AND "Myalgic 
Encephalomyelitis" = 10 
Leptin AND ME-CFS = 9 
Leptin AND MECFS = 0 
Leptin AND Febricula = 0 
Leptin AND “Neurocirculatory 
Asthenia" = 0 
Leptin AND “Atypical Poliomyelitis" = 0 
Leptin AND Akureyri = 0 
Leptin AND "Royal Free" = 57 
Leptin AND Tapanui = 0 





and each term 
was separately 
matched with 
leptin.  It 
allowed an 
oblique to be 
used so 
ME/CFS (3) 















Search Terms - Exact Comments Found  
Leptin AND "Systemic Exertion 
Intolerance Disease" = 0 
Leptin AND POTS = 123 
"postural orthostatic tachycardia 




only accepts 8 
boolean 
operators as a 
maximum and 
returned too 
many results so 
it has been 
broken down to 
smaller 
searches.  Each 
pair needs to 
be search 
separately or 
you get less 
rather than 
more. 
  duplicates 94 
subtotal   959(865)  
  
  Page 
 
181 
Table 29 All 85 Excluded Studies 
 




Reasons for exclusion 














Recent studies have implicated leptin as a 'stress' 
hormone and highlighted its association with increases 
in inflammatory cytokines, C-reactive protein and 
cortisol. In order to investigate the exact temporal 
leptin response to stress we undertook a detailed 
longitudinal study of circulating leptin concentrations 
during the well-defined surgical injury of 
cholecystectomy. Circulating concentrations of cortisol, 
free fatty acids, leptin and C-reactive protein were 
measured at 3, 6, 9, 12, 18, 24, 48 and 72 h from the 
start of surgery in nine patients. There was a significant 
correlation between baseline concentrations of leptin 
and BMI (r = 0.893, P < 0.001). Over the 72 h from the 
start of surgery there were significant (P < 0.05) 
increases in the concentrations of all analytes (peak 
median concentrations); cortisol (6 h), free fatty acids (9 
h), leptin (18 h) and C-reactive protein (48 h). 
Interestingly the timing of the leptin peak at 
approximately 18 h after an acute inflammatory 
stimulus is exactly the same as previously reported for 
interleukin 6.  
2000 Cytokine #284 Exclusion reason: Wrong 
patient population; Martin 
Lewis (2020-04-29 
14:27:22)(Select): Study 2. 
Large number of 
postmenopausal women. 
Maybe provide a good 
reference for variability etc. ; 
Michael Musker (2020-04-22 
16:44:45)(Select): Exclude: 
Refers to plasma levels 
following acute surgery.  
Wrong study population.  
provides leptin levels over 24 
hours following surgery and 
suggests leptin levels mirror 
the relationship between 
cortisol and IL6.;  









Reasons for exclusion 















There has been much interest in the role of the immune 
system in the pathophysiology of chronic fatigue 
syndrome (CFS), as CFS may develop following an 
infection and cytokines are known to induce acute 
sickness behaviour, with similar symptoms to CFS. Using 
the PRISMA (Preferred Reporting Items for Systematic 
reviews and Meta-analyses) guidelines, a search was 
conducted on PubMed, Web of Science, Embase and 
PsycINFO, for CFS related-terms in combination with 
cytokine-related terms. Cases had to meet established 
criteria for CFS and be compared with healthy controls. 
Papers retrieved were assessed for both inclusionary 
criteria and quality. 38 papers met the inclusionary 
criteria. The quality of the studies varied. 77 serum or 
plasma cytokines were measured without immune 
stimulation. Cases of CFS had significantly elevated 
concentrations of transforming growth factor-beta 
(TGF-Œ≤) in five out of eight (63%) studies. No other 
cytokines were present in abnormal concentrations in 
the majority of studies, although insufficient data were 





#728 Exclusion reason: Systematic 
Review - exclude; Michael 
Musker (2020-04-19 
16:28:54)(Select): After 
further discussion, I will 
exclude this as it is a 
systematic review - see table 
1 (although it only cites other 
papers as it is a systematic 
review and then only states 
that results are higher or 
lower).  See Hornig et al 2015 
reference table 1); Martin 
Lewis (2020-04-29 
11:25:35)(Select): I assume 
other reviews need to be 
acknowledged;  



















Generalized pain with tender points in specific areas 
accompanied by systemic symptoms such as fatigue and 
stiffness is characteristic of fibromyalgia (FM) 
syndrome. The genesis of FM is still being investigated 
with conflicting data on factors including autonomic 
dysfunction, neurotransmitters, and hormones often in 
combination with external stressful events. However, 
recent research is starting to suggest that there is a 
previously underappreciated subtype of fibromyalgia 
called inflammatory Fibromyalgia (iFM). Recent studies 
have described cytokines, inflammatory markers, sleep 
disorders, hyperalgesia, cognitive dysfunction, serum 
leptin levels and other inflammatory indicators as 
potential markers for iFM. This article will; 1) review the 
inflammatory markers and abnormal levels of other 
laboratory indicators that can help to identify the 
subgroup of patients that fall into the new category of 
Inflammatory Fibromyalgia [1-5] and 2) review all 
completed trials that were focused on treating this new 
category of disease. Through this review it is hoped that 
and further understanding of the complexity of the 




#223 Exclusion reason: No leptin 
results; Michael Musker 
(2020-10-04 
21:48:44)(Select): After 
reviewing the paper, there 
are no results.  I contacted 
the author who said they 
used a multitest assay that 
only provides a summary 
result.; Michael Musker 
(2020-09-16 
10:15:53)(Select): I was able 
to obtain the results from the 
author who advised that they 
don't have specific leptin 
results as part of this study.  
No leptin results in article so 
exclude. The paper refers to 
the Quismorio abstract, but 
provides no results just says 
Leptin is higher in cases using 
this reference (20), and in the 
diagram refers to reference 
21 but references only go up 
to 20.; Michael Musker  








Peggy et al. 
Today, most Americans are overweight, with a steadily 
increasing proportion of the population qualifying as 
obese. Most Americans also experience some form of 
pain, such as lower back pain or headache, and often 
the condition is chronic. Thus, it is no surprise that a 
large number of overweight individuals experience 
chronic pain. The probability of two very common 
conditions occurring concurrently is simply the product 
of their individual probabilities. Clearly, the trick here is 
to tease apart whether a significant relationship exists 
between weight and pain and to discern any causal 
factors involved. It may be, as is often assumed, that 
extra weight leads to conditions such as lower back 
pain. It may also be that the pain experience alters 
neural control of energy balance, resulting in either 
under- or overweight individuals. Alternatively, there 
may be a common factor that predisposes individuals to 
both an abnormal energy balance state, either obesity 
or an underweight condition, and chronic pain. Finally, 
there may be different answers for different types of 
pain and for different energy imbalances. (PsycINFO 










#330 Exclusion reason: No results 
provided; Michael Musker 
(2020-09-16 
10:14:18)(Select): This text 
has only verbal reference to 
the role of leptin but has not 
results within the text of this 
chapter. - Exclude; Michael 
Musker (2020-04-22 
22:56:40)(Select): The book is 
available in Barr Smith, will 
retrieve book and review 
chapter;  









Reasons for exclusion 
following consensus  














Leptin has central importance in the global obesity and 
cardiovascular disease problem. Leptin is principally 
secreted by adipocytes and acts in the hypothalamus to 
suppress appetite and food intake, increase energy 
expenditure, and regulate body weight. Based on 
clinical translation of specific and networked actions, 
leptin affects the cardiovascular system and may be a 
marker and driver of cardiometabolic risk factors with 
interventions that are actionable by cardiologists. 
Leptin subnetwork analysis demonstrates a statistically 
significant role for ethnoculturally and 
socioeconomically appropriate lifestyle intervention in 
cardiovascular disease. Emergent mechanistic 
components and potential diagnostic or therapeutic 
targets include hexokinase 3, urocortins, clusterin, sialic 
acid-binding immunoglobulin-like lectin 6, C-reactive 
protein, platelet glycoprotein VI, albumin, pentraxin 3, 
ghrelin, obestatin prepropeptide, leptin receptor, 
neuropeptide Y, and corticotropin-releasing factor 
receptor 1. Emergent associated symptoms include 
weight change, eating disorders, vascular necrosis, 
chronic fatigue, and chest pain. Leptin-targeted 
therapies are reported for lipodystrophy and leptin 
deficiency, but they are investigational for leptin 
resistance, obesity, and other chronic diseases. 
2018 Global 
Heart 
#228 Exclusion reason: No leptin 
results; Michael Musker 
(2020-04-22 
00:18:24)(Select): Exclude: 
No results here. Another 
extensive discussion on the 
interplay of leptin and the 
neuroimmune system - great 
article: 'Leptin is a pleiotropic 
stress- an ancient anorexigen, 
immunomodulator, and 
growth factor, with signaling 
pathways and neural 
substrates conserved over 
350 million years, having a 
key physiologic role during 
starvation, and now situated 
as a central player in 
cardiometabolic networking 
research;  



























Background Neuroendocrine immunology in 
musculoskeletal diseases is an emerging scientific field. 
It deals with the aspects of efferent neuronal and 
neurohormonal bearing on the peripheral immune and 
musculoskeletal systems. This review aims to add new 
information that appeared since 2001. Search strategy 
in a continuous process, year by year, this search 
strategy yielded relevant papers that were screened 
and collected in a database, which build the platform of 
this review. Results The main findings are the anti-
inflammatory role of androgens, the loss of androgens 
(androgen drain), the bimodal role of estrogens 
(support B cells and inhibit macrophages and T cells), 
increased conversion of androgens to estrogens in 
inflammation (androgen drain), disturbances of the 
gonadal axis, inadequate amount of HPA axis hormones 
relative to inflammation (disproportion principle), 
biologics partly improve neuroendocrine axes, anti-
corticotropin-releasing hormone therapies improve 
inflammation (antalarmin), bimodal role of the 
sympathetic nervous system (proinflammatory early, 
anti-inflammatory late‚ most probably due to 
catecholamine-producing local cells), anti-inflammatory 
role of alpha melanocyte-stimulating hormone, 
vasoactive intestinal peptide, and the Vagus nerve via 







#29 Exclusion reason: No leptin 
results; Michael Musker 
(2020-04-22 
16:19:15)(Select): Exclude: An 
explanatory document, with 
no results provided.  It 
specifically states in the 
introduction  'We do not 
touch non-inflammatory 
fibromyalgia or stress-related 
aspects of rheumatic diseases 
because these subjects are 
demonstrated elsewhere in 
extensive form';  


































Characterized by chronic widespread pain, generalized 
hyperalgesia, and psychological stress, fibromyalgia 
(FM) is difficult to diagnose and lacks effective 
treatments. Endocannabinoids‚ -
arachidonoylethanolamide (AEA), 2-
arachidonoylglycerol (2-AG), and the related 
oleoylethanolamide (OEA), palmitoylethanolamide 
(PEA), and stearoylethanolamide (SEA)‚ are endogenous 
lipid mediators with analgesic and anti-inflammatory 
characteristics, in company with psychological 
modulating properties (eg, stress and anxiety), and are 
included in a new emerging "ome," the 
endocannabinoidome. . This case-control study 
compared the concentration differences of AEA, OEA, 
PEA, SEA, and 2-AG in 104 women with FM and 116 
healthy control subjects. All participants rated their 
pain, anxiety, depression, and current health status. The 
relationships between the lipid concentrations and the 
clinical assessments were investigated using powerful 
multivariate data analysis and traditional bivariate 
statistics. The concentrations of OEA, PEA, SEA, and 2-
AG were significantly higher in women with FM than in 
healthy control subjects; significance remained for OEA 




#33 Exclusion reason: No leptin 
results; Michael Musker 
(2020-04-22 
22:15:52)(Select): Exclude: 
Discusses many lipids except 









(SEA)‚are endogenous lipid 
mediators with analgesic and 
anti-inflammatory 
characteristics, in company 
with psychological 
modulating properties (eg, 
stress and anxiety), and are 
included in a new emerging 
‚ome,‚ the 
endocannabinoidome.  No 
leptin results provided;  


















Sasso, E. H. 
Quantitative and regular assessment of disease activity 
in rheumatoid arthritis (RA) is required to achieve 
treatment targets such as remission and to optimise 
clinical outcomes. To assess inflammation accurately, 
predict joint damage and monitor treatment response, 
a measure of disease activity in RA should reflect the 
pathological processes resulting in irreversible joint 
damage and functional disability. The Vectra DA blood 
test is an objective measure of disease activity for 
patients with RA. Vectra DA provides an accurate, 
reproducible score on a scale of 1 to 100 based on the 
concentrations of 12 biomarkers that reflect the 
pathophysiologic diversity of RA. The analytical validity, 
clinical validity, and clinical utility of Vectra DA have 
been evaluated for patients with RA in registries and 
prospective and retrospective clinical studies. As a 
biomarker-based instrument for assessing disease 
activity in RA, the Vectra DA test can help monitor 
therapeutic response to methotrexate and biologic 
agents and assess clinically challenging situations, such 
as when clinical measures are confounded by non-
inflammatory pain from fibromyalgia. Vectra DA scores 
correlate with imaging of joint inflammation and are 
predictive for radiographic progression, with high 
Vectra DA scores being associated with more frequent 
and severe progression and low scores being predictive 







#75 Exclusion reason: No leptin 
results; Michael Musker 
(2020-04-22 
15:53:52)(Select): Exclude: 
only mentions leptin as one 
of 12 biomarkers that make 
up the commercial Vectra DA 
test.  No results provided on 
leptin.;  









Reasons for exclusion 










 Leptin has also been shown to induce changes in 
monocyte properties that are potentially involved in 
atherogenesis. Furthermore, leptin is also thought to 
have pleiotropic actions contributing to obesity 
complications besides body weight regulation. 
Adiponectin is another hormone produced by adipose 
tissue and is inversely correlated with body fat mass, 
insulin resistance, and risk for type 2 diabetes mellitus. 
In conclusion, some of the effects of leptin and 
adiponectin on insulin sensitivity could be mediated via 
changes in NHE-1 activity 
2011 Angiology #92 Exclusion reason: No results 
provided; Michael Musker 
(2020-04-22 
15:47:23)(Select): Exclude: A 
brief about a previous study, 
but contains no results or 
information on MECFS or 
Fibromyalgia - 'Leptin has 
also been shown to induce 
changes in monocyte 
properties that are 
potentially involved in 
atherogenesis. Furthermore, 
leptin is also thought to have 
pleiotropic actions 
contributing to obesity 
complications besides body 
weight regulation.';  
























Background: Sodium/hydrogen exchanger-1 (NHE-1) 
contributes to maintaining intracellular pH (pHi). We 
assessed the effect of glucose, insulin, leptin and 
adrenaline on NHE-1 activity in human monocytes in 
vitro. These cells play a role in atherogenesis and 
disturbances in the hormones evaluated are associated 
with obesity and diabetes. Methods and Results: 
Monocytes were isolated from 16 healthy obese and 10 
lean healthy subjects. NHE-1 activity was estimated by 
measuring pHi with a fluorescent dye. pHi was assessed 
pre- and post-incubation with glucose, insulin, leptin 
and adrenaline. Experiments were repeated after 
adding a NHE-1 inhibitor (cariporide) or an inhibitor of 
protein kinase C (PKC), nitric oxide synthase (NOS), 
nicotinamide adenine dinucleotide phosphate (NADPH) 
oxidase, phosphoi- nositide 3-kinases (PI3K) or actin 
polymerization. Within the whole study population, 
glucose enhanced NHE-1 activity by a processes 
involving PKC, NOS, PI3K and actin polymerization (p = 
0.0006 to 0.01). IInsulin-mediated activation of NHE-1 
(p = <0.0001 to 0.02) required the classical isoforms of 
PKC, NOS, NADPH oxidase and PI3K. Leptin increased 
NHE-1 activity (p = 0.0004 to 0.04) through the 






#93 Exclusion reason: Wrong 
patient population; Michael 
Musker (2020-04-22 
15:43:57)(Select): Exclude: no 
reference to MECFS or other 
diseases such as fibromyalgia.  
Article focuses on the 
intracellular effects of leptin 
such as intracellular PH and 
other effects on cells in obese 
and lean health subjects.;  
























F. F.; Finn, 
J. D.; Forti, 
G.; 
Giwercman
, A.; Han, T. 
S.; 
Huhtaniemi
, I. T.; Kula, 





A. J.; et al. 
Objective: It has been suggested that elevated levels of 
C-reactive protein (CRP) might interfere with leptin 
signalling and contribute to leptin resistance. Our aim 
was to assess whether plasma levels of CRP influence 
leptin resistance in humans, and our hypothesis was 
that CRP levels would modify the cross-sectional 
relationships between leptin and measures of adiposity. 
Design and methods: We assessed four measures of 
adiposity: BMI, waist circumference, fat mass and body 
fat (%) in 2113 British Regional Heart Study (BRHS) men 
(mean (S.D.) age 69 (5) years), with replication in 760 
(age 69 (6) years) European Male Ageing Study (EMAS) 
subjects. Results: In BRHS subjects, leptin correlated 
with CRP (Spearman's r=0.22, P<0.0001). Leptin and 
CRP correlated with all four measures of adiposity (r 
value range: 0.22-0.57, all P<0.0001). Ageadjusted 
mean levels for adiposity measures increased in relation 
to leptin levels, but CRP level did not consistently 
influence the Œ≤-coefficients of the regression lines in a 
CRP-stratified analysis. In BRHS subjects, the BMI vs 
leptin relationship demonstrated a weak statistical 
interaction with CRP (P=0.04). We observed no similar 
interaction in EMAS subjects and no significant 
interactions with other measures of adiposity in BRHS 





#103 Exclusion reason: Another 
Major Disease; Michael 
Musker (2020-04-22 
15:36:30)(Select): Exclude: 
provides leptin levels 
between patients with 
cardiac issues and diabetics - 
no mention of mecfs or 
fibromyalgia;  







































In recent years, it has become clear that chronic 
systemic low-grade inflammation is at the root of many, 
if not all, typically Western diseases associated with the 
metabolic syndrome. While much focus has been given 
to sedentary lifestyle as a cause of chronic 
inflammation, it is less often appreciated that chronic 
inflammation may also promote a sedentary lifestyle, 
which in turn causes chronic inflammation. Given that 
even minor increases in chronic inflammation reduce 
brain volume in otherwise healthy individuals, the 
bidirectional relationship between inflammation and 
sedentary behaviour may explain why humans have lost 
brain volume in the last 30,000 years and also 
intelligence in the last 30 years. We review evidence 
that lack of physical activity induces chronic low-grade 
inflammation and, consequently, an energy conflict 
between the selfish immune system and the selfish 
brain. Although the notion that increased physical 
activity would improve health in the modern world is 
widespread, here we provide a novel perspective on 
this truism by providing evidence that recovery of 
normal human behaviour, such as spontaneous physical 
activity, would calm proinflammatory activity, thereby 
allocating more energy to the brain and other organs, 
and by doing so would improve human health. 
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Objectives: To determine the dependence of plasma 
leptin concentrations upon circulating noradrenaline 
(NA) and thyroid hormones (TH) in humans. Design: 
Cross-sectional study in 40 newly diagnosed untreated 
patients with primary thyroid disease, and 69 lean and 
obese euthyroid control subjects. Measurements: 
Plasma leptin, NA, free T3 (fT3) and TSH in the fasting 
state. Anthropometry and % body fat (electrical 
bioimpedance). Results: Leptin levels were highest in 37 
obese euthyroid and 22 hypothyroid (median 
[interquartiles] 31.5 [19.0-48.0], 19.2 [11.5-31.5] ng ml-
1), and lowest in 32 lean euthyroid and 18 hyperthyroid 
subjects (6.6 [3.9-14.4], 8.9 [5.5-11.1]; ANOVA, P < 
0.0001). Plasma NA was similar in all groups (P = n.s.). In 
obese controls. TSH correlated with % body fat and 
leptin (r = 0.67, r = 0.61; P < 0.001). Treatment of 
hypothyroidism (n = 10) with T4 reduced leptin from 
20.8 [11.8-31.6] to 12.9 [4.6-21.2] (P = 0.005) with no 
change in BMI. Conclusions: Thyroid status modifies 
leptin secretion independently of adiposity and NA. The 
data suggest leptin thyroid interactions at hypothalamic 
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Musker (2020-04-22 
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OBJECTIVE: To study interactions between leptin and 
the pituitary- thyroid axis, both in euthyroid and 
dysthyroid states. SUBJECTS AND MEASUREMENTS: We 
investigated the relationships of plasma leptin to levels 
of free thyroid hormones and TSH in 18 patients with 
newly diagnosed hyperthyroidism, 22 with newly 
diagnosed primary hypothyroidism, and 32 lean (body 
mass index [BMI] <30) and 37 obese (BMI> 30 kg/m2) 
euthyroid subjects. Hypothyroid patients were 
restudied during thyroxine replacement treatment. 
RESULTS: Median [interquartile range] plasma leptin 
concentrations were highest in obese euthyroid 
subjects (31-5 [19.0-48.0] and in untreated hypothyroid 
patients (19.2 [11.5-31.5]), and lowest levels in 
untreated hyperthyroid patients (8.9 [5.5-11.1])and 
lean euthyroid control subjects (6.6 [3.9-14.4]g/l 
(Kruskall-Wallis one-way analysis of variance; 
P<0.0001). In euthyroid subjects, plasma leptin levels 
were higher in obese than in lean subjects (P<0.00001). 
In obese subjects plasma levels of TSH correlated With 
percentage body fat (r=0.67; P<0.001) and plasma 
leptin (r=0.61; P<0.001). In untreated hyperthyroid 
subjects plasma leptin was unrelated to free T3, and in 
untreated hypothyroidism plasma leptin was unrelated 
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Pile, K. All rheumatologists care for patients with the 
Ofibromyalgic syndrome O, but the diagnosis of 
fibromyalgia (FM) remains a controversial. This 
presentation will review pathogenetic mechanisms as a 
starting point to discuss actual and conceptual 
interventions that may improve the current and future 
quality of life of those presenting. FM is a common 
chronic pain condition, characterised by widespread 
pain and decreased pain threshold, with allodynia and 
hyperalgesia. Additionally disturbed non-restorative 
sleep patterns, fatigue, mood changes, and irritability of 
bladder and bowel are commonly described. The 
absence of peripheral pathology has focussed research 
on central nervous system pain sensitisation with 
altered pain modulation at the level of spine and brain. 
Education, physical, psychological, and pharmacological 
are utilised in the multi-faceted armamentarium of 
therapy. Genetically suggested mechanisms will be 
discussed as will the potential role of cytokines leptin, 
and brain-derived neurotrophic factor. Therapeutic 
targets include alpha2-delta ligands, reuptake inhibition 
of serotonin, noradrenaline, and dopamine. Antagonism 
of substance- P, and opioid will be reviewed, in 
additions to medications targeting sleep. 
2014 Int J 
Rheum 
Dis 
#167 Exclusion reason: No leptin 
results; Michael Musker 
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Obesity is a multifactorial disease. Among its causes are 
physical inactivity and overeating. In addition, other 
factors may play an important role in the development 
of overweight/obesity. For example, certain hormones 
including leptin, insulin and ghrelin, may influence 
appetite and consequently body weight. Obesity 
frequently co-exists with metabolic disorders including 
dyslipidemia, hypertension and insulin resistance, thus 
constituting the metabolic syndrome which is 
characterized by increased cardiovascular risk. Lack of 
comprehensive knowledge on obesity-related issues 
makes both prevention and treatment difficult. This 
review considers the psychobiological and 
neuroendocrine mechanisms of appetite and food 
intake. Whether these factors, in terms of obesity 
prevention and treatment, will prove to be relevant in 
clinical practice (including reducing the cardiovas-cular 
risk associated with obesity) remains to be established. 
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Leptin seems to regulate various physiological 
mechanisms besides body weight. Leptin plays a role in 
vascular biology and pathology as well as renal function. 
In addition, leptin has been implicated in the regulation 
of fertility and reproduction. The effect of 
pharmaceutical agents on circulating plasma leptin 
levels has been assessed. Among the drugs investigated 
are glitazones, statins, fibrates, serotonin reuptake 
inhibitors and cannabinoid-1 receptor antagonists. 
Since these agents are used to treat pathological 
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Gaab et al. 
Background: Chronic fatigue syndrome (CFS) is 
associated with hypocortisolism, but it is not yet clear 
the extent to which enhanced negative feedback may 
underlie this finding. Methods: We undertook a low-
dose dexamethasone (0.5 mg) suppression test in 18 
CFS patients and 20 matched, healthy controls. We 
measured salivary cortisol levels at 0800 h, 1200 h, 
1600 h and 2000 h before and after the administration 
of 0.5 mg of dexamethasone. Results: Basal cortisol 
output was raised in this group of CFS patients 
compared to controls. Overall, the percentage 
suppression following dexamethasone administration 
was no different between CFS (mean +/- sem: 80.4 +/- 
4.4%) and controls (76.2 +/- 4.9 %). However, the sub-
group of patients with CFS and comorbid depression (n 
= 9) showed a significant hypersuppression of salivary 
cortisol in response to dexamethasone (89.0 +/- 1.9%; p 
< 0.05 v controls). Limitations: The sub-group analysis 
was on small numbers and should be considered 
preliminary. Dexamethasone probes only glucocorticoid 
medicated negative feedback but does not probe 
mineralocorticoid feedback, the other main 
physiological feedback mechanism.  
2009 Journal of 
Affective 
Disorders 
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results; Michael Musker 
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Overall, the percentage 
suppression 
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administration was no 
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controls (76.2 ¬± 4.9 %). 
However, the sub-group of 
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Hare, B. D. 
Obesity and pain present serious public health concerns 
in our society. Evidence strongly suggests that comorbid 
obesity is common in chronic pain conditions, and pain 
complaints are common in obese individuals. In this 
paper, we review the association between obesity and 
pain in the general population as well as chronic pain 
patients. We also review the relationship between 
obesity and pain response to noxious stimulation in 
animals and humans. Based upon the existing research, 
we present several potential mechanisms that may link 
the two phenomena, including mechanical/structural 
factors, chemical mediators, depression, sleep, and 
lifestyle. We discuss the clinical implications of obesity 
and pain, focusing on the effect of weight loss, both 
surgical and noninvasive, on pain. The literature 
suggests that the two conditions are significant 
comorbidities, adversely impacting each other. The 
nature of the relationship however is not likely to be 
direct, but many interacting factors appear to 
contribute. Weight loss for obese pain patients appears 
to be an important aspect of overall pain rehabilitation, 
although more efforts are needed to determine 
strategies to maintain long-term benefit. 
2015 Journal of 
Pain 
Research 
#197 Exclusion reason: No leptin 
results; Michael Musker 
(2020-04-22 
10:48:09)(Select): Exclude: 
only discusses leptin in the 
context of join pain, but does 
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synovial leptin level.84 
Increased leptin level in OA  



































Borish et al. 
Functional somatic syndromes (FSS) are defined by a 
constellation of symptoms for which after thorough 
medical examination no structural pathology and no 
proportional tissue abnormalities can be identified. 
Pathophysiology of these syndromes has remained 
elusive and treatment options are limited. Current 
research efforts acknowledge the importance of stress 
as a potential risk factor in the manifestation and 
maintenance of FSS. A substantial body of research has 
focused on psychological stress factors as well as 
alterations of the endocrine stress system (the 
hypothalamic-pituitary-adrenal, HPA axis, in particular), 
the immune system, and the autonomic nervous system 
(ANS). Dysregulation of these systems might explain 
some of the symptoms of FSS. In this review, we 
describe studies reporting stress-related findings in 
three of the most prevalent and well-described FSS, i.e. 
chronic fatigue syndrome (CFS), irritable bowel 
syndrome (IBS), and fibromyalgia syndrome (FMS). 
Psychobiological processes which seem to play a role in 
the translation of stress into functional symptoms and 
syndromes are discussed. (PsycINFO Database Record 
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Alvi  et al. 
Background: The blood-brain barrier acts as a highly 
regulated interface; its dysfunction may exacerbate, 
and perhaps initiate, neurological and neuropsychiatric 
disorders. Methods: In this narrative review, focussing 
on redox, inflammatory and mitochondrial pathways 
and their effects on the blood-brain barrier, a model is 
proposed detailing mechanisms which might explain 
how increases in blood-brain barrier permeability occur 
and can be maintained with increasing inflammatory 
and oxidative and nitrosative stress being the initial 
drivers. Results: Peripheral inflammation, which is 
causatively implicated in the pathogenesis of major 
psychiatric disorders, is associated with elevated 
peripheral pro-inflammatory cytokines, which in turn 
cause increased blood-brain barrier permeability. 
Reactive oxygen species, such as superoxide radicals 
and hydrogen peroxide, and reactive nitrogen species, 
such as nitric oxide and peroxynitrite, play essential 
roles in normal brain capillary endothelial cell 
functioning; however, chronically elevated oxidative 
and nitrosative stress can lead to mitochondrial 
dysfunction and damage to the blood-brain barrier. 
Activated microglia, redox control of which is mediated 
by nitric oxide synthases and nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidases, secrete 
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The World Health Organization classifies myalgic 
encephalomyelitis/chronic fatigue syndrome (ME/cfs) 
as a nervous system disease. Together with other 
diseases under the G93 heading, ME/cfs shares a triad 
of abnormalities involving elevated oxidative and 
nitrosative stress (O&NS), activation of immuno-
inflammatory pathways, and mitochondrial 
dysfunctions with depleted levels of adenosine 
triphosphate (ATP) synthesis. There is also abundant 
evidence that many patients with ME/cfs (up to around 
60 %) may suffer from autoimmune responses. Awide 
range of reported abnormalities in ME/cfs are highly 
pertinent to the generation of autoimmunity. Here we 
review the potential sources of autoimmunity which are 
observed in people with ME/cfs. The increased levels of 
pro-inflammatory cytokines, e.g., interleukin-1 and 
tumor necrosis factor-alpha, and increased levels of 
nuclear factor-kappaB predispose to an autoimmune 
environment. Many cytokine abnormalities conspire to 
produce a predominance of effector B cells and 
autoreactive T cells. The common observation of 
reduced natural killer cell function in ME/cfs is a source 
of disrupted homeostasis and prolonged effector T cell 
survival. B cells may be pathogenic by playing a role in 
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It is of importance whether myalgic 
encephalomyelitis/chronic fatigue syndrome (ME/CFS) 
is a variant of sickness behavior. The latter is induced by 
acute infections/injury being principally mediated 
through proinflammatory cytokines. Sickness is a 
beneficial behavioral response that serves to enhance 
recovery, conserves energy and plays a role in the 
resolution of inflammation. There are 
behavioral/symptomatic similarities (for example, 
fatigue, malaise, hyperalgesia) and dissimilarities 
(gastrointestinal symptoms, anorexia and weight loss) 
between sickness and ME/CFS. While sickness is an 
adaptive response induced by proinflammatory 
cytokines, ME/CFS is a chronic, disabling disorder, 
where the pathophysiology is related to activation of 
immunoinflammatory and oxidative pathways and 
autoimmune responses. While sickness behavior is a 
state of energy conservation, which plays a role in 
combating pathogens, ME/CFS is a chronic disease 
underpinned by a state of energy depletion. While 
sickness is an acute response to infection/injury, the 
trigger factors in ME/CFS are less well defined  
2013 BMC 
Medicine 
#541 Exclusion reason: No leptin 
results; Michael Musker 
(2020-04-22 
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Many studies have established the routes by which the 
immune and central nervous (CNS) systems 
communicate. This network of connections permits the 
CNS to regulate the immune system through both 
neuroendocrine and neuronal pathways. In turn, the 
immune system signals the CNS through neuronal and 
humoral routes, via immune mediators and cytokines. 
This regulatory system between the immune system 
and CNS plays an important role in susceptibility and 
resistance to autoimmune, inflammatory, infectious 
and allergic diseases. This review focuses on the 
regulation of the immune system via the 
neuroendocrine system, and underlines the link 
between neuroendocrine dysregulation and 
development of major depressive disorders, 
autoimmune diseases and osteoporosis.  
2005 Molecular 
Psychiatry 
#336 Exclusion reason: No leptin 
results; Michael Musker 
(2020-04-22 
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Sluka, K.  
Fibromyalgia (FM) is a chronic pain syndrome 
characterized by widespread pain, depression, and 
mood and sleep disturbances. There is currently no 
consensus on the pathogenesis of FM. Overweight 
women are 60-70% more likely to develop fibromyalgia 
and experience more severe pain symptoms than 
normal women. Adipose cells release pro-inflammatory 
cytokines (IL-6, TNF-Œ±, Leptin) that are linked to pain 
pathogenesis. This study aims to determine the 
relationship between weight or body mass index (BMI) 
and pain in fibromyalgia. A sample of 93 women was 
recruited for participation in a set of tests which classify 
the pain felt by the participants. Pearson Product 
Moment Correlation (r) analyses were done between 
BMI and the pain levels. One-way analysis of variance 
(ANOVA) was used to determine group differences in 
pain measures. For a sub-analysis consisting of 27 
patients, blood samples were acquired from the 
participants. The Peripheral Blood Mononuclear Cell 
layer (PBMC) was isolated. Monocyte phenotype was 
determined using fluorescence-activated cell sorting 
(FACS) and a Pearson Product Moment Correlation (r) 
analysis was done. We found that there is no 
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Introduction Both hypothalamo-pituitary-insulin-like 
growth factor-1 (IGF-1) axis and ghrelin levels may be 
altered in fibromyalgia syndrome (FMS) due to 
increased somatostatin tone. The aim of this study is to 
compare hypothalamo-pituitary-IGF-1 axis, ghrelin 
concentrations and their relations in premenopausal 
women with FMS and premenopausal healthy controls. 
Methods Seventy-five women (47 FMS and 28 healthy 
women) were enrolled in the study. Fasting plasma 
glucose, serum growth hormone (GH), insulin, C-
peptide, IGF-1, insulin-like growth factor binding 
protein-3 (IGFBP-3) and ghrelin levels were measured. 
Depressive symptoms were assessed using beck 
depression inventory. Pain intensity and sleep 
disturbance were recorded on a visual analog scale. The 
activity of daily living was assessed by fibromyalgia 
impact questionnaire. Results There were no significant 
differences in GH, IGF-1, IGFBP-3, glucose, insulin, and 
C-peptide levels between patients and controls 
(p>0.05), whereas ghrelin levels were significantly lower 
in patients than controls (p<0.05). Ghrelin levels were 
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A few examples of hypothalamic, peptidergic disorders 
leading to clinical signs and symptoms are presented in 
this review. Increased activity of corticotropin-releasing 
hormone (CRH) neurons in the paraventricular nucleus 
(PVN) and decreased activity of the vasopressin neurons 
in the biological clock and of the thyroxine-releasing 
hormone (TRH) neurons in the PVN contribute to the 
signs and symptoms of depression. In men, the central 
nucleus of the bed nucleus of the stria terminalis (BSTc) 
is about twice as large and contains twice as many 
somatostatin neurons as in women. In transsexuals this 
sex difference is reversed, pointing to a role of this 
structure in gender. Luteinizing hormone-releasing 
hormone (LHRH) neurons are formed in the fetal 
olfactory placade and migrate along the terminal nerve 
fibers into the hypothalamus. In Kallmann's syndrome 
the migration process of the LHRH (gonadotropin-
releasing hormone) neurons is aborted, which explains 
the joint occurrence of hypogonadotropic 
hypogonadism and anosmia in this syndrome. In 
postmenopausal women, the neurons of the 
infundibular nucleus hypertrophy and become 
hyperactive because of the disappearance of the 
estrogen feedback and contain hyperactive peptidergic 
neurons. Climacteric flushes may be caused by 
hyperactivity of the neurokinin-B or LHRH neurons in 
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The interconnected nature of the endocrine, immune 
and nervous systems has been well established. The 
central nervous system innervates the primary and 
secondary immune organs and the endocrine glands 
through direct axonal contact. Hormonal signals from 
the endocrine system influence both the nervous and 
immune systems with differential effects based on sex 
and environmental exposures. Immune cells can 
communicate by either cytokine or neurotransmitter 
release to signal the endocrine, gastrointestinal, and 
nervous systems. This review focuses on the effects of 
environmental toxicants on the inter-play between 
these systems with inclusion of effects from the 
microbiome and exposome. Endocrine disrupting 
chemicals and xenoestrogenic compounds affect the 
hypothalamic-pituitary-adrenal or gonadal axis, which 
can lead to hormonal alterations of communication 
between the nervous and immune systems. Immune 
responses within the nervous system and the delicate 
balance between appropriate response to 
infection/disease and detrimental effects through 
inappropriate response are discussed. Environmental 
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 KEY POINTS  Fatigue associated with medical disorders 
can have a significant impact on functional status, 
quality of life, and clinical outcomes. A variety of 
medical diseases can be associated with fatigue, 
including renal, hematological, and endocrine 
pathologies.  The pathophysiology of fatigue and 
sleepiness in the setting of some common medical 
problems is discussed in this review.  Treatment focuses 
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The evidence about the health benefits of regular 
physical activity is well established. Exercise intensity is 
a significant variable and structured high-intensity 
interval training (HIIT) has been demonstrated to 
improve both whole-body and skeletal muscle 
metabolic health in different populations. Conversely, 
fatigue accumulation, if not resolved, leads to 
overwork, chronic fatigue syndrome (CFS), overtraining 
syndrome up to alterations of endocrine function, 
immune, systemic inflammation, and organic diseases 
with health threat. In response to temporary increases 
in stress during training, some athletes are unable to 
maintain sufficient caloric intake, thus suffering a 
negative energy balance that causes further stress. The 
regulation of the energy balance is controlled by the 
central nervous system through an elaborate 
interaction of the signalling that involves different 
tissues such as leptin, adiponectin and ghrelin whose 
provide important feedback to the hypothalamus to 
regulate the energy balance.  
2019 Free 
Radic Res 
#351 Exclusion reason: No leptin 
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(2020-04-21 
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Objectives: Asthenia, or heightened fatiguability, is 
typically characterized by a positive energy balance, 
often disposes to weight gain, and is comorbid with 
depression. Conversely, cachexia is characterized by 
increased energy expenditure despite falling caloric 
intake, resulting in loss of adipose tissue and muscle 
mass. The cytokine gammainterferon (IFNG) has been 
implicated both in chronic fatigue syndrome and 
cachexia, suggesting that it may exert modulatory 
influence over satiety and/or energy homeostatic 
mechanisms such as leptin or neuropeptide Y. In the 
present study, we sought to determine the possible role 
of the biallelic IFNG genetic polymorphism (IFNG3) in 
asthenia and obesity. Methods: We examined the 
IFNG3 marker in 163 non-Hispanic Caucasian subjects 
(college students) evaluated for asthenia, and an 
additional 62 middle-aged and older non-Hispanic 
Caucasian females recruited as part of an obesity study. 
Results: In the college student sample, the IFNG3 
marker was found to be associated with asthenia (mean 
asthenia scores/sample: 11 = 55.6(34], 12 = 50.8(79], 22 
= 48.0[50];P< .0025). In the obesity sample, a similar 
correspondence was found between IFNG3 and body-
mass index (11 = 35.6[12], 12 = 30.0[29], 22 = 26.7[21]; 
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Persistent fatigue is a common problem (‚àº20‚Äì45% of 
U.S. population), with higher prevalence and severity in 
people with medical conditions such as cancer, 
depression, fibromyalgia, heart failure, sleep apnea and 
multiple sclerosis. There are few FDA-approved 
treatments for fatigue and great disagreement on how 
to measure fatigue, with over 250 instruments used in 
research. Many instruments define fatigue as ‚Äúa lack 
of energy‚Äù, thus viewing energy and fatigue states as 
opposites on a single bipolar continuum. In this paper, 
we hypothesize that energy and fatigue are distinct 
perceptual states, should be measured using separate 
unipolar scales, have different mechanisms, and deficits 
should be treated using tailored therapies. Energy and 
fatigue independence has been found in both 
exploratory and confirmatory factor analysis studies. 
Experiments in various fields, including behavioral 
pharmacology and exercise science, often find changes 
in energy and not fatigue, or vice versa. If the 
hypothesis that energy and fatigue are independent is 
correct, there are likely different mechanisms that drive 
energy and fatigue changes. Energy could be increased 
by elevated dopamine and norepinephrine transmission 
and binding. Fatigue could be increased by elevated 
brain serotonin and inflammatory cytokines and 
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Sasso, E. H. 
Background Clinical assessment of rheumatoid arthritis 
(RA) patients may be challenging when objective 
measures, such as C-reactive protein (CRP), do not 
show elevated disease activity or when patients have 
concomitant, non-inflammatory pain, as occurs with 
fibromyalgia (FM). A multi-biomarker disease activity 
(MBDA) blood test has been developed to assess RA 
disease activity with a score, ranging from 1-100, that is 
calculated using a validated algorithm with 12 serum 
protein biomarkers (VCAM-1, EGF, VEGF-A, IL-6, TNF-RI, 
YKL-40, MMP-1, MMP-3, leptin, resistin, SAA, CRP). 
Objectives To evaluate the role of the MBDA score in 
the assessment of RA disease activity in a cohort of 
established RA patients, including patients with low CRP 
levels and those with and without concomitant FM. 
Methods 208 RA patients from BRASS, a large 
prospective observational cohort, were randomly 
selected for a substudy of pain in RA. For the present 
cross-sectional study, DAS28-CRP components, the 
Widespread Pain Index (to diagnose FM by a modified 
version of the 2010 ACR Diagnostic Criteria for FM), and 
the MBDA blood test were obtained at the initial 
substudy visit. 198 of 208 patients had complete data 
and were included in this analysis.  
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Background/Purpose: Clinical assessment of 
rheumatoid arthritis (RA) may be challenging if patients 
have fibromyalgia (FM) or if C-reactive protein (CRP) is 
low (≤ 1 mg/dL). A multi-biomarker disease activity 
(MBDA) blood test has been developed to assess RA 
disease activity with a score (range: 1-100) that is 
calculated using a validated algorithm for 12 serum 
protein biomarkers (VCAM-1, EGF, VEGF-A, IL-6, TNF-RI, 
MMP-1, MMP-3, YKL-40, leptin, resistin, SAA, CRP). The 
present study evaluated the role of the MBDA score for 
assessing disease activity in a cohort of established RA 
patients, including patients with concomitant FM or low 
CRP. Methods: 208 RA patients from a prospective 
observational cohort were randomly selected for a 
substudy of pain in RA. For the present cross-sectional 
study, DAS28-CRP components, the Widespread Pain 
Index (to diagnose FM by a modified version of the 
2010 ACR Diagnostic Criteria for FM), and the MBDA 
(Vectra‰ DA) score were evaluated for the initial 
substudy visit. 198 patients with non-missing baseline 
MBDA score and DAS28-CRP components were 
included. Measures of disease activity were compared 
between patients with RA+FM vs. RA without FM using: 
t-test or Wilcoxon rank sum tests; multivariate 
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Background/Purpose: Clinical 
assessment of rheumatoid 
arthritis (RA) may be 
challenging if patients have 
fibromyalgia (FM) or if C-
reactive protein (CRP) is low 
(1 mg/dL). A multi-biomarker 
disease activity (MBDA) blood 
test has been developed to 
assess RA disease activity 
with a score (range: 1‚to 100) 
that is calculated using a 
validated algorithm for 12 
serum protein biomarkers  
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The gut microbiota has recently been recognized for its 
role in immune regulation, and changes in gut 
microbiota may be the basis for an increased incidence 
of autoimmune diseases and asthma in developed 
countries. Beneficial microbes produce factors that are 
distributed systemically, and therefore can influence 
peripheral inflammatory responses. Such symbiosis 
factors are important for the control and resolution of 
inflammation and autoimmune diseases. Here we 
discuss immune regulation by recently identified 
symbiosis factors and how certain environmental 
factors favor their production and influence the 
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Chronic Fatigue Syndrome (CFS) and Fibromyalgia (FM) 
are both chronic disorders that have a devastating 
effect on the lives of the affected patients and their 
families. Both conditions have overlapping clinical 
features that partly resemble those of inflammatory 
disorders. The etiology is still not understood, and it is 
suggested that the immune system might be a 
contributing factor. So far, the results are inconclusive. 
The purpose of this study was to compare the two 
conditions and investigate the level of the inflammatory 
marker high-sensitivity CRP (hsCRP) in CFS and FM 
patients compared to healthy controls. Female 
participants aged 18-60 years were enrolled in this 
study. The group consisted of 49 CFS patients, 57 FM 
patients, and 54 healthy controls. hsCRP levels were 
significantly higher for both the CFS and the FM groups 
compared to healthy controls when adjusting for age, 
smoking, and BMI (p < .001). There was no difference 
between the two patient groups. The level of hsCRP 
was affected by BMI but not by age and smoking. 
Patients with CFS and FM have higher concentrations of 
hsCRP compared to healthy controls. This remains 
significant even after adjusting for BMI. CFS and FM 
cannot be distinguished from each other on the basis of 
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inflammatory marker high-
sensitivity CRP (hsCRP) in CFS 
and FM patients compared to 
healthy controls.';  









Reasons for exclusion 



















The secretion of interleukin-6 (IL-6) is modulated by 
immune, hormonal and metabolic stimuli in a cell-
specific manner. We investigated the effect of 
cytokines, TNFŒ± and IL-1Œ≤, and insulin on IL-6 
release from human adipocytes and peripheral blood 
cells (PBC). Adipocytes released IL-6 constitutively (after 
5h: 5.64 [1.61‚Äì15.30]pgml‚àí1, after 10h: 15.95 
[2.34‚Äì45.59]pgml‚àí1, p=0.007), while PBC secretion 
did not change significantly over this period. LPS 
stimulated IL-6 secretion in PBC after 5h but was 
without effect on adipocytes. TNFŒ± and insulin 
induced IL-6 production from PBC, but had no effect on 
adipocytes. IL-1Œ≤, however, induced a substantial 
increase in IL-6 release in adipocytes and PBC (all 
p<0.05). Adipose tissue production of IL-1Œ≤ was 
assessed in vivo by measuring arterio-venous 
differences across the subcutaneous abdominal adipose 
bed. Net release of IL-1Œ≤ was not observed, 
suggesting that under basal conditions there is no 
detectable release of this cytokine into the circulation 
from this depot. In conclusion (1) PBC demonstrate 
regulated IL-6 release, while the adipocyte release has a 
large constitutive component;  
2003 Cytokine #564 Exclusion reason: Wrong 
comparator; Michael Musker 
(2020-04-20 
12:20:05)(Select): Exclude: 
this is an important article on 
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Fibromyalgia;  
































Background: Chronic fatigue syndrome (CFS) is a 
complex, multi-symptom illness with a multisystem 
pathogenesis involving alterations in the nervous, 
endocrine and immune systems. Abnormalities in stress 
responses have been identified as potential triggers or 
mediators of CFS symptoms. This study focused on the 
stress mediator neuropeptide Y (NPY). We hypothesized 
that NPY would be a useful biomarker for CFS. 
Methods: The CFS patients (n = 93) were from the 
Chronic Fatigue and Related Disorders Clinic at the 
University of Miami and met the 1994 case definition of 
Fukuda and colleagues. Healthy sedentary controls (n = 
100)) were from NIH or VA funded studies. Another 
fatiguing, multi-symptom illness, Gulf War Illness (GWI), 
was also compared to CFS. We measured NPY in plasma 
using a radioimmunoassay (RIA). Psychometric 
measures, available for a subset of CFS patients 
included: Perceived Stress Scale, Profile of Mood States, 
ATQ Positive & Negative Self-Talk Scores, the COPE, the 
Beck Depression Inventory, Fatigue Symptom Inventory, 
Cognitive Capacity Screening Examination, Medical 
Outcomes Survey Short Form-36, and the Quality of Life 
Scale. Results: Plasma NPY was elevated in CFS subjects, 
compared to controls (p = .000) and to GWI cases (p = 
.000). Receiver operating characteristics (ROC) curve 
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 We read with interest the article by Liao et al., 
suggesting that the counterbalance between leptin and 
cortisol may be associated with comorbid depression 
and anxiety. Leptin, the product of the obese gene 
mainly integrating metabolic, secreted by adipocytes, 
controls energy balance and exerts pleiotropic actions, 
immune, neuroendocrine and behavioral responses.2 
Leptin may provide negative feedback inhibition to the 
hypothalamus–pituitary–adrenal (HPA) axis, which is 
crucial for adapting to chronic stress, and 
psychopathology would be the result if such a 
mechanism of counterbalance was impaired. 
Liao et al. proposed leptin as valid neuroendocrinologic 
marker for the hypervigilant state. Fibromyalgia (FM) is 
a common clinical condition defined as persistent, 
widespread musculoskeletal pain, in the presence of 
tender points at specific anatomical sites. Fibromyalgia 
is more than just a pain syndrome; it includes a protean 
series of disturbances, mainly involving autonomic, 
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Comments on an article by Walid K Jerjes et al (see 
record 2006-01484-009). The authors stated that the 
aim of their study was to obtain comprehensive 
information on basal hypothalamic-pituitary-adrenal 
(HPA) axis activity in chronic fatigue syndrome (CFS) 
patients. In my opinion, however, some shortcomings 
make the interpretation of their results difficult. Firstly, 
data on urinary free cortisol (UFC) excretion are at 
variance with early findings, which reported increased 
UFC excretion in the early morning and a low excretion 
rate of UFC at later daytime. Interpretation of urinary 
free cortison (UFCn) data is further complicated by the 
fact that UFC and UFCn excretion changes with daytime. 
Thus, it may be expected from the aforementioned 
findings that urinary free cortisone (UFCn) values in 
their study were quite variable and that they did not 
give information as to whether chronic fatigue 
syndrome may affect the renal metabolism of 
cortisone. (PsycINFO Database Record (c) 2016 APA, all 
rights reserved) 
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Although sleep complaints are often reported in 
patients with fibromyalgia syndrome (FMS), there is no 
conclusive evidence that these complaints represent 
symptomatic disorders of sleep physiology. Thus, the 
question of the role of sleep disturbances as an 
etiological or maintenance factor in FMS remains open. 
This study identifies the subjective and objective 
characteristics of sleep disturbances in adult women 
diagnosed with FMS. We carried out a systematic 
review of publications since 1990, the publication year 
of the American College of Rheumatology criteria of 
FMS. We selected empirical studies comparing sleep 
characteristics of adult women with FMS and healthy 
women or women with rheumatic diseases. We 
identified 42 articles. Patients with FMS were more 
likely to exhibit sleep complaints and also a less 
efficient, lighter and fragmented sleep. The evidence of 
a FMS signature on objective measures of sleep is 
inconsistent, however, as the majority of studies lacks 
statistical power. Current evidence cannot confirm the 
role played by sleep physiology in the pathogenesis or 
maintenance of FMS symptoms; nonetheless, it is clear 
that sleep disturbances are present in this syndrome. 
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Diani, S. D. 
Sara 
Chronic diseases are defined diseases whose symptoms 
last for at least six months and tend to worsen over 
time. In Europe, they cause at least 86% of deaths. In 
this speculative unifying model I set a new hypothesis 
for the etiology of the majority of chronic diseases. 
The main aim is to put order and observe our organism 
in a systemic way, connecting pathologies we now see 
as disconnected phenomena, with the conceptual 
frameworks of complex systems and network medicine. 
Chronic diseases could be caused by a first unsolved 
acute infection. In case the pathogen cannot be 
completely eliminated, it becomes a persistent 
infectious. After the acute episode, some mild 
symptoms will occur and probably disappear; the 
chronic disease will remain latent over time. It will 
manifest even after years or decades, in the presence of 
another acute infection, a particular stress, trauma, or 
another event. The presence of the persistent infectious 
elicits changes in the immune and systemic regulation, 
and these processes degenerate over time. They will 
assume their rules and patterns, being independent 
from the initial stimulus. The key to understand the 
dynamics and individuality of chronic diseases is the 
immune system and its networks. The immune 
mechanisms that can lead to the persistent response 
are mainly the switch from the Th1 to the Th2 immunity 
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Summary Over the past 30 years, a sharp rise in the 
prevalence of overweight and obesity has been noted in 
both children and adults. Health consequences include 
biomechanical, biochemical and psychosocial factors, 
with broad implications toward central adiposity and a 
number of conditions with which it relates. Substantial 
new information has surfaced within the last decade 
that alters previous concepts regarding the role of 
adipose tissue in health and in disease. This literature 
review explores the role that white adipose tissue 
(WAT) plays within a cascade of endocrine interfaces 
that have significant health consequences. WAT is now 
known to be an active participant in regulating 
physiological and pathological processes, including 
immunity and inflammation and to play a primary role 
in the development of a triad of hormonal imbalance 
(leptin resistance, adrenaline resistance, insulin 
resistance). Particular focus is placed on leptin hormone 
and its potential influences on inflammation and a host 
of other metabolic disturbances. 
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BACKGROUND: The objective of this study is to analyze 
the influence of a 14-week periodized circuit training 
protocol on patients with knee osteoarthritis (OA), in 
randomized intervention groups, on thigh intermuscular 
adipose tissue (interMAT), body composition, systemic 
inflammation, cartilage degradation, and its 
repercussion on pain, functional performance and 
quality of life. METHODS: This study presents a protocol 
for a randomized controlled trial. Sixty selected 
participants diagnosed with knee OA grades II and III, 
40-65 years old and BMI < 30 kg/m(2,) will be randomly 
divided into three groups:periodized circuit training, 
strength training, and educational protocol. The circuit 
training and strength training protocols consist of 14-
week training protocols conducted 3 times a week. The 
circuit training group will perform selected exercises 
previously stratified as light, moderate, and intense, 
arranged progressively in a circuit model, the strength 
group will perform regular strength exercises, and the 
educational protocol group will participate in a 14-week 
protocol with lectures twice a month about healthy 
lifestyles. Baseline and follow-up evaluations will be 
conducted for thigh interMAT (computed tomography), 
body composition (DXA), inflammation (IL-1beta, IL-6, 
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 Notes that over the past decade, numerous studies 
have attempted to link chronic fatigue syndrome (CFS) 
or similar states to neuroendocrine dysfunction. This 
chapter provides an overview of the accumulated 
evidence. It includes not only studies looking directly at 
endocrine function, but also those using endocrine tests 
to assess other etiologic factors, such as monoamine 
dysfunction. (PsycINFO Database Record (c) 2019 APA, 
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Hunt et al. 
Investigated basal levels of dehydroepiandrostenedione 
(DHEA) and its sulphate (DHEA-S), the cortisol/DHEA 
molar ratio and the responsiveness of DHEA to 
stimulation by corticotrophin-releasing hormone (CRH). 
We also assessed these parameters prior to and 
following treatment with low dose oral hydrocortisone. 
Basal levels of serum DHEA, DHEAS and cortisol were 
measured in 16 patients with CFS without depression 
and in 16 controls matched for age, gender, weight, 
body mass index and menstrual history. Basal levels of 
DHEA were higher in the patient, compared to the 
control, group, while levels of DHEAS in patients were 
not different from controls. Higher DHEA levels were 
correlated with higher disability scores. Levels of DHEA 
and DHEAS were lower in patients following treatment 
with hydrocortisone. There was a rise in DHEA 
responsiveness to CRH in the patients after treatment 
but this did not attain significance. DHEA levels are 
raised in CFS and correlate with the degree of self-
reported disability. Hydrocortisone therapy leads to a 
reduction in these levels towards normal, and an 
increased DHEA response to CRH, most marked in those 
who show a clinical response to this therapy. (PsycINFO 
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Cleare, A. J. Many studies of patients with long-standing chronic 
fatigue syndrome (CFS) have found alterations to the 
hypothalamo-pituitary-adrenal (HPA) axis, including 
mild hypocortisolism, heightened negative feedback 
and blunted responses to challenge. However, recent 
prospective studies of high-risk cohorts suggest that 
there are no HPA axis changes present during the early 
stages of the genesis of fatiguing illnesses. Moreover, 
HPA axis changes can be reversed by modifying 
behavioural features of the illness, such as inactivity, 
deconditioning and sleep disturbance. Nevertheless, 
raising levels of cortisol pharmacologically can 
temporarily alleviate symptoms of fatigue. This article 
presents the case that there is no specific change to the 
HPA axis in CFS and that the observed changes are of 
multifactorial aetiology, with some factors occurring as 
a consequence of the illness. Nevertheless, the HPA axis 
might play a role in exacerbating or perpetuating 
symptoms late on in the course of the illness. 
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Background. Previous literature data have pointed out 
the potential role of leptin in the modulation of 
inflammatory processes associated with arthritis. It is 
considered that leptin is implicated in bone 
remodelling, has protective qualities in the complex 
pathogenesis of septic arthritis, could be considered as 
an additional marker of inflammation in rheumatoid 
arthritis and also an independent regulator of the TSH 
levels. Objectives. Our study was focused on the 
investigation of the leptin potential role in 
differentiating between the patterns of arthritis 
associated with hypothyroidism. Methods. We have 
investigated 19 patients with joint effusions and clinical 
signs of hypothyroidism in comparison with 21 patients 
with clinical hypothyroidism and absence of arthritic 
signs. All the patients were evaluated before the 
initiation of hormone replacement therapy. The two 
groups were matched for sex (11.1 % vs. 13.8% males), 
age (54.45¬±7.8 vs. 56,79¬±11.6 years old) and BMI 
(28.67¬± 2.45 vs. 29.7¬±3.52kg/m2). The leptin serum 
levels were quantified using a human leptin EIA kit. 
Results. The free T4 levels for the two groups were 
0.25¬±0.18 vs. 0.29¬±O. 13 ng/dl and the TSH levels 
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The consumption of Western-type calorically rich diets 
combined with chronic overnutrition and a sedentary 
lifestyle in Western societies evokes a state of chronic 
metabolic inflammation, termed metaflammation. 
Metaflammation contributes to the development of 
many prevalent non-communicable diseases (NCDs), 
and these lifestyle-associated pathologies represent a 
rising public health problem with global epidemic 
dimensions. A better understanding of how modern 
lifestyle and Western diet (WD) activate immune cells is 
essential for the development of efficient preventive 
and therapeutic strategies for common NCDs. Here, we 
review the current mechanistic understanding of how 
the Western lifestyle can induce metaflammation, and 
we discuss how this knowledge can be translated to 
protect the public from the health burden associated 
with their selected lifestyle. 
2019 Immunity #661 Exclusion reason: No results 
provided; Michael Musker 
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Summary Chronic fatigue is a typical symptom of 
neurological diseases, and is most disabling in multiple 
sclerosis, postpoliomyelitis, poststroke, and in chronic 
fatigue syndrome. Disorders of neuromuscular junction 
transmission and metabolic diseases cause muscle 
fatigability, which is characterised by failure to sustain 
the force of muscle contraction (peripheral fatigue). 
Fatigue is also seen in diseases that affect the central, 
peripheral, and autonomic nervous systems (central 
fatigue). Enhanced perception of effort and limited 
endurance of sustained physical and mental activities 
are the main characteristics of central fatigue. 
Metabolic and structural lesions that disrupt the usual 
process of activation in pathways interconnecting the 
basal ganglia, thalamus, limbic system, and higher 
cortical centre are implicated in the pathophysiological 
process of central fatigue. A state of pre-existing 
relative hypocortisolaemia might sensitise the 
hypothalamic-pituitary-adrenal axis to development of 
persistent central fatigue after stress. The contributions 
of physiological, cognitive, and affective changes 
underlying fatigue are variable, and treatment is largely 
symptomatic and rehabilitative. 
2004 The 
Lancet 
#671 Exclusion reason: No leptin in 
article; Michael Musker 
(2020-04-19 
17:41:22)(Select): Exclude: 
only an explanatory 
document no leptin results 
provided;  









Reasons for exclusion 





































Ageing of the global population has become a public 
health concern with an important socio-economic 
dimension. Ageing is characterized by an increase in the 
concentration of inflammatory markers in the 
bloodstream, a phenomenon that has been termed 
‚inflammageing‚ The inflammatory response is 
beneficial as an acute, transient reaction to harmful 
conditions, facilitating the defense, repair, turnover and 
adaptation of many tissues. However, chronic and low 
grade inflammation is likely to be detrimental for many 
tissues and for normal functions. We provide an 
overview of low grade inflammation (LGI) and 
determine the potential drivers and the effects of the 
‚’inflamed‚’ phenotype observed in the elderly. We 
discuss the role of gut microbiota and immune system 
crosstalk and the gut-brain axis. Then, we focus on 
major health complications associated with LGI in the 
elderly, including mental health and wellbeing, 
metabolic abnormalities and infections. Finally, we 
discuss the possibility of manipulating LGI in the elderly 
by nutritional interventions. We provide an overview of 
the evidence that exists in the elderly for omega-3 fatty 
acid, probiotic, prebiotic, antioxidant and polyphenol 
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For a long time biologic markers have been searched 
and alterations of these markers with treatment were 
studied. Zang discovered Leptin in 1994, since then 
many studies were performed in general medicine and 
psychiatry. Leptin draw attention because of its central 
and peripheric effects. Leptin is synthesized in adipose 
tissue as a 167-aminoacide polypeptide and then 
transform in to a 146-aminoacide polypeptide in 
circulatory system It is also found at hypothalamus and 
amygdala in brain. In recent researches, some 
evidences were determined that leptin is not only 
involved in food intake and energy consumption but 
also involved in sleep regulation sexual behavior, and 
impulsivity. These evidences gave rise to a lot of 
studies, which had been performed to designate the 
role of leptin in psychiatric disorders and conditions like 
depression, bipolar disorder, suicidality and eating 
disorder. In this article researches of leptin in psychiatry 
literature were reviewed.  
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 Endocrine problems are common and varied, and often 
require multidisciplinary management. In our unit, for 
example, we have a specialist clinic for patients with 
thyroid and parathyroid disorders, and patients are 
managed jointly by an endocrinologist and 
otolaryngologist. 
This combination of specialists means that management 
decisions are based on consensus opinions covering all 
aspects of the endocrine disease. We have therefore 
written the following article covering new 
developments in both the medical and surgical aspects 
of endocrine disease. 
* Primary hyperparathyroidism: when to operate? An 
increased awareness of hypercalcaemia has developed 
since the introduction of the serum autoanalyser in the 
1970s. This, along with the wide availability of 
parathyroid hormone (PTH) assays, has led to more 
frequent and earlier diagnosis of primary 
hyperparathyroidism (PHPT). Also, while in the past 
most patients diagnosed with PHPT were symptomatic, 
nowadays most are asymptomatic. 
Symptomatic patients may have renal stones, bone 
pain, pathologic fractures, proximal muscle weakness, 
depression, lethargy and vague aches and pains. In 
patients with `asymptomatic' PHPT, the future risk of 
2000 Practition
er 
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Reasons for exclusion 
following consensus  
developing complications of PHPT ranges from 23 to 62 
per cent at ten years.1 The most likely risks are 
progressive, silent bone loss and nephrolithiasis or 
nephrocalcinosis with renal dysfunction. 
































Fibromyalgia syndrome (FMS) is a prevalent and 
disabling chronic pain disorder. Past research suggests 
that obesity is a common comorbidity and may be 
related to the severity of FMS. The main objective of 
the present study was to evaluate the relationships 
between FMS and obesity in the multiple FMS-related 
domains: hyperalgesia, symptoms, physical abilities, 
and sleep. A total of 215 FMS patients completed a set 
of self-report inventories to assess FMS-related 
symptoms and underwent the tender point (TP) 
examination, physical performance testing, and 7-day 
home sleep assessment. Forty-seven percent of our 
sample was obese and an additional 30% was 
overweight. Obesity was related significantly to greater 
pain sensitivity to TP palpation particularly in the lower 
body areas, reduced physical strength and lower-body 
flexibility, shorter sleep duration, and greater 
restlessness during sleep. The results confirmed that 
obesity is a prevalent comorbidity of FMS that may 
contribute to the severity of the problem. Potential 
mechanisms underlying the relationship are discussed. 
Perspective: This report presents how obesity may be 
interrelated to fibromyalgia pain, disability, and sleep. 
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Chronic fatigue syndrome (CFS) is a complex illness 
defined by unexplained disabling fatigue as its core 
feature and a combination of other accompanying 
symptoms, such as diffuse pain, subjective cognitive 
impairment, and sleep problems. Medical conditions 
that may explain the prolonged fatigue as well as a 
number of psychiatric diagnoses exclude a patient from 
the diagnosis of CFS (Reeves et al., 2003). Recently, 
efforts have been made to assess case-defining 
symptoms of CFS objectively. Persons are classified as 
having CFS if they meet the following three empirically 
derived criteria as assessed by psychometrically 
evaluated questionnaires (Reeves et al., 2005): (1) 
severe fatigue; (2) substantial functional impairment; 
and (3) presence of substantial accompanying 
symptoms. Because CFS is a diagnosis of exclusion, a 
thorough medical history and assessment are required 
before the diagnosis can be formally established. This 
chapter discusses the prevalence, pathophysiology, risk 
factors, comorbidity, and treatment of CFS. (PsycINFO 
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Purpose The complex and varied presentation of 
myalgic encephalomyelitis/chronic fatigue syndrome 
(ME/CFS) has made it difficult to diagnose, study, and 
treat. Its symptoms and likely etiology involve multiple 
components of endocrine and immune regulation, 
including the hypothalamic-pituitary-adrenal axis, the 
hypothalamic-pituitary-gonadal axis, and their 
interactive oversight of immune function. We propose 
that the persistence of ME/CFS may involve changes in 
the regulatory interactions across these physiological 
axes. We also propose that the robustness of this new 
pathogenic equilibrium may at least in part explain the 
limited success of conventional single-target therapies. 
Methods A comprehensive model was constructed of 
female endocrine‚Äìimmune signaling consisting of 28 
markers linked by 214 documented regulatory 
interactions. This detailed model was then constrained 
to adhere to experimental measurements in a subset of 
17 candidate immune markers measured in peripheral 
blood of patients with ME/CFS and healthy control 
subjects before, during, and after a maximal exercise 
challenge. A set of 26 competing numerical models 
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Oxidative and nitrosative stress (O&NS) is causatively 
implicated in the pathogenesis of Alzheimer's and 
Parkinson's disease, multiple sclerosis, chronic fatigue 
syndrome, schizophrenia and depression. Many of the 
consequences stemming from O&NS, including damage 
to proteins, lipids and DNA, are well known, whereas 
the effects of O&NS on lipoprotein-based cellular 
signalling involving palmitoylation and plasma 
membrane lipid rafts are less well documented. The aim 
of this narrative review is to discuss the mechanisms 
involved in lipid-based signalling, including 
palmitoylation, membrane/lipid raft (MLR) and n-3 
polyunsaturated fatty acid (PUFA) functions, the effects 
of O&NS processes on these processes and their role in 
the abovementioned diseases. S-palmitoylation is a 
post-translational modification, which regulates protein 
trafficking and association with the plasma membrane, 
protein subcellular location and functions. 
Palmitoylation and MRLs play a key role in neuronal 
functions, including glutamatergic neurotransmission, 
and immune-inflammatory responses. Palmitoylation, 
MLRs and n-3 PUFAs are vulnerable to the corruptive 
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We measured sleep and 24-hour hormonal profiles in 
11 healthy young males after 6 days of sleep restriction 
and after 6 days of sleep recovery. At the end of sleep 
restriction, we observed reduced amounts of slow wave 
sleep (SWS) and rapid eye movement (REM) sleep and 
an alteration in the temporal distribution of these sleep 
stages, i.e. an increased pressure for REM sleep at the 
beginning of the sleep period and a decrease in the 
amount of slow wave activity (SWA) during the first 
sleep cycle. These later abnormalities are usually 
observed in depression. In addition, numerous 
alterations in the 24-hour hormonal profiles were 
observed in the state of sleep debt. The amount of 
melatonin secreted was reduced because of a delay in 
the onset of the nocturnal secretion and a reduction in 
the value of the acrophase. The 24-hour mean TSH 
levels were reduced and the nocturnal TSH elevation 
was markedly dampened, most likely as a result of 
elevated levels of thyroid hormones. Since these 
alterations are qualitatively and quantitatively similar to 
those observed during aging and sometimes during 
depression, a state of sleep debt is likely to increase the 
severity of depression and widespread age-related 
chronic conditions such as obesity, diabetes and 
hypertension. (PsycINFO Database Record (c) 2016 APA, 
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Executive cognitive and neurologic abnormalities are 
commonly seen in patients with a chronic inflammatory 
response syndrome (CIRS) acquired following exposure 
to the interior environment of water-damaged buildings 
(WDB), but a clear delineation of the physiologic or 
structural basis for these abnormalities has not been 
defined. Symptoms of affected patients routinely 
include headache, difficulty with recent memory, 
concentration, word finding, numbness, tingling, 
metallic taste and vertigo. Additionally, persistent 
proteomic abnormalities in inflammatory parameters 
that can alter permeability of the blood‚Äìbrain barrier, 
such as C4a, TGFB1, MMP9 and VEGF, are notably 
present in cases of CIRS-WDB compared to controls, 
suggesting a consequent inflammatory injury to the 
central nervous system. Findings of gliotic areas in MRI 
scans in over 45% of CIRS-WDB cases compared to 5% 
of controls, as well as elevated lactate and depressed 
ratios of glutamate to glutamine, are regularly seen in 
MR spectroscopy of cases. This study used the 
volumetric software program NeuroQuant¬Æ (NQ) to 
determine specific brain structure volumes in 
consecutive patients (N=17) seen in a medical clinic 
specializing in inflammatory illness. Each of these 
patients presented for evaluation of an illness thought 
to be associated with exposure to WDB, and received 
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, R. C.; 
House, D. 
E. 
The human health risk for chronic illnesses involving 
multiple body systems following inhalation exposure to 
the indoor environments of water-damaged buildings 
(WDBs) has remained poorly characterized and the 
subject of intense controversy. The current study 
assessed the hypothesis that exposure to the indoor 
environments of WDBs with visible microbial 
colonization was associated with illness. The study used 
a cross-sectional design with assessments at five time 
points, and the interventions of cholestyramine (CSM) 
therapy, exposure avoidance following therapy, and 
reexposure to the buildings after illness resolution. The 
methodological approach included oral administration 
of questionnaires, medical examinations, laboratory 
analyses, pulmonary function testing, and 
measurements of visual function. Of the 21 study 
volunteers, 19 completed assessment at each of the 
five time points. Data at Time Point 1 indicated multiple 
symptoms involving at least four organ systems in all 
study participants, a restrictive respiratory condition in 
four participants, and abnormally low visual contrast 
sensitivity (VCS) in 18 participants. Serum leptin levels 
were abnormally high and alpha melanocyte stimulating 
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, R. C.; 
House, D. 
E. 
Occupants of water-damaged buildings (WDBs) with 
evidence of microbial amplification often describe a 
syndrome involving multiple organ systems, commonly 
referred to as "sick building syndrome" (SBS), following 
chronic exposure to the indoor air. Studies have 
demonstrated that the indoor air of WDBs often 
contains a complex mixture of fungi, mycotoxins, 
bacteria, endotoxins, antigens, lipopolysaccharides, and 
biologically produced volatile compounds. A case-series 
study with medical assessments at five time points was 
conducted to characterize the syndrome after a double-
blinded, placebo-controlled clinical trial conducted 
among a group of study participants investigated the 
efficacy of cholestyramine (CSM) therapy. The general 
hypothesis of the time series study was that chronic 
exposure to the indoor air of WDBs is associated with 
SBS. Consecutive clinical patients were screened for 
diagnosis of SBS using criteria of exposure potential, 
symptoms involving at least five organ systems, and the 
absence of confounding factors. Twenty-eight cases 
signed voluntary consent forms for participation in the 
time-series study and provided samples of microbial 
contaminants from water-damaged areas in the 
buildings they occupied. Twenty-six participants with a 
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Jason et al. 
Background: Despite extensive research, no reliable 
biological marker for chronic fatigue syndrome (CFS) 
has yet been identified. However, hyperactivation of 
melanotrophs in the pituitary gland and increased levels 
of plasma alpha-melanocyte-stimulating hormone 
(alpha-MSH) have recently been detected in an animal 
model of chronic stress. Because CFS is considered to 
be caused partly by chronic stress events, increased 
alpha-MSH plasma levels may also occur in CFS 
patients. We therefore examined alpha-MSH levels in 
CFS patients. Methods: Fifty-five CFS patients, who 
were previously diagnosed within 10 years of with the 
disease, were enrolled in this study. Thirty healthy 
volunteers were studied as controls. Fasting bloods 
samples were collected in the morning and evaluated 
for their plasma levels of alpha-MSH, 
adrenocorticotropic hormone (ACTH), serum cortisol 
and dehydroepiandrosterone sulfate (DHEA-S). Mean 
levels of alpha-MSH were compared between the CFS 
and control groups using Welch's t test. Results: The 
mean plasma alpha-MSH concentration in the CFS 
group (17.9 +/- 1.0 pg/mL) was significantly higher than 
that in healthy controls (14.5 +/- 1.0 pg/mL, p = 0.02). 
However, there was a wide range of values in the CFS 
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de Kruijf de 
Nicola 
Deng et al.  
The purpose of this longitudinal blood sampling study 
was to examine relationships between sex hormones 
and fibromyalgia pain. Eight women meeting case 
definition criteria for fibromyalgia provided venous 
blood samples and reported their fibromyalgia pain 
severity over 25 consecutive days. All women exhibited 
normal menstrual cycles and were not taking oral 
contraceptives. Cortisol, and the sex hormones 
estradiol, progesterone, and testosterone, were 
assayed from serum. A linear mixed model was used to 
determine if fluctuations of sex hormones were 
associated with changes in pain severity. In the entire 
sample, day to day changes in progesterone (P = .002) 
as well as testosterone (P = .015) were significantly and 
inversely correlated with pain severity. There was no 
relationship between estradiol and pain (P = .551) or 
cortisol and pain (P = .633). These results suggest that 
progesterone and testosterone play a protective role in 
fibromyalgia pain severity. Sex and other hormones 
may serve to increase as well as decrease fibromyalgia 
pain severity. Perspective: Sex hormones fluctuate 
normally in women with fibromyalgia, but may still 
contribute to pain severity. (PsycINFO Database Record 
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INTRODUCTION: Physical activity is associated with 
improved fibrinolytic activity and reduced risk for 
cardiovascular disease. High levels of leptin and low 
levels of adiponectin, both adipocyte-derived 
hormones, or adipokines, are related to dysfibrinolysis 
and risk for cardiovascular disease. In this study, we 
explored if improved fibrinolytic activity during exercise 
could be linked to changes in leptin and adiponectin 
levels. MATERIALS AND METHODS: Twenty healthy men 
(mean age 36 years) participated in a 14-day long skiing 
expedition in the Swedish mountains. They were 
randomly assigned to either a 40% or a 30% fat-based 
diet. Anthropometry, lipids, fibrinolytic activity (PAI-1 
activity, tPA activity and mass) and adipokines (leptin 
and adiponectin) were measured before, during and six 
weeks after the expedition. RESULTS: PAI-1 activity and 
circulating levels of leptin decreased whereas levels of 
adiponectin increased during exercise. The fall in PAI-1 
activity showed a strong linear association with changes 
in leptin and adiponectin levels (p = 0.001 and p < 
0.001, respectively). Changes in leptin and adiponectin 
levels were independent of decreasing waist 
circumference. However, the association between 
anthropometric measures and adipokines changed 
considerably during the expedition.  
2008 Thromb 
Res 
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We describe a radioimmunoassay (RIA) for total leptin 
and a gel filtration procedure for the separation of free 
and bound leptin in human serum. The RIA, based on a 
locally prepared antibody, has a minimum detection 
limit of 0.9 ng/mL, a working range (CV < 10%) of 2.5-50 
ng/mL, inter-assay precision of 10.2, 7.2 and 8.9%CV at 
7.9, 15.4 and 30.0 ng/mL, respectively, 94% recovery of 
exogenous leptin (range 81.1-120.6%), exhibited 
parallelism and demonstrated no significant cross-
reactivity or interferences. A difference plot of results 
from this method and those from a commercially 
available kit (Linco Research) demonstrated satisfactory 
agreement up to concentrations of 50 ng/mL total 
leptin, with no significant bias. A gender-dependent 
correlation was obtained between body mass index 
(BMI) and total leptin (r = 0.91, P <0.001, n = 75 for 
men; r = 0.79, P < 0.001, n = 72 for women), with 
women having higher leptin concentrations than men 
for any given BMI. Gel filtration studies (inter-assay 
precision: 4.7%CV, n=18) demonstrated that a variable 
fraction (between 10% and 40%) of total leptin in serum 
was bound with high affinity (K(eq)= 1.0-1.45 <x> 109 
L/mol) to a non-albumin, non-lipid macromolecule. 
Binding affinities were found to be similar irrespective 
of gender or fat mass.  
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Fatigue that persists for 6 months or more is termed 
chronic fatigue. Chronic fatigue (CF) in combination 
with a minimum of 4 of 8 symptoms and the absence of 
diseases that could explain these symptoms, constitute 
the case definition for chronic fatigue 
syndrome/myalgic encephalomyelitis (CFS/ME). 
Inflammation, immune system activation, autonomic 
dysfunction, impaired functioning in the hypothalamic-
pituitary-adrenal axis, and neuroendocrine 
dysregulation have all been suggested as root causes of 
fatigue. The identification of objective markers 
consistently associated with CFS/ME is an important 
goal in relation to diagnosis and treatment, as the 
current case definitions are based entirely on physical 
signs and symptoms. This review is focused on the 
recent literature related to biomarkers for fatigue 
associated with CFS/ME and, for comparison, those 
associated with other diseases. These markers are 
distributed across several of the body's core regulatory 
systems. A complex construct of symptoms emerges 
from alterations and/or dysfunctions in the nervous, 
endocrine and immune systems. We propose that new 
insight will depend on our ability to develop and deploy 
an integrative profiling of CFS/ME pathogenesis at the 
molecular level. Until such a molecular signature is 
obtained efforts to develop effective treatments will 
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Chen et al. 
Cytokines are proteins produced by leukocytes and 
other cells that function as intercellular mediators 
acting on several target tissues, resulting in multiple 
biologic actions. Over the last decade, medical research 
has explored the interaction between cytokines and 
sleep disorders. The aim of this review is to illustrate 
recent advances in knowledge about the relationship 
between cytokines and disorders of excessive 
sleepiness. Cytokines may have an important role in 
mediating excessive daytime sleepiness in sleep loss or 
insomnia. Alterations of the immune system have also 
been associated with narcolepsy. The relationship 
between cytokines and hormonal regulatory 
mechanisms may explain symptoms like fatigue and 
sleepiness in chronic inflammatory diseases. Cytokines 
may play an important role in the pathogenesis of 
obstructive sleep apnea and cardiovascular 
consequences of this condition. New biologic 
treatments targeting cytokines have been investigated 
in conditions characterized by sleep disturbance. 
2008 Sleep 
Medicine 
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The allostatic load model expands the stress-disease 
literature by proposing a temporal cascade of multi-
systemic physiological dysregulations that contribute to 
disease trajectories. By incorporating an allostatic load 
index representing neuroendocrine, immune, 
metabolic, and cardiovascular system functioning, 
numerous studies have demonstrated greater 
prediction of morbidity and mortality over and beyond 
traditional detection methods employed in biomedical 
practice. This article reviews theoretical and empirical 
work using the allostatic load model vis-√†-vis the 
effects of chronic stress on physical and mental health. 
Specific risk and protective factors associated with 
increased allostatic load are elucidated and policies for 
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Aim: This paper is a report of a concept analysis of 
chronic fatigue. Background: Fatigue is a prevalent 
symptom encompassing both acute and chronic 
manifestations. It is chronic fatigue that is most 
problematic because of its duration and impact on life 
quality. The rise in prevalence of chronic conditions will 
result in a need to address coexistent symptoms, 
clarification of which is needed. Chronic fatigue is one 
of the most common symptoms in chronic illness. 
Clarification of the concept and an understanding of its 
use by discipline are needed. Data sources: The 
evolutionary method of concept analysis was used to 
ascertain the attributes, antecedents, consequences 
and surrogate terms for chronic fatigue. A review of the 
literature published between 1966 and 2007 was 
carried out to determine the contextual use of the 
concept of chronic fatigue among disciplines. Sources 
used for this analysis included CINAHL, Medline, 
PsychINFO and Social Work Abstracts and the search 
yielded 66 papers. Results: The chronic fatigue 
experience is associated with a multitude of physical, 
psychological and social factors. The defining attributes 
of chronic fatigue are constancy, abnormality, whole-
body experience, inexplicability and disabling. The 
antecedents of chronic fatigue are physical disease, 
psychopathology, female gender and a history of abuse.  
2008 Journal of 
Advanced 
Nursing 
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DeKloet  et 
al. 
Objective: Enhancement of negative feedback control 
of the HPA axis in patients with chronic fatigue 
syndrome (CFS) has been reported using the low dose 
dexamethasone suppression test. We have developed 
the use of prednisolone (5 mg) as a more physiologically 
appropriate alternative to dexamethasone in the 
investigation of mild degrees of glucocorticoid 
resistance or supersensitivity. The objective of the study 
was to use this test to look for alterations in negative 
feedback control of the HPA axis in CFS patients. 
Methods: Fifteen patients with CFS were recruited after 
fulfilling strict criteria including the absence of 
comorbid psychiatric diagnosis. They collected urine 
between 0900 and 1800 h and saliva at 0900 h pre-
prednisolone. At midnight, they took prednisolone (5 
mg) orally and then collected urine and saliva at the 
same intervals the following day. Results: Salivary 
cortisol was lower in CFS subjects pre-prednisolone 
than controls. Urinary cortisol metabolites were lower 
in CFS subjects pre-prednisolone, but did not reach 
significance. Both measures were significantly lower in 
CFS subjects post-dose. Mean percentage suppression 
of both salivary cortisol and urinary cortisol metabolites 
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Myalgic Encephalomyelitis (ME) continues to cause 
significant morbidity worldwide with an estimated one 
million cases in the United States. Hurdles to 
establishing consensus to achieve accurate evaluation 
of patients with ME continue, fueled by poor 
agreement about case definitions, slow progress in 
development of standardized diagnostic approaches, 
and issues surrounding research priorities. Because 
there are other medical problems, such as early MS and 
Parkinson's Disease, which have some similar clinical 
presentations, it is critical to accurately diagnose ME to 
make a differential diagnosis. In this article, we explore 
and summarize advances in the physiological and 
neurological approaches to understanding, diagnosing, 
and treating ME. We identify key areas and approaches 
to elucidate the core and secondary symptom clusters 
in ME so as to provide some practical suggestions in 
evaluation of ME for clinicians and researchers. This 
review, therefore, represents a synthesis of key 
discussions in the literature, and has important 
implications for a better understanding of ME, its 
biological markers, and diagnostic criteria. There is a 
clear need for more longitudinal studies in this area 
with larger data sets, which correct for multiple testing. 
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Considerable debate surrounds the search for the 
defining features of patients with myalgic 
encephalomyelitis (ME) and chronic fatigue syndrome 
(CFS). Current case definitions were created through 
clinical consensus. Failure to operationalize these case 
definitions has led to considerable variability in the 
identification of patients. In addition, some case 
definitions do not require cardinal symptoms of this 
illness, whereas other case definitions do require core 
symptoms of this illness, and these latter case criteria 
appear to identify a more impaired group of patients. 
Criterion variance is most likely to occur when 
operationally explicit criteria do not exist for diagnostic 
categories, or when there are varying criteria for 
contrasting case definitions, which is an impediment to 
the research in this field. To deal with this problem, it is 
possible to differentiate those that meet more loosely 
defined criteria from those that are more narrowly and 
defined, thus differentiating CFS from ME. In order to 
progress the search for biological markers and effective 
treatments, essential features need to be 
operationalized and broadly used to increase the 
probability that individuals included in samples have 
the same underlying illness. (PsycINFO Database Record 
(c) 2016 APA, all rights reserved) 
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Cleare p  
et al. 
Chronic fatigue immune dysfunction syndrome (CFIDS) 
is a heterogenous problem with an ambiguous origin 
and characterized by a severe disabling physical and 
mental fatigue that is exacerbating by minor strain. 
There has been a great deal of interest in 
neuroendocrinology on this challenging syndrome and 
neuroendocrinologic data obtained so far will be 
reviewed in this paper. Many studies had been 
performed to investigate the function of the 
hypothalamic-pituitary-adrenal (HPA) axis in CFIDS but 
the results are quite conflicting. Overall evidence of 
those neuroendocrinologic studies and hormonal 
treatment will be discussed in this article. Many of the 
HPA axis studies indicate a reduced cortisol output and 
symptom production are correlated in at least some 
CFIDS patients. There is some evidence for heightened 
negative feedback and changes in glucocorticoid 
receptor function for impaired ACTH and cortisol 
responses. Furthermore, a mutation in the gene which 
controls the production of corticosteroid-binding 
globulin (CBG) which is associated with complete loss of 
function of CBG was identified recently in CFIDS. 
However, there is no consensus on a specific 
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Objectives: Leptin is an important factor involved in the 
regulation of feeding behavior, and its discovery has 
opened new perspectives in the study of obesity. Given 
that patients with a diagnosis of affective disorders 
frequently show appetite loss, weight decrease and 
dysfunctions of the hypothalamic-pituitary-adrenal axis, 
and that leptin seems to induce anorexia by interacting 
with specific neuroendocrine and neurotransmission 
systems involved in mood regulation, a possible 
relationship between leptin serum levels and mood 
disorders can be hypothesized. The aim of this article is 
to provide the reader with a comprehensive review 
addressing this issue. Methods: A systematic review of 
the literature on the relationships between leptin, 
ghrelin and mood disorders has been carried by 
searching PubMed for all studies on this topic in the 
period 1995-2010. Results: Interestingly, it was found 
that still very few studies have directly investigated 
leptin plasma levels in affective disorders. Significant 
reduction of leptin plasma levels in depressed patients 
has been occasionally reported, however other studies 
have not confirmed this finding (Table I). Conclusions:  
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Purpose The pathogenesis of chronic fatigue syndrome 
or myalgic encephalomyelitis (CFS/ME) is complex and 
remains poorly understood. Evidence regarding the use 
of drug therapies in CFS/ME is currently limited and 
conflicting. The aim of this systematic review was to 
examine the existing evidence on the efficacy of drug 
therapies and determine whether any can be 
recommended for patients with CFS/ME. Methods 
MEDLINE, EMBASE, and PubMed databases were 
searched from the start of their records to March 2016 
to identify relevant studies. Randomized controlled 
trials focusing solely on drug therapy to alleviate and/or 
eliminate chronic fatigue symptoms were included in 
the review. Any trials that considered graded exercise 
therapy, cognitive behavior therapy, adaptive pacing, or 
any other nonpharmaceutical treatment plans were 
excluded. The inclusion criteria were examined to 
ensure that study participants met specific CFS/ME 
diagnostic criteria. Study size, intervention, and end 
point outcome domains were summarized. Findings A 
total of 1039 studies were identified with the search 
terms; 26 studies met all the criteria and were 
considered suitable for review. Three different 
diagnostic criteria were identified: the Holmes criteria, 
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Fatigue is an integral component of illness and sickness 
behavior. This chapter reviews possible links between 
fatigue, mood states, immunodepression, and the 
incidence of illness, particularly upper respiratory tract 
infections. In terms of fatigue, our work has focused 
mainly on the biochemical markers (tryptophan, 
branched chain amino acids) involved in central fatigue 
in endurance athletes (with/without unexplained 
underperformance syndrome) in chronic fatigue 
syndrome, and in postoperative fatigue. We have also 
looked at tryptophan from a different perspective by 
undertaking a functional magnetic resonance imaging 
(fMRI) study on the brain in healthy humans, 
with/without tryptophan supplementation, undertaking 
a cognition function task. The availability of tryptophan 
has consequences for immune function. In prolonged 
exercise, mucosal protection may be impaired as a 
consequence of oronasal breathing. Individuals involved 
in our studies have often had a high incidence of minor 
illnesses, particularly upper respiratory tract infections 
(URTI), after prolonged, exhaustive exercise such as a 
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Çaliş, H. T.  
Objective: The aim of this study is to investigate leptin, 
basal cortisol, basal dehydroepiandrosterone sulfate 
(DHEAS) levels in female patients with fibromyalgia and 
their relationship with psychological status and quality 
of life. Materials-Methods: The study was performed in 
49 female patients and 35 healthy controls aged 
between 20-55 years. Serum leptin, basal cortisol and 
basal DHEAS levels were compared between patient 
and control group. The patients and the controls were 
assessed using Hamilton Anxiety Rating Scale, Hamilton 
Depression Scale, SCL90-R (Symptom Check List), 
Fibromyalgia Impact Questionnaire, Visual Analog Scale 
(VAS), Modified Fatigue Impact Scale, Nottingham 
Health Profile. The relationship of these scales with 
leptin, cortisol and DHEAS levels were investigated 
Results: There were no significant differences in the 
mean levels of basal cortisol and DHEAS between the 
fibromyalgia and control groups (p>0.05), but leptin 
levels were significantly higher in patients with primary 
fibromyalgia (p<0.05). HAM-A scores were positively 
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 et al. 
Autoimmune rheumatic diseases are characterised by 
an abnormal immune system response, complement 
activation, cytokines dysregulation and inflammation. In 
last years, despite many progresses in managing these 
patients, it has been shown that clinical remission is 
reached in less than 50% of patients and a personalised 
and tailored therapeutic approach is still lacking 
resulting in a significant gap between guidelines and 
real-world practice. In this context, the need for 
biomarkers facilitating early diagnosis and profiling 
those individuals at the highest risk for a poor outcome 
has become of crucial interest. A biomarker generally 
refers to a measured characteristic which may be used 
as an indicator of some biological state or condition. 
Three different types of medical biomarkers has been 
suggested: i. mechanistic markers; ii. clinical disease 
markers; iii. therapeutic markers. A combination of 
biomarkers from these different groups could be used 
for an ideal more accurate diagnosis and treatment. 
However, although a growing body of evidence is 
focused on improving biomarkers, a significant amount 
of this information is not integrated on standard clinical 
care. The overarching aim of this work was to clarify the 
meaning of specific biomarkers during autoimmune 
diseases; their possible role in confirming diagnosis, 
predicting outcome and suggesting specific treatments. 
2019 Autoimm
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 This section of the supplement “Fatigue: A New 
Frontier” will discuss 3 issues that have significant 
import for elucidating mechanisms by which fatigue 
occurs and its evaluation and treatment. These issues 
are clearly not the only ones that are important for 
future research or clinical practice, but they are the 
most prevalent issues raised in the articles of this 
supplement. They present significant challenges in both 
research and clinical arenas and offer substantial 
research opportunity. There exists a body of published 
data that leave a number of unresolved key issues. 
These include: 1) What are our best metrics for 
measuring fatigue? 2) Do the constructs of peripheral 
and central fatigue advance our understanding of 
fatigue syndromes or create arbitrary limitations? 3) 
Will a better understanding of the interactions among 
immunoregulation and metabolic control of energy 
production and utilization (and performance and 
perception) help us derive a comprehensive approach 
to the management of fatigue? 
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Gool et al. 
This article focuses on the neuroendocrine 
infrastructure of the adaptive response to stress and on 
its effects on the major endocrine axes in the body. Also 
discussed is the altered regulation or dysregulation of 
the adaptive response in various physiologic and 
pathophysiologic states, which may influence the 
growth and development of an individual and define 
the vulnerability of this individual to endocrine, 
psychiatric, or immunologic disease. (PsycINFO 
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Elias et al. 
Objective: To evaluate ictal adipokine levels in episodic 
migraineurs and their association with pain severity and 
treatment response. Methods: This was a double-blind, 
placebo-controlled trial evaluating peripheral blood 
specimens from episodic migraineurs at acute pain 
onset and 30 to 120 minutes after treatment with 
sumatriptan/naproxen sodium vs placebo. Total 
adiponectin (T-ADP), ADP multimers (high molecular 
weight [HMW], middle molecular weight, and low 
molecular weight [LMW]), leptin, and resistin levels 
were evaluated by immunoassays. Results: Thirty-four 
participants (17 responders, 17 nonresponders) were 
included. In all participants, pretreatment pain severity 
increased with every quartile increase in both the 
HMW:T-ADP ratio (coefficient of variation [CV] 0.51; 
95%confidence interval [CI]: 0.08, 0.93; p = 0.019) and 
resistin levels (CV 0.58; 95% CI: 0.21, 0.96; p = 0.002), 
but was not associated with quartile changes in leptin 
levels. In responders, T-ADP (CV 20.98; 95% CI: 21.88, 
20.08; p = 0.031) and resistin (CV 20.95; 95%CI: 21.83, 
20.07; p = 0.034) levels decreased 120 minutes after 
treatment as compared with pretreatment. In addition, 
in responders, the HMW:T-ADP r 
2015 Neurolog
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Born et al. 
Neural systems that identify and respond to salient 
stimuli are critical for survival in a complex and 
changing environment. In addition, interindividual 
differences, including genetic variation and hormonal 
and metabolic status likely influence the behavioral 
strategies and neuronal responses to environmental 
challenges. Here, we examined the relationship 
between leptin allelic variation and plasma leptin levels 
with DAD2/3R availability in vivo as measured with 
[11C]raclopride PET at baseline and during a 
standardized pain stress challenge. Allelic variation in 
the leptin gene was associated with varying levels of 
dopamine release in response to the pain stressor, but 
not with baseline D2/3 receptor availability. Circulating 
leptin was also positively associated with stress-induced 
dopamine release. These results show that leptin serves 
as a regulator of neuronal function in humans and 
provides an etiological mechanism for differences in 
dopamine neurotransmission in response to salient 
stimuli as related to metabolic function. The capacity 
for leptin to influence stress-induced dopaminergic 
function is of importance for pathological states where 
dopamine is thought to play an integral role, such as 
mood, substance-use disorders, eating disorders, and 
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Though potentially linked to the basic physiology of 
stress response we still have no clear understanding of 
Gulf War Illness (GWI), a debilitating illness presenting 
with a complex constellation of immune, endocrine and 
neurological symptoms. Here we compared male GWI 
(n=20) with healthy veterans (n=22) and subjects with 
chronic fatigue syndrome/myalgic encephalomyelitis 
(CFS/ME) (n=7). Blood was drawn during a Graded 
eXercise Test (GXT) prior to exercise, at peak effort 
(VO2 max) and 4-h post exercise. Affymetrix HG U133 
plus 2.0 microarray gene expression profiling in 
peripheral blood mononuclear cells (PBMCs) was used 
to estimate activation of over 500 documented 
pathways. This was cast against ELISA-based 
measurement of 16 cytokines in plasma and flow 
cytometric assessment of lymphocyte populations and 
cytotoxicity. A 2-way ANOVA corrected for multiple 
comparisons (q statistic <0.05) indicated significant 
increases in neuroendocrine-immune signaling and 
inflammatory activity in GWI, with decreased apoptotic 
signaling. Conversely, cell cycle progression and 
immune signaling were broadly subdued in CFS. Partial 
correlation networks linking pathways with symptom 
severity via changes in immune cell abundance, 
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Clinicians are often challenged by patients presenting 
with a syndrome of chronic and diffuse full body pain 
with long standing fatigue and a cluster of related 
symptoms. Fibromyalgia has become the commonly 
accepted term for this syndrome. Diagnosis is 
established through recognized subjective symptoms, 
such as tender points and other indicators of chronic 
full body pain and fatigue. Suspected triggers have 
included bacterial and viral infections, toxins, allergens, 
and emotional and physical trauma. Unknown causes 
limit the prescription of effective treatments; however, 
neuropathic pain and fatigue have been identified as 
key components so dual reuptake inhibitors and anti-
convulsants have shown some effectiveness for some 
patients. Based upon laboratory and clinical studies of 
the last decade, this article proposes a model for a 
subset of fibromyalgia patients who have prolonged 
immune activation with related oxidative and 
nitrogenous stress leading to multiple hormonal 
repression, disrupted collagen physiology, neuropathic 
pain and fatigue. This integrative model of fibromyalgia 
is based on chronic up-regulation of the immune 
system with subsequent hormonal, connective tissue 
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Cleare, A. J. Chronic fatigue syndrome (CFS) is a common and 
disabling problem; although most likely of 
biopsychosocial origin, the nature of the 
pathophysiological components remains unclear. There 
has been a wealth of interest in the endocrinology of 
this condition, which will be reviewed in this article. 
Most studied has been the hypothalamic-pituitary-
adrenal (HPA) axis; although the quality of many studies 
is poor, the overall balance of evidence points to 
reduced cortisol output in at least some patients, with 
some evidence that this is linked to symptom 
production or persistence. There is evidence for 
heightened negative feedback and glucocorticoid 
receptor function and for impaired ACTH and cortisol 
responses to a variety of challenges. However, there is 
no evidence for a specific or uniform dysfunction of the 
HPA axis. Given the many factors that may impinge on 
the HPA axis in CFS, such as inactivity, sleep 
disturbance, psychiatric comorbidity, medication, and 
ongoing stress, it seems likely that HPA axis disturbance 
is heterogeneous and of multifactorial etiology in CFS. 
Studies assessing GH, dehydroepiandrostenedione and 
its sulfate, melatonin, leptin, and neuroendocrine-
monoamine interactions are also reviewed.  
2003 Endocr 
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